# ::snt CEBPG transcription factor correlates with antioxidant and DNA repair genes in normal bronchial epithelial cells but not in individuals with bronchogenic carcinoma .
# ::tok CEBPG transcription factor correlates with antioxidant and DNA repair genes in normal bronchial epithelial cells but not in individuals with bronchogenic carcinoma .
# ::alignments 21-22|0.0.2.2.0 18-19|0.0.2.2.1 16-17|0.0.1 15-16|0 14-15|0.0.2.1.0.1.0 13-14|0.0.2.1.0.1.0.1 12-13|0.0.2.1.0.1 11-12|0.0.2.1.0.1.0.0 9-10|0.0.2.2 8-9|0.0.2.1.0 7-8|0.0.2.1 6-7|0.0.2 5-6|0.0.2.0 3-4|0.0 2-3|0.0.0 1-2|0.0.2.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:34.949
(c2 / contrast-01 
      :ARG2 (c4 / correlate-01 
            :ARG0 (f / factor) 
            :ARG1 - 
            :op1-of (a / and 
                  :op2 (a2 / antioxidant) 
                  :op3 (d / DNA 
                        :mod-of (r / repair-01 
                              :ARG0 (t / transcription) 
                              :ARG1 (b / bronchial 
                                    :mod-of (c3 / cell 
                                          :ARG1-of (n / normal-02) 
                                          :mod (e / epithelial))))) 
                  :op4 (g / gene 
                        :consist-of (c / carcinoma) 
                        :consist-of (i / individual)))))

# ::snt Cigarette smoking is the primary cause of bronchogenic carcinoma ( BC ) , yet only 10 -- 15 % of heavy smokers develop BC and it is likely that this variation in risk is , in part , genetically determined .
# ::tok Cigarette smoking is the primary cause of bronchogenic carcinoma ( BC ) , yet only 10 -- 15 % of heavy smokers develop BC and it is likely that this variation in risk is , in part , genetically determined .
# ::alignments 39-40|0.0.0.0.0.0.1 38-39|0.0.0.0.0.0.1.1 32-33|0.0.0.0.0.0.2.0.2 30-31|0.0.0.0.0.0.1.0 29-30|0.0.0.0.0.0.1.0.0 27-28|0.0.0.0.0.0.2.0 24-25|0.0.0.0.0.0.2 23-24|0.0.0.0.0.0.0 22-23|0.0.0.0.0.0 21-22|0.0.0.0+0.0.0.0.0 20-21|0.0.0.0.0.1 18-19|0.0.0.0.0.0.2.0.1 17-18|0.0.0.0.0.0.2.0.1.0 15-16|0.0.0.0.0.0.2.0.2.0 14-15|0.0.0.0.0.0.2.0.2.1 13-14|0.0.0.0.0.0.1.2 10-11|0.0.0.0.0.0.2.0.0 8-9|0.1 5-6|0 4-5|0.2 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:36.363
(c2 / cause-01 
      :ARG0 (s2 / smoke-02 
            :ARG1 (c3 / cigarette 
                  :ARG1-of (s / smoke-02 
                        :ARG0 (p / person 
                              :ARG0-of (d2 / develop-02 
                                    :ARG1 "BC" 
                                    :ARG1-of (d / determined-02 
                                          :ARG0 (v / variation 
                                                :mod (t / this)) 
                                          :manner (g / genetics) 
                                          :op1-of (y / yet)) 
                                    :op1-of (a / and 
                                          :op2 (l / likely-01 
                                                :ARG0 "BC" 
                                                :ARG1 (p2 / percentage-entity 
                                                      :value 15) 
                                                :time (r / risk-01 
                                                      :ARG0 10 
                                                      :ARG1 (o / only))))) 
                              :mod (h / heavy))))) 
      :ARG1 (c / carcinoma) 
      :mod (p3 / primary))

# ::snt We previously reported a set of antioxidant genes for which transcript abundance was lower in normal bronchial epithelial cells ( NBEC ) of BC individuals compared to non-BC individuals .
# ::tok We previously reported a set of antioxidant genes for which transcript abundance was lower in normal bronchial epithelial cells ( NBEC ) of BC individuals compared to non-BC individuals .
# ::alignments 28-29|0.2.0.2.0.0 25-26|0.2.0.2.0 24-25|0.2.0.2 23-24|0.2.0.2.1 20-21|0.3.0.0+0.3.0+0.3 18-19|0.2.0 17-18|0.2.0.0 16-17|0.2.0.1 15-16|0.2 13-14|0.1.0.0 11-12|0.1.0.0.0 10-11|0.1.0.0.0.0.0+0.1.0.0.0.0 7-8|0.1.0 6-7|0.1.0.1 4-5|0.1 2-3|0 1-2|0.4 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:37.646
(r / report-01 
      :ARG0 (w / we) 
      :ARG1 (s / set 
            :consist-of (g / gene 
                  :ARG0-of (l / low-04 
                        :ARG1 (a / abundance 
                              :mod (t / thing 
                                    :ARG1-of (t2 / transcribe-01)))) 
                  :part-of (a2 / antioxidant))) 
      :manner-of (n2 / normal-02 
            :ARG1 (c2 / cell 
                  :mod (e / epithelial) 
                  :mod (b / bronchial) 
                  :part-of (i2 / individual 
                        :ARG0-of (c / compare-01 
                              :ARG2 (i / individual)) 
                        :mod "BC"))) 
      :mod (o / organization 
            :name (n / name 
                  :op1 "NBEC")) 
      :time (p / previous))

# ::snt In unpublished studies of the same NBEC samples , transcript abundance values for several DNA repair genes were correlated with these antioxidant genes .
# ::tok In unpublished studies of the same NBEC samples , transcript abundance values for several DNA repair genes were correlated with these antioxidant genes .
# ::alignments 22-23|0.2 21-22|0.2.1 20-21|0.2.2 18-19|0 16-17|0.2.0.1 15-16|0.2.0 14-15|0.2.0.0 13-14|0.2.0.1.0 11-12|0.0 10-11|0.0.0 9-10|0.0.1.0+0.0.1 7-8|0.1.0.0+0.1.0 6-7|0.1.0.0.0.0.0+0.1.0.0.0.0+0.1.0.0.0 5-6|0.1.0.1 2-3|0.1 1-2|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:38.656
(c / correlate-01 
      :ARG1 (v / value 
            :mod (a2 / abundance) 
            :mod (t2 / thing 
                  :ARG1-of (t3 / transcribe-01))) 
      :ARG2 (s4 / study-01 
            :ARG1 (t4 / thing 
                  :ARG1-of (s2 / sample-01 
                        :ARG0 (o / organization 
                              :name (n / name 
                                    :op1 "NBEC"))) 
                  :ARG1-of (s3 / same-01)) 
            :mod (u / unpublish)) 
      :manner (g / gene 
            :ARG1-of (r / repair-01 
                  :mod (d / DNA) 
                  :mod-of (g2 / gene 
                        :quant (s / several))) 
            :mod (a / antioxidant) 
            :mod (t / this)))

# ::snt From these data , we hypothesized that antioxidant and DNA repair genes are co-regulated by one or more transcription factors and that inter-individual variation in expression and/or function of one or more of these transcription factors is responsible for inter-individual variation in risk for BC .
# ::tok From these data , we hypothesized that antioxidant and DNA repair genes are co-regulated by one or more transcription factors and that inter-individual variation in expression and/or function of one or more of these transcription factors is responsible for inter-individual variation in risk for BC .
# ::alignments 44-45|0.0.0.0.0.1 42-43|0.0.0.0.0 40-41|0.0.0.0.2.1 37-38|0.0.0.0.2 35-36|0.0.0.0.0.0.0 34-35|0.0.0.0.0.0 33-34|0.0.0.0.0.0.0.0 31-32|0.0.0.0.1.1.1.0 30-31|0.0.0.0.1.1.1 27-28|0.1 25-26|0 23-24|0.0.0.0.2.0 20-21|0.0.0.0 19-20|0.2.0 18-19|0.2 17-18|0.2.0.0.0 16-17|0.2.0.0 11-12|0.0.0.0.1.1.2 10-11|0.0.0.0.1.0 9-10|0.0.0.0.1 8-9|0.0.0.0.1.1 7-8|0.0.0.0.1.1.0 5-6|0.0.0 4-5|0.0 2-3|0.0.1 1-2|0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:39.726
(e / express-01 
      :ARG0 (w / we 
            :ARG0-of (h / hypothesize-01 
                  :ARG1 (a / and 
                        :ARG0-of (r / risk-01 
                              :ARG1 (t / transcription 
                                    :mod-of (f / factor 
                                          :mod (t2 / this))) 
                              :ARG2 "BC") 
                        :op1 (d / DNA 
                              :ARG1-of (r3 / repair-01) 
                              :op2-of (a2 / and 
                                    :op1 (a3 / antioxidant) 
                                    :op1-of (o / or 
                                          :op2 (m / more)) 
                                    :op3 (g / gene))) 
                        :op2 (r2 / responsible-01 
                              :ARG0 (v2 / variation) 
                              :ARG1 (v / variation)))) 
            :poss-of (d2 / data 
                  :mod (t4 / this))) 
      :ARG1 (f2 / function-01) 
      :ARG2 (t3 / transcription 
            :mod-of (f3 / factor 
                  :op2-of (o2 / or 
                        :op1 (m2 / more)))))

# ::snt The putative transcription factor recognition sites common to six of the antioxidant genes were identified through in silico DNA sequence analysis .
# ::tok The putative transcription factor recognition sites common to six of the antioxidant genes were identified through in silico DNA sequence analysis .
# ::alignments 20-21|0.0.0.1 19-20|0.0.0.1.0 18-19|0.0.0.1.0.0 14-15|0.0.0 12-13|0.0 11-12|0 8-9|0.0.0.0.2.0 6-7|0.0.0.0.2 5-6|0.0.0.0 4-5|0.0.0.0.0 3-4|0.0.0.0.0.1 2-3|0.0.0.0.1 1-2|0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:40.413
(a2 / antioxidant 
      :mod-of (g / gene 
            :ARG0-of (i / identify-01 
                  :ARG1 (s2 / site 
                        :location-of (r / recognize-01 
                              :ARG0 (p / putative) 
                              :ARG1 (f / factor)) 
                        :location-of (t / transcription) 
                        :mod (c / common 
                              :mod 6)) 
                  :manner (a / analyze-01 
                        :ARG1 (s / sequence 
                              :mod (d / DNA))))))

# ::snt The transcript abundance values of these transcription factors ( n = 6 ) and an expanded group of antioxidant and DNA repair genes ( n = 16 ) were measured simultaneously by quantitative PCR in NBEC of 24 non-BC and 25 BC individuals .
# ::tok The transcript abundance values of these transcription factors ( n = 6 ) and an expanded group of antioxidant and DNA repair genes ( n = 16 ) were measured simultaneously by quantitative PCR in NBEC of 24 non-BC and 25 BC individuals .
# ::alignments 42-43|0.0.1.2.3.1 41-42|0.0.1.2.3.1.0 40-41|0.0.1.2.3.1.1 39-40|0.0.1.2.3 37-38|0.0.1.2.3.0.1 35-36|0.0.1.2.3.0.0.0+0.0.1.2.3.0.0+0.0.1.2.3.0 32-33|0.0.0 30-31|0.0.1.2.4 29-30|0.0.1.2 26-27|0.2.0.1 22-23|0.3 21-22|0.2.0 20-21|0.2 19-20|0 18-19|0.1 16-17|0.0.1.2.1 15-16|0.0 13-14|0.0.1 11-12|0.2.0.0 7-8|0.0.1.2.2 6-7|0.0.1.2.2.0 5-6|0.0.1.2.2.1 3-4|0.0.1.1 2-3|0.0.1.0 1-2|0.0.1.2.0.0+0.0.1.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:41.908
(a2 / and 
      :ARG1-of (e / expand-01 
            :ARG0 (q / quantitative) 
            :op3-of (a4 / and 
                  :op1 (a5 / abundance) 
                  :op2 (v / value) 
                  :op4 (m / measure-01 
                        :ARG0 (t3 / thing 
                              :ARG1-of (t4 / transcribe-01)) 
                        :ARG1 (g2 / group) 
                        :ARG2 (f / factor 
                              :mod (t / transcription) 
                              :mod (t2 / this)) 
                        :location (a / and 
                              :op1 (o / organization 
                                    :name (n / name 
                                          :op1 "NBEC") 
                                    :op1 24) 
                              :op2 (i / individual 
                                    :mod "BC" 
                                    :quant 25)) 
                        :manner (s / simultaneous)))) 
      :op1 (a3 / antioxidant) 
      :op2 (d / DNA 
            :mod-of (r / repair-01 
                  :ARG0 6 
                  :ARG1 16)) 
      :op3 (g / gene))

# ::snt CEBPG transcription factor was significantly ( p < 0.01 ) correlated with eight of the antioxidant or DNA repair genes in non-BC individuals but not in BC individuals .
# ::tok CEBPG transcription factor was significantly ( p < 0.01 ) correlated with eight of the antioxidant or DNA repair genes in non-BC individuals but not in BC individuals .
# ::alignments 27-28|0.2.2.0.0 26-27|0.2.2.0 24-25|0.2.0 23-24|0 22-23|0.1.0.1.1 19-20|0.1 18-19|0.1.0.1 17-18|0.1.0.1.0 16-17|0.1.0 15-16|0.1.0.0 12-13|0.0 10-11|0.2 4-5|0.2.2 2-3|0.2.1 1-2|0.2.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:42.099
(c / contrast-01 
      :ARG0 8 
      :ARG1 (g / gene 
            :op3-of (o / or 
                  :op1 (a / antioxidant) 
                  :op2 (r / repair-01 
                        :ARG1 (d / DNA) 
                        :ARG3 (i2 / individual)))) 
      :ARG2 (c2 / correlate-01 
            :ARG0 - 
            :ARG1 (f / factor 
                  :mod (t / transcription)) 
            :ARG2 (s / significant-02 
                  :ARG1 (B / "BC" 
                        :mod-of (i / individual)))))

# ::snt In BC individuals the correlation with CEBPG was significantly ( p < 0.01 ) lower than that of non-BC individuals for four of the genes ( XRCC1 , ERCC5 , GSTP1 , and SOD1 ) and the difference was nearly significant for GPX1 .
# ::tok In BC individuals the correlation with CEBPG was significantly ( p < 0.01 ) lower than that of non-BC individuals for four of the genes ( XRCC1 , ERCC5 , GSTP1 , and SOD1 ) and the difference was nearly significant for GPX1 .
# ::alignments 40-41|0.0.1 39-40|0.0.1.2 37-38|0.0.1.1 35-36|0.0 32-33|0 24-25|0.0.1.1.0 21-22|0.0.1.1.0.0 19-20|0.0.1.0 16-17|0.0.0.2 14-15|0.0.0 8-9|0.0.0.1 4-5|0.0.0.0 2-3|0.0.2 1-2|0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:42.514
(a2 / and 
      :op2-of (a / and 
            :op1 (l / low-04 
                  :ARG1 (c / correlation) 
                  :ARG1-of (s2 / significant-02) 
                  :compared-to (t / that)) 
            :op3 (s / significant-02 
                  :ARG0 (i / individual) 
                  :ARG1 (d / differ-02 
                        :ARG1 (g / gene 
                              :quant 4)) 
                  :mod (n / nearly)) 
            :topic-of (i2 / individual 
                  :mod "BC")))

# ::snt The only other transcription factor correlated with any of these five target genes in non-BC individuals was E2F1 .
# ::tok The only other transcription factor correlated with any of these five target genes in non-BC individuals was E2F1 .
# ::alignments 17-18|0.2.1.0.0+0.2.1.0+0.2.1 15-16|0.1 12-13|0.0 11-12|0 10-11|0.1.0 9-10|0.0.0 7-8|0.2.0.0 5-6|0.2.0 4-5|0.2 3-4|0.2.4 2-3|0.2.3 1-2|0.2.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:42.779
(t / target-01 
      :ARG1 (g / gene 
            :mod (t2 / this)) 
      :ARG3 (i / individual 
            :quant 5) 
      :op1-of (f / factor 
            :ARG0-of (c / correlate-01 
                  :ARG1 (a / any)) 
            :domain-of (o / organization 
                  :name (n / name 
                        :op1 "E2F1")) 
            :mod (o3 / only) 
            :mod (o2 / other) 
            :mod (t3 / transcription)))

# ::snt E2F1 was correlated with GSTP1 among non-BC individuals , but in contrast to CEBPG , there was no significant difference in this correlation in non-BC individuals compared to BC individuals .
# ::tok E2F1 was correlated with GSTP1 among non-BC individuals , but in contrast to CEBPG , there was no significant difference in this correlation in non-BC individuals compared to BC individuals .
# ::alignments 29-30|0.0.1.0.0.0.1 28-29|0.0.1.0.0.0.1.0 26-27|0.0.1.0.0.0 25-26|0.0.1.0.0 22-23|0.0.1.0.0.0.0 21-22|0.0.1.0.0.0.0.0 19-20|0.0.1.0.0.0.0.1 18-19|0.0.1.0.0.0.0.1.0 17-18|0.0.1.0.0.0.1.0.0 11-12|0.0.1.0 9-10|0 7-8|0.0.0 2-3|0.0 0-1|0.0.1.1.0+0.0.1.1+0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:43.473
(c4 / contrast-01 
      :ARG1 (c5 / correlate-01 
            :ARG0 (i3 / individual) 
            :ARG1 (o / organization 
                  :ARG1-of (c3 / contrast-01 
                        :ARG0 (i2 / individual 
                              :ARG1-of (c / compare-01 
                                    :ARG0 (c2 / correlation 
                                          :mod (t / this) 
                                          :prep-in-of (d / differ-02 
                                                :ARG1-of (s / significant-02))) 
                                    :ARG2 (i / individual 
                                          :mod (B / "BC" 
                                                :poss -))))) 
                  :name (n / name 
                        :op1 "E2F1"))))

# ::snt We conclude that CEBPG is the transcription factor primarily responsible for regulating transcription of key antioxidant and DNA repair genes in non-BC individuals .
# ::tok We conclude that CEBPG is the transcription factor primarily responsible for regulating transcription of key antioxidant and DNA repair genes in non-BC individuals .
# ::alignments 22-23|0.1.0.0.1.0 19-20|0.1.0.0.0.1 18-19|0.1.0.0.0.1.0 17-18|0.1.0.0.0.1.0.0 16-17|0.1.0.0.0 15-16|0.1.0.0.0.0 14-15|0.1.0.0.0.0.0 12-13|0.1.0.0.1 11-12|0.1.0.0 9-10|0.1.0 8-9|0.1.0.1 7-8|0.1 6-7|0.1.1 1-2|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:44.550
(c / conclude-02 
      :ARG0 (w / we) 
      :ARG1 (f / factor 
            :ARG0-of (r3 / responsible-01 
                  :ARG1 (r2 / regulate-01 
                        :ARG0 (a / and 
                              :op1 (a2 / antioxidant 
                                    :ARG1-of (k / key-02)) 
                              :op2 (g / gene 
                                    :mod (r / repair-01 
                                          :ARG1 (d / DNA)))) 
                        :ARG1 (t / transcription 
                              :location (i / individual))) 
                  :degree (p / primary)) 
            :mod (t2 / transcription)))

# ::snt Further , we conclude that the heavy smokers selected for development of BC are those who have sub-optimal regulation of antioxidant and DNA repair genes by CEBPG .
# ::tok Further , we conclude that the heavy smokers selected for development of BC are those who have sub-optimal regulation of antioxidant and DNA repair genes by CEBPG .
# ::alignments 24-25|0.1.0.2.2 23-24|0.1.0.2.1.0 22-23|0.1.0.2.1 21-22|0.1.0.2 20-21|0.1.0.2.0 18-19|0.1.0.2.2.0 12-13|0.1.1.0 10-11|0.1.1 8-9|0.1 7-8|0.1.0.0+0.1.0 6-7|0.1.0.1 3-4|0 2-3|0.0 0-1|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:44.964
(c / conclude-02 
      :ARG0 (w / we) 
      :ARG1-of (s / select-01 
            :ARG0 (p / person 
                  :ARG0-of (s2 / smoke-02) 
                  :mod (h / heavy) 
                  :op1-of (a / and 
                        :op2 (a2 / antioxidant) 
                        :op3 (d / DNA 
                              :ARG1-of (r / repair-01)) 
                        :op4 (g / gene 
                              :ARG1-of (r2 / regulate-01)))) 
            :ARG3 (d2 / develop-02 
                  :ARG1 "BC")) 
      :mod (f / further))

# ::snt BC is currently the leading cause of cancer-related death in the United States , causing 28 % of all cancer deaths [ 1 ] .
# ::tok BC is currently the leading cause of cancer-related death in the United States , causing 28 % of all cancer deaths [ 1 ] .
# ::alignments 22-23|0.0.0.1.1.0 20-21|0.0 19-20|0 18-19|0.0.0.1.1.1 16-17|0.0.0.0 15-16|0.0.0.0.0 14-15|0.0.0.1.2 11-13|0.0.0.1.3.1+0.0.0.1.3.0.1+0.0.0.1.3.0.0+0.0.0.1.3.0+0.0.0.1.3 8-9|0.0.0.1.1 7-8|0.0.0.1.1.2 5-6|0.0.0.1 4-5|0.0.0 2-3|0.0.0.1.4 0-1|0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:45.472
(c / cancer 
      :mod-of (d / death 
            :ARG0-of (l / lead-01 
                  :ARG1 (p / percentage-entity 
                        :value 28) 
                  :ARG2 (c5 / cause-01 
                        :ARG0 "BC" 
                        :ARG1 (d2 / die-01 
                              :ARG0 1 
                              :ARG1 (a / all) 
                              :mod (c4 / cancer-relat)) 
                        :ARG1-of (c2 / cause-01) 
                        :location (c3 / country 
                              :name (n / name 
                                    :op1 "United" 
                                    :op2 "States") 
                              :wiki "United_States") 
                        :time (c6 / current)))))

# ::snt Although cigarette smoking is the primary risk factor , only 10 -- 15 % of heavy smokers ( greater than 20 pack years ) develop BC [ 1-3 ] .
# ::tok Although cigarette smoking is the primary risk factor , only 10 -- 15 % of heavy smokers ( greater than 20 pack years ) develop BC [ 1-3 ] .
# ::alignments 25-26|0.0.1.0 24-25|0.0.0.2.0.0 22-23|0.0.0.2.0.0.0.2+0.0.0.2.0.0.0 21-22|0.0.1 20-21|0.0.0.2.0.0.0.1 18-19|0.0.0.2.0.0.0.0 16-17|0.0.0.0+0.0.0 15-16|0.0.0.1 13-14|0.0.0.2.0 12-13|0.0.0.2 10-11|0.0.0.2.0.0.1.0 9-10|0.0.0.2.0.0.1 7-8|0.0.2 6-7|0.0.2.0 5-6|0.0.2.0.0 2-3|0.0 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:46.395
(c / cigarette 
      :ARG1-of (s2 / smoke-02 
            :ARG0 (p2 / person 
                  :ARG0-of (s / smoke-02) 
                  :mod (h / heavy) 
                  :quant (1 / 15 
                        :value-of (p3 / percentage-entity 
                              :ARG0-of (d / develop-02 
                                    :ARG1 (t / temporal-quantity 
                                          :op1-of (g / great) 
                                          :quant 20 
                                          :unit (y / year)) 
                                    :time (o / only 
                                          :op1 10))))) 
            :ARG2 (p / pack-01 
                  :ARG1 "BC") 
            :domain-of (f / factor 
                  :ARG1-of (r / risk-01 
                        :mod (p4 / primary)))))

# ::snt Antioxidant and DNA repair enzymes that provide protection from the effects of cigarette smoke are expressed in the progenitor cells for BC , normal bronchial epithelial cells ( NBEC ) [ 1 ] .
# ::tok Antioxidant and DNA repair enzymes that provide protection from the effects of cigarette smoke are expressed in the progenitor cells for BC , normal bronchial epithelial cells ( NBEC ) [ 1 ] .
# ::alignments 31-32|0.0.0 28-29|0.0.1.1.0.0+0.0.1.1.0+0.0.1.1 26-27|0.0.1.0.1.1.0 25-26|0.0.1.0.1.1.0.0 24-25|0.0.1.0.1.1.0.1 23-24|0.0.1.0.1.1 21-22|0.0.1.0.3 19-20|0.0.1.0.0.0 18-19|0.0.1.0.0.0.0 15-16|0.0.1.0.0 13-14|0 12-13|0.1 10-11|0.0.1.0.2 7-8|0.0 6-7|0.0.1 4-5|0.0.1.0 3-4|0.0.1.0.2.0 2-3|0.0.1.0.2.0.0 1-2|0.0.1.0.1 0-1|0.0.1.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:47.163
(s / smoke 
      :ARG1-of (p2 / protect-01 
            :ARG0 1 
            :ARG1-of (p3 / provide-01 
                  :ARG0 (e4 / enzym 
                        :ARG1-of (e2 / express-01 
                              :manner (c2 / cell 
                                    :mod (p / progenitor))) 
                        :op2-of (a / and 
                              :op1 (a2 / antioxidant) 
                              :op3 (n2 / normal-02 
                                    :ARG1 (c / cell 
                                          :mod (e / epithelial) 
                                          :mod (b / bronchial)))) 
                        :part-of (e3 / effect 
                              :op1 (r / repair-01 
                                    :ARG1 (d / DNA))) 
                        :part-of "BC") 
                  :ARG2 (o / organization 
                        :name (n / name 
                              :op1 "NBEC")))) 
      :mod (c3 / cigarette))

# ::snt Inherited inter-individual variation in the function of these genes plays a role in determining risk for BC [ 4-6 ] .
# ::tok Inherited inter-individual variation in the function of these genes plays a role in determining risk for BC [ 4-6 ] .
# ::alignments 16-17|0.0.0.0.1.0 14-15|0.0.0.0.1 13-14|0.0.0.0 11-12|0.0.0 9-10|0.0 8-9|0.0.0.0.0 7-8|0.0.0.0.0.1 5-6|0.0.0.0.0.0 2-3|0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:47.329
(v / variation 
      :ARG0-of (p / play-02 
            :ARG1 (r2 / role 
                  :domain (d / determine-01 
                        :ARG0 (g / gene 
                              :ARG1-of (f / function-01) 
                              :mod (t / this)) 
                        :ARG1 (r / risk-01 
                              :ARG1 "BC")))) 
      :ARG1-of (i / inherit-01))

# ::snt Antioxidant enzymes protect NBEC from reactive oxygen species produced by interaction with and metabolism of xenobiotics such as pollution and cigarette smoke [ 4-7 ] as well as those produced by normal cellular metabolism .
# ::tok Antioxidant enzymes protect NBEC from reactive oxygen species produced by interaction with and metabolism of xenobiotics such as pollution and cigarette smoke [ 4-7 ] as well as those produced by normal cellular metabolism .
# ::alignments 33-34|0.0.2.0.0.0.0 32-33|0.0.2.0.0.0.0.1 31-32|0.0.2.0.0.0 29-30|0.0.2.0.0.0.0.0 21-22|0.2 20-21|0.2.0 19-20|0.1.0 18-19|0.1.0.2 16-17|0.1.0.1 15-16|0.1.0.0 13-14|0.1 12-13|0 10-11|0.0.2.0.0 8-9|0.0.2.0 7-8|0.0.2 6-7|0.0.2.1 5-6|0.1.0.2.0 3-4|0.0.1.0.0+0.0.1.0+0.0.1 2-3|0.0 1-2|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:47.949
(a2 / and 
      :op1 (p4 / protect-01 
            :ARG0 (e / enzym 
                  :mod (a3 / antioxidant)) 
            :ARG1 (o2 / organization 
                  :name (n2 / name 
                        :op1 "NBEC")) 
            :ARG2 (s3 / species 
                  :ARG1-of (p3 / produce-01 
                        :ARG0 (i / interact-01 
                              :ARG1 (n / normal-02 
                                    :ARG1 (m / metabolism 
                                          :ARG1-of (p / produce-01) 
                                          :mod (c / cell))))) 
                  :mod (o / oxygen))) 
      :op2 (m2 / metabolism 
            :example (a / and 
                  :example-of (x / xenobiotic) 
                  :op1 (s2 / such) 
                  :op2 (p2 / pollute-01 
                        :ARG1 (r / reactive)))) 
      :op3 (s / smoke-02 
            :ARG1 (c2 / cigarette)))

# ::snt Reactive oxygen species cause many damaging reactions including denaturation of proteins , cross-linking of lipids and proteins and modification of nucleic acid bases , which can lead to cancer [ 7 ] .
# ::tok Reactive oxygen species cause many damaging reactions including denaturation of proteins , cross-linking of lipids and proteins and modification of nucleic acid bases , which can lead to cancer [ 7 ] .
# ::alignments 30-31|0.0.1 28-29|0 26-27|0.0 25-26|0.0.2 22-23|0.0.0 21-22|0.0.0.1 18-19|0.0.0.0 17-18|0.0.0.0.0 16-17|0.0.0.0.0.2.0.0 15-16|0.0.0.0.0.2.0 14-15|0.0.0.0.0.2 12-13|0.0.0.0.0.1 10-11|0.0.0.0.0.0 8-9|0.0.0.0.0.0.0 6-7|0.0.0.0.0.0.0.0.0 5-6|0.0.0.0.0.0.0.0 4-5|0.0.0.0.0.0.0.0.0.1 3-4|0.0.0.0.0.0.0.0.0.0 2-3|0.0.0.0.0.0.0.0.0.0.0 1-2|0.0.0.0.0.0.0.0.0.0.0.0 0-1|0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:48.972
(c / cancer 
      :purpose-of (l / lead-03 
            :ARG0 (b / base 
                  :ARG1-of (m / modify-01 
                        :op4-of (a2 / and 
                              :op1 (p3 / protein 
                                    :mod-of (d / denaturation 
                                          :ARG1-of (d2 / damage-01 
                                                :ARG0 (r / react-01 
                                                      :ARG1-of (c3 / cause-01 
                                                            :ARG0 (s / species 
                                                                  :mod (o / oxygen))) 
                                                      :quant (m2 / many))))) 
                              :op2 (c2 / cross-link) 
                              :op3 (l2 / lipid 
                                    :op1-of (a3 / and 
                                          :op2 (p2 / protein))))) 
                  :mod (a / acid)) 
            :ARG1 7 
            :ARG1-of (p / possible-01 
                  :ARG0 (r2 / reactive))))

# ::snt DNA repair enzymes repair the frequent damage to DNA caused by oxidant stress as well as other stresses , including bulky adducts derived from carcinogens in cigarette smoke [ 8 ] .
# ::tok DNA repair enzymes repair the frequent damage to DNA caused by oxidant stress as well as other stresses , including bulky adducts derived from carcinogens in cigarette smoke [ 8 ] .
# ::alignments 29-30|0.0.0.0.0.0.0.0 27-28|0 26-27|0.0 24-25|0.0.0.0.2.0.0.0.1 22-23|0.0.0.0.2.0.0.0 21-22|0.0.0.0.2.0.0.0.0 20-21|0.0.0.0.2.0.0.0.0.0 17-18|0.0.0.0.1 16-17|0.0.0.0.1.0 12-13|0.0.0.0.0.0.0 11-12|0.0.0.0.0.0.0.1 9-10|0.0.0.0.0.0 8-9|0.0.0.0.0 6-7|0.0.0.0 5-6|0.0.0 3-4|0.0.0.0.2 2-3|0.0.0.0.2.0 1-2|0.0.0.0.2.0.0 0-1|0.0.0.0.2.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:49.458
(s / smoke 
      :mod (c / cigarette 
            :ARG0-of (f / frequent-02 
                  :ARG1 (d3 / damage-01 
                        :ARG1 (d2 / DNA 
                              :ARG1-of (c3 / cause-01 
                                    :ARG0 (s3 / stress-02 
                                          :ARG0 8 
                                          :ARG1 (o2 / oxidant)))) 
                        :ARG1-of (s2 / stress-01 
                              :mod (o / other)) 
                        :ARG1-of (r / repair-01 
                              :ARG0 (e / enzym 
                                    :mod (r2 / repair-01 
                                          :ARG1 (d / derive-01 
                                                :ARG1 (a / adduct 
                                                      :mod (b / bulky)) 
                                                :ARG2 (c2 / carcinogen)) 
                                          :mod (d4 / DNA))))))))

# ::snt We previously reported that an interactive transcript abundance index comprising antioxidant genes was lower in NBEC of BC individuals compared to non-BC individuals , suggesting that BC individuals are selected on the basis of poor antioxidant protection [ 9 ] .
# ::tok We previously reported that an interactive transcript abundance index comprising antioxidant genes was lower in NBEC of BC individuals compared to non-BC individuals , suggesting that BC individuals are selected on the basis of poor antioxidant protection [ 9 ] .
# ::alignments 38-39|0.0.1.1.1.1.0 36-37|0.0.1.1.1.1.1.0.0.0 35-36|0.0.1.1.1.1.1.0.0.0.0 34-35|0.0.1.1.1.0 29-30|0.0.1.1.1.1.1 27-28|0.0.1.1.1.1.1.0 26-27|0.0.1.1.1.1.1.0.0 24-25|0.0.1.1.1.1 22-23|0.0.1.1.1.1.1.0.0.0.1 19-20|0.0.1.1.1.1.1.0.0.0.1.0 18-19|0.0.1.1.1.1.1.0.0.0.1.0.0 17-18|0.0.1.1.1.1.1.0.0.0.1.0.0.0 15-16|0.0.1.1.1.2.0.0+0.0.1.1.1.2.0+0.0.1.1.1.2 13-14|0.0.1.1.1 11-12|0.1 10-11|0.1.0 9-10|0 8-9|0.0 7-8|0.0.0 6-7|0.0.1.0+0.0.1 5-6|0.0.2 2-3|0.0.1.1 1-2|0.0.1.1.2 0-1|0.0.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:51.476
(c2 / comprise-01 
      :ARG1 (i4 / index 
            :mod (a3 / abundance) 
            :mod (t / thing 
                  :ARG1-of (t2 / transcribe-01) 
                  :ARG2-of (r / report-01 
                        :ARG0 (w / we) 
                        :ARG1 (l / low-04 
                              :ARG0 (p2 / poor) 
                              :ARG1 (s2 / suggest-01 
                                    :ARG0 9 
                                    :ARG1 (s / select-01 
                                          :ARG1 (i / individual 
                                                :mod (B / "BC" 
                                                      :ARG0-of (p / protect-01 
                                                            :ARG1 (a / antioxidant) 
                                                            :mod (i2 / individual 
                                                                  :ARG2-of (c / compare-01 
                                                                        :ARG0 (i3 / individual 
                                                                              :mod "BC")))))))) 
                              :ARG2 (o / organization 
                                    :name (n / name 
                                          :op1 "NBEC"))) 
                        :time (p3 / previous))) 
            :mod (i5 / interactive)) 
      :ARG2 (g / gene 
            :mod (a2 / antioxidant)))

# ::snt In that study , there was a tendency towards correlation in transcript abundance between several pairs of antioxidant or DNA repair genes in non-BC individuals , but not in BC individuals .
# ::tok In that study , there was a tendency towards correlation in transcript abundance between several pairs of antioxidant or DNA repair genes in non-BC individuals , but not in BC individuals .
# ::alignments 30-31|0.0.0.1.0.0.0 29-30|0.0.0.1.0.0 27-28|0.0.0.4.0.0 26-27|0 24-25|0.0.0.4.0.1 21-22|0.0.0.0.0 20-21|0.0.0.4.0 19-20|0.0.0.4 18-19|0.0.0 17-18|0.0 15-16|0.0.0.0 14-15|0.0.0.0.1 12-13|0.0.0.3.1 11-12|0.0.0.3.0+0.0.0.3 9-10|0.0.0.2 7-8|0.0.0.1 2-3|0.0.0.1.0 1-2|0.0.0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:52.027
(c / contrast-01 
      :ARG1 (a / antioxidant 
            :op2-of (o / or 
                  :ARG2-of (p / pair-01 
                        :ARG1 (g / gene) 
                        :quant (s / several)) 
                  :example-of (t3 / tendency 
                        :ARG0-of (s2 / study-01 
                              :ARG1 (B / "BC" 
                                    :mod-of (i / individual)) 
                              :mod (t4 / that))) 
                  :example-of (c2 / correlation) 
                  :op1 (t / thing 
                        :ARG1-of (t2 / transcribe-01) 
                        :mod-of (a2 / abundance)) 
                  :op3 (d / DNA 
                        :mod-of (r / repair-01 
                              :ARG1 - 
                              :ARG3 (i2 / individual))))))

# ::snt Gene pairs included in that observation were GSTP1/GPX1 , CAT/GPX3 , and GPX3/SOD1 .
# ::tok Gene pairs included in that observation were GSTP1/GPX1 , CAT/GPX3 , and GPX3/SOD1 .
# ::alignments 12-13|0.1.0.0+0.1.0+0.1 11-12|0 5-6|0.0.1.0 4-5|0.0.1.0.0 2-3|0.0.1 1-2|0.0 0-1|0.0.0.0.0+0.0.0.0+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:52.146
(a / and 
      :op1 (p / pair-01 
            :ARG0 (p2 / person 
                  :name (n2 / name 
                        :op1 "Gene")) 
            :ARG1-of (i / include-01 
                  :ARG2 (o / observation 
                        :mod (t2 / that)))) 
      :op2 (t / thing 
            :name (n / name 
                  :op1 "GPX3/SOD1")))

# ::snt Correlation is one typical characteristic of co-regulated genes .
# ::tok Correlation is one typical characteristic of co-regulated genes .
# ::alignments 7-8|0.2 6-7|0.2.0 4-5|0 3-4|0.0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:52.168
(c2 / characteristic 
      :ARG1-of (t / typical-02) 
      :domain (c3 / correlation) 
      :mod (g / gene 
            :part-of (c / co-regulat)))

# ::snt Another is shared transcription factor recognition sites in the regulatory regions of those genes [ 10 ] .
# ::tok Another is shared transcription factor recognition sites in the regulatory regions of those genes [ 10 ] .
# ::alignments 15-16|0.0.0.1 13-14|0.0.0.0.1 10-11|0.0.0.0 9-10|0.0.0.0.0 6-7|0.0 5-6|0 4-5|0.1 3-4|0.0.1 2-3|0.0.0 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:52.339
(r3 / recognize-01 
      :ARG0 (s / site 
            :ARG1-of (s2 / share-01 
                  :ARG2 (r / region 
                        :ARG1-of (r2 / regulate-01) 
                        :part-of (g / gene)) 
                  :op1-of 10) 
            :location-of (t / transcription) 
            :mod (a / another)) 
      :ARG1 (f / factor))

# ::snt Based on the above findings , it was hypothesized first , that there is inter-individual variation in regulation of key antioxidant and DNA repair genes by one or more transcription factors and second , that individuals with sub-optimal regulation are selected for development of BC if they smoke cigarettes .
# ::tok Based on the above findings , it was hypothesized first , that there is inter-individual variation in regulation of key antioxidant and DNA repair genes by one or more transcription factors and second , that individuals with sub-optimal regulation are selected for development of BC if they smoke cigarettes .
# ::alignments 48-49|0.1.0.0.0.1.2.2.0.0.0 47-48|0.1.0.0.0.1.2.2.0.0 46-47|0.1.0.0.0.1.2.2.0 44-45|0.1.0.0.0.1.2.0 42-43|0.1.0.0.0.1.2 40-41|0.1.0.0.0.1.2.2 38-39|0.1.0.0.0.1.2.1.0 35-36|0.1.0.0.0.1.2.1 31-32|0.1.0.0 30-31|0.1.0 29-30|0.1 28-29|0.0 27-28|0 24-25|0.1.0.0.0.1.1 23-24|0.1.0.0.0.1.1.0 22-23|0.1.0.0.0.1.1.0.1 21-22|0.1.0.0.0.1 20-21|0.1.0.0.0.0 19-20|0.1.0.0.0.0.0 17-18|0.1.0.0.0 15-16|0.1.0.0.0.1.0 8-9|0.1.0.0.0.0.0.0 4-5|0.1.0.0.0.0.0.0.0.0.0+0.1.0.0.0.0.0.0.0.0 3-4|0.1.0.0.0.1.1.0.0 0-1|0.1.0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:53.442
(o / or 
      :op1 (m / more) 
      :op2 (t2 / transcription 
            :mod-of (f / factor 
                  :op1-of (a / and 
                        :ARG0-of (r3 / regulate-01 
                              :ARG1 (a3 / antioxidant 
                                    :ARG1-of (k / key-02 
                                          :ARG1-of (h / hypothesize-01 
                                                :ARG1-of (b / base-02 
                                                      :ARG2 (t3 / thing 
                                                            :ARG1-of (f2 / find-01)))))) 
                              :op1-of (a2 / and 
                                    :example-of (v / variation) 
                                    :op2 (g / gene 
                                          :mod (r2 / repair-01 
                                                :ARG1 (a4 / above) 
                                                :mod (d2 / DNA))) 
                                    :op3 (d / develop-02 
                                          :ARG1 "BC" 
                                          :ARG2 (i / individual 
                                                :ARG1-of (r / regulate-01)) 
                                          :ARG3-of (s2 / select-01 
                                                :ARG1 (t / they 
                                                      :ARG0-of (s / smoke-02 
                                                            :ARG1 (c / cigarette)))))))))))

# ::snt To test these hypotheses , transcription factor recognition sites common to the regulatory regions of the above correlated gene pairs were identified through in silico DNA sequence analysis , and their transcript abundance measured simultaneously with an expanded group of ten antioxidant and six DNA repair genes .
# ::tok To test these hypotheses , transcription factor recognition sites common to the regulatory regions of the above correlated gene pairs were identified through in silico DNA sequence analysis , and their transcript abundance measured simultaneously with an expanded group of ten antioxidant and six DNA repair genes .
# ::alignments 46-47|0.0.1.0.1.1.2.1 45-46|0.0.1.0.1.1.2.0.0 44-45|0.0.1.0.1.1.2.0.0.0 43-44|0.0.1.0.1.1.2.1.0 42-43|0.0.1.0.1.1.2 41-42|0.0.1.0.1.1.2.0 38-39|0.0.1.0.1.1.1 37-38|0.0.1.0.1.1.1.0 34-35|0.0.1.0.1.1.0.2 33-34|0.0.1.0.1.1.0 32-33|0.0.1.0.1.1.0.1 31-32|0.0.1.0.1.1.0.1.0.0+0.0.1.0.1.1.0.1.0 29-30|0.0.1.0.1.1 27-28|0.0.1.0.1.0 26-27|0.0.1.0.1.1.0.0 25-26|0.0.1.0.1.0.1 21-22|0.0.1.0.1 19-20|0.0.1.0.1.0.1.0 18-19|0.0.1.0.1.0.1.0.0 17-18|0.0.1.0.1.0.1.0.1 16-17|0.0.1.0.1.1.1.0.0 13-14|0.0.1.0 12-13|0.0.1.0.0 9-10|0.0.1 8-9|0.0 7-8|0 6-7|0.1 5-6|0.0.1.0.1.0.0 3-4|0.1.0.0+0.1.0 2-3|0.0.1.0.0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:55.317
(r4 / recognize-01 
      :ARG0 (s3 / site 
            :ARG1-of (t6 / test-01) 
            :mod (c2 / common 
                  :beneficiary (r2 / region 
                        :ARG1-of (r3 / regulate-01 
                              :ARG0 (t5 / this)) 
                        :ARG1-of (i / identify-01 
                              :manner (a5 / analyze-01 
                                    :ARG0 (t3 / transcription) 
                                    :ARG1 (d2 / DNA 
                                          :ARG0-of (p / pair-01 
                                                :ARG1 (g3 / gene) 
                                                :ARG1-of (c / correlate-01)))) 
                              :op1-of (a4 / and 
                                    :op2 (m / measure-01 
                                          :ARG0 (s2 / sequence) 
                                          :ARG1 (a3 / abundance 
                                                :mod (t / thing 
                                                      :ARG1-of (t2 / transcribe-01))) 
                                          :manner (s / simultaneous)) 
                                    :op3 (g2 / group 
                                          :ARG0-of (e / expand-01 
                                                :ARG1 (a6 / above))) 
                                    :op4 (a / and 
                                          :op1 (a2 / antioxidant 
                                                :part (r / repair-01 
                                                      :ARG1 (d / DNA))) 
                                          :op2 (g / gene 
                                                :quant 6))))))) 
      :ARG1 (f / factor 
            :mod-of (t4 / thing 
                  :ARG1-of (h / hypothesize-01))))

# ::snt Brush biopsy samples of normal bronchial epithelium were obtained for research studies at the time of diagnostic bronchoscopy according to previously described methods [ 9,11 ] .
# ::tok Brush biopsy samples of normal bronchial epithelium were obtained for research studies at the time of diagnostic bronchoscopy according to previously described methods [ 9,11 ] .
# ::alignments 22-23|0.0 21-22|0.0.0 20-21|0.0.0.0 18-19|0 17-18|0.1.2.0 16-17|0.1.2.0.0 14-15|0.1.2 11-12|0.1.1 10-11|0.1.1.0 8-9|0.1 6-7|0.1.0.1.1 5-6|0.1.0.1.1.1 4-5|0.1.0.1.1.0 2-3|0.1.0.1+0.1.0 1-2|0.1.0.1.0 0-1|0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:55.746
(s / say-01 
      :ARG0 (m / method 
            :ARG1-of (d / describe-01 
                  :time (p / previous))) 
      :ARG1 (o / obtain-01 
            :ARG1 (t2 / thing 
                  :ARG1-of (b4 / brush-01) 
                  :ARG1-of (s3 / sample-01 
                        :ARG0 (b3 / biopsy) 
                        :ARG2 (e / epithelium 
                              :ARG1-of (n / normal-02) 
                              :mod (b2 / bronchial)))) 
            :ARG2 (s2 / study-01 
                  :ARG1 (r / research-01)) 
            :time (t / time 
                  :part-of (b / bronchoscopy 
                        :mod (d2 / diagnostic)))))

# ::snt Normal bronchial epithelium in the lung not involved with cancer was brushed prior to biopsy of the suspected cancerous area .
# ::tok Normal bronchial epithelium in the lung not involved with cancer was brushed prior to biopsy of the suspected cancerous area .
# ::alignments 19-20|0.0 18-19|0 17-18|0.0.0 14-15|0.0.1 12-13|0.0.1.0 11-12|0.0.1.0.0 9-10|0.0.1.0.0.0 7-8|0.0.1.0.0.0.0 6-7|0.0.1.0.0.0.0.1 5-6|0.0.1.0.0.0.0.0 2-3|0.0.1.0.0.1 1-2|0.0.1.0.0.1.0 0-1|0.0.1.0.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:55.956
(c / cancerou 
      :mod-of (a / area 
            :ARG1-of (s / suspect-01) 
            :poss-of (b / biopsy 
                  :op1-of (p / prior 
                        :manner-of (b2 / brush-off-02 
                              :ARG0 (c2 / cancer 
                                    :ARG2-of (i / involve-01 
                                          :ARG1 (l / lung) 
                                          :polarity -)) 
                              :ARG1 (e / epithelium 
                                    :mod (b3 / bronchial) 
                                    :mod (n / normal)))))))

# ::snt Samples were collected in a manner satisfying all requirements of the Institutional Review Board for the Medical University of Ohio .
# ::tok Samples were collected in a manner satisfying all requirements of the Institutional Review Board for the Medical University of Ohio .
# ::alignments 16-20|0.2.0.0.0.0.1.0.3+0.2.0.0.0.0.1.0.2+0.2.0.0.0.0.1.0.1+0.2.0.0.0.0.1.0.0+0.2.0.0.0.0.1.0+0.2.0.0.0.0.1 11-14|0.2.0.0.0.0.0.2+0.2.0.0.0.0.0.1+0.2.0.0.0.0.0.0+0.2.0.0.0.0.0+0.2.0.0.0.0 8-9|0.2.0.0.0+0.2.0.0 7-8|0.2.1 6-7|0.2.0+0.2 5-6|0.1 2-3|0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:56.720
(c / collect-01 
      :ARG1 (s2 / sample-01) 
      :ARG2 (m / manner) 
      :consist-of (p / person 
            :ARG0-of (s / satisfy-01 
                  :ARG1 (t / thing 
                        :ARG1-of (r / require-01 
                              :ARG0 (o2 / organization 
                                    :name (n2 / name 
                                          :op1 "Institutional" 
                                          :op2 "Review" 
                                          :op3 "Board") 
                                    :part-of (o / organization 
                                          :name (n / name 
                                                :op1 "Medical" 
                                                :op2 "University" 
                                                :op3 "of" 
                                                :op4 "Ohio")))))) 
            :quant (a / all)))

# ::snt Each BC diagnosis and subtype identification was determined by histopathological examination in the Department of Pathology at the Medical University of Ohio .
# ::tok Each BC diagnosis and subtype identification was determined by histopathological examination in the Department of Pathology at the Medical University of Ohio .
# ::alignments 18-22|0.0.1.1.0.3+0.0.1.1.0.2+0.0.1.1.0.1+0.0.1.1.0.0+0.0.1.1.0+0.0.1.1 13-16|0.0.1.0.2+0.0.1.0.1+0.0.1.0.0+0.0.1.0+0.0.1 10-11|0.0 9-10|0.0.0 7-8|0 5-6|0.1.2 4-5|0.1.2.0 3-4|0.1 2-3|0.1.1 1-2|0.1.1.0 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:57.054
(d / determined-02 
      :ARG0 (e / examine-01 
            :ARG0 (h / histopathological) 
            :ARG1 (o2 / organization 
                  :name (n2 / name 
                        :op1 "Department" 
                        :op2 "of" 
                        :op3 "Pathology") 
                  :part-of (o / organization 
                        :name (n / name 
                              :op1 "Medical" 
                              :op2 "University" 
                              :op3 "of" 
                              :op4 "Ohio")))) 
      :ARG1 (a / and 
            :mod (e2 / each) 
            :op1 (d2 / diagnosi 
                  :mod "BC") 
            :op2 (i / identify-02 
                  :ARG1 (s / subtype))))

# ::snt NBEC samples from a total of 49 individuals , including 24 non-BC individuals and 25 BC individuals , were evaluated in this study .
# ::tok NBEC samples from a total of 49 individuals , including 24 non-BC individuals and 25 BC individuals , were evaluated in this study .
# ::alignments 22-23|0.0 21-22|0.0.1 19-20|0.0.0 16-17|0.2 15-16|0.2.0 14-15|0.2.1 13-14|0 12-13|0.1 10-11|0.1.0 7-8|0.0.0.0.0.1.0 6-7|0.0.0.0.0.1.0.0 4-5|0.0.0.0.0.1 1-2|0.0.0.0.0+0.0.0.0 0-1|0.0.0.0.0.0.0.0+0.0.0.0.0.0.0+0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:57.184
(a / and 
      :ARG1-of (s / study-01 
            :ARG2-of (e / evaluate-01 
                  :ARG1 (t3 / thing 
                        :ARG1-of (s2 / sample-01 
                              :ARG0 (o / organization 
                                    :name (n / name 
                                          :op1 "NBEC")) 
                              :ARG2 (t2 / total-01 
                                    :ARG1 (i3 / individual 
                                          :quant 49))))) 
            :mod (t / this)) 
      :op1 (i2 / individual 
            :quant 24) 
      :op2 (i / individual 
            :mod "BC" 
            :quant 25))

# ::snt The biographical characteristics of these individuals are presented in Table 1 .
# ::tok The biographical characteristics of these individuals are presented in Table 1 .
# ::alignments 10-11|0.0.0 9-10|0.0 7-8|0 5-6|0.1.0.0 4-5|0.1.0.0.0 2-3|0.1.0+0.1 1-2|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:57.222
(p / present-01 
      :ARG0 (t / table 
            :mod 1) 
      :ARG1 (t3 / thing 
            :ARG2-of (c / characteristic-02 
                  :ARG1 (i / individual 
                        :mod (t2 / this))) 
            :mod (b / biographical)))

# ::snt Total RNA samples extracted from NBEC were reverse transcribed using M-MLV reverse transcriptase and oligo dT primers as previously described [ 9,11 ] .
# ::tok Total RNA samples extracted from NBEC were reverse transcribed using M-MLV reverse transcriptase and oligo dT primers as previously described [ 9,11 ] .
# ::alignments 19-20|0.0.1 18-19|0.0.1.0 16-17|0.0.3.0.0 13-14|0.0.3.0 12-13|0.0.3.1 11-12|0.0.3.1.0 10-11|0.0.3.1.0.0.0.0+0.0.3.1.0.0.0+0.0.3.1.0.0 9-10|0.0.3 8-9|0.0.3.2 7-8|0.0.3.2.0 5-6|0.0.2.0.0.0+0.0.2.0.0+0.0.2.0 3-4|0.0.2 2-3|0+0.0 1-2|0.0.4 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:58.294
(s / sample-01 
      :ARG1 (t4 / thing 
            :ARG1-of (t5 / total-01) 
            :ARG1-of (d / describe-01 
                  :time (p / previous)) 
            :ARG1-of (e / extract-01 
                  :ARG2 (o / organization 
                        :name (n2 / name 
                              :op1 "NBEC"))) 
            :ARG2-of (u / use-01 
                  :ARG0 (a / and 
                        :op1 (p2 / primer)) 
                  :ARG1 (t / transcriptase 
                        :ARG0-of (r / reverse-01 
                              :ARG1 (t2 / thing 
                                    :name (n / name 
                                          :op1 "M-MLV")))) 
                  :ARG1-of (t3 / transcribe-01 
                        :ARG1-of (r2 / reverse-01))) 
            :mod (r3 / rna)))

# ::snt Standardized RT ( StaRT ) - PCR was used for transcript abundance measurement in these studies .
# ::tok Standardized RT ( StaRT ) - PCR was used for transcript abundance measurement in these studies .
# ::alignments 15-16|0.1.0 14-15|0.1.0.1 12-13|0.1 11-12|0.1.2 10-11|0.1.1.0+0.1.1 8-9|0 3-4|0.1.0.0 0-2|0.0.0.1+0.0.0.0+0.0.0+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:58.720
(u / use-01 
      :ARG1 (t4 / thing 
            :name (n / name 
                  :op1 (s3 / Standardized) 
                  :op2 (r / RT))) 
      :ARG2 (m / measure-01 
            :ARG0 (s / study-01 
                  :ARG1-of (s2 / start-01) 
                  :mod (t / this)) 
            :ARG1 (t2 / thing 
                  :ARG1-of (t3 / transcribe-01)) 
            :mod (a / abundance)))

# ::snt With StaRT-PCR , an internal standard for each gene within a standardized mixture of internal standards ( SMIS ) is included in each PCR reaction .
# ::tok With StaRT-PCR , an internal standard for each gene within a standardized mixture of internal standards ( SMIS ) is included in each PCR reaction .
# ::alignments 24-25|0.2 22-23|0.2.1 20-21|0 17-18|0.2.0.0.0 15-16|0.0 14-15|0.0.0 12-13|0.0.1 11-12|0.0.1.0 8-9|0.2.0.1 7-8|0.2.0.1.0 5-6|0.2.0 4-5|0.2.0.0 1-2|0.1.0.0+0.1.0+0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:11:58.941
(i / include-01 
      :ARG1 (s2 / standard 
            :ARG1-of (i2 / internal-02) 
            :consist (m / mixture 
                  :ARG1-of (s3 / standardize-01))) 
      :ARG2 (t / thing 
            :name (n / name 
                  :op1 "StaRT-PCR")) 
      :manner (r / react-01 
            :ARG1 (s4 / standard 
                  :mod (i3 / internal-02 
                        :ARG1 (s / smi)) 
                  :mod (g / gene 
                        :mod (e2 / each))) 
            :mod (e / each)))

# ::snt After amplification , products were electrophoresed on an Agilent 2100 Bioanalyzer using DNA Chips with DNA 1000 Kit reagents for visualization according to the manufacturer 's protocol ( Agilent Technologies Deutschland GmbH , Waldbronn , Germany ) .
# ::tok After amplification , products were electrophoresed on an Agilent 2100 Bioanalyzer using DNA Chips with DNA 1000 Kit reagents for visualization according to the manufacturer 's protocol ( Agilent Technologies Deutschland GmbH , Waldbronn , Germany ) .
# ::alignments 35-36|0.1.0.0.1+0.1.0.0.0.0+0.1.0.0.0+0.1.0.0 33-34|0.1.1.0.0.0+0.1.1.0.0+0.1.1.0 28-32|0.0.0.0.0.3+0.0.0.0.0.2+0.0.0.0.0.1+0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 26-27|0.0 24-25|0.0.0 21-22|0 20-21|0.0.0.1 18-19|0.1 17-18|0.1.1.1.0+0.1.1.1+0.1.1 16-17|0.1.1.2 15-16|0.1.2 13-14|0.1.0 12-13|0.1.0.1 11-12|0.1.0.2 10-11|0.1.0.2.0 9-10|0.1.0.2.0.0.0+0.1.0.2.0.0 8-9|0.1.0.2.0.1.0.0+0.1.0.2.0.1.0+0.1.0.2.0.1 3-4|0.1.0.2.1 1-2|0.0.0.2 0-1|0.0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:00.279
(s / say-01 
      :ARG0 (p / protocol 
            :poss (m / manufacture-01 
                  :ARG0 (o / organization 
                        :name (n3 / name 
                              :op1 "Agilent" 
                              :op2 "Technologies" 
                              :op3 "Deutschland" 
                              :op4 "GmbH")) 
                  :ARG1 (v / visualization) 
                  :ARG2 (a / amplification 
                        :op1-of (a2 / after)))) 
      :location (r / reagent 
            :ARG2-of (c3 / chip-01 
                  :ARG0 (c / country 
                        :name (n / name 
                              :op1 "Germany") 
                        :wiki "Germany") 
                  :ARG1 (d2 / DNA) 
                  :ARG1-of (u / use-01 
                        :ARG0 (b / bioanalyz 
                              :mod (d3 / date-entity 
                                    :year 2100) 
                              :mod (o2 / organization 
                                    :name (n5 / name 
                                          :op1 "Agilent"))) 
                        :ARG2 (p3 / product))) 
            :mod (p2 / person 
                  :mod (c2 / country 
                        :name (n2 / name 
                              :op1 "Waldbronn")) 
                  :name (n4 / name 
                        :op1 "Kit") 
                  :quant 1000) 
            :mod (d / DNA)))

# ::snt The StaRT-PCR technology is licensed to Gene Express , Inc. ( Toledo , OH ) .
# ::tok The StaRT-PCR technology is licensed to Gene Express , Inc. ( Toledo , OH ) .
# ::alignments 13-14|0+0.0+0.0.0 11-12|0.0.1.1.0 9-10|0.0.1.1.2.0.0+0.0.1.1.2.0+0.0.1.1.2 6-8|0.0.1.0.1+0.0.1.0.0+0.0.1.0+0.0.1 4-5|0.0.1.1 2-3|0.0.1.1.1 1-2|0.0.1.1.1.0.0.0+0.0.1.1.1.0.0+0.0.1.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:00.503
(o / OH 
      :ARG2-of (h / have-rel-role-91 
            :ARG0 (p / person) 
            :ARG1 (p2 / person 
                  :name (n2 / name 
                        :op1 "Gene" 
                        :op2 "Express") 
                  :purpose-of (l / license-01 
                        :ARG0 (t / toledo) 
                        :ARG1 (t2 / technology 
                              :mod (t3 / thing 
                                    :name (n3 / name 
                                          :op1 "StaRT-PCR"))) 
                        :ARG2 (o2 / organization 
                              :name (n / name 
                                    :op1 "Inc."))))))

# ::snt Many of the reagents are available commercially and were obtained through Gene Express , Inc. for this study .
# ::tok Many of the reagents are available commercially and were obtained through Gene Express , Inc. for this study .
# ::alignments 17-18|0.1.0 16-17|0.1.0.0 11-13|0.2.0.1+0.2.0.0+0.2.0+0.2 9-10|0.1 7-8|0 6-7|0.0.1 5-6|0.0 3-4|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:00.562
(a / and 
      :op1 (a2 / available-02 
            :ARG1 (r / reagent 
                  :quant (m / many)) 
            :location (c / commercial)) 
      :op2 (o / obtain-01 
            :purpose (s / study-01 
                  :mod (t / this))) 
      :op3 (p / person 
            :name (n / name 
                  :op1 "Gene" 
                  :op2 "Express")))

# ::snt StaRT-PCR reagents for each of the measured genes that were not commercially available , including primers and SMIS , were prepared according to previously described methods [ 11,12 ] .
# ::tok StaRT-PCR reagents for each of the measured genes that were not commercially available , including primers and SMIS , were prepared according to previously described methods [ 11,12 ] .
# ::alignments 25-26|0.0 24-25|0.0.0 23-24|0.0.0.1 21-22|0 20-21|0.1 17-18|0.2.1 16-17|0.2 15-16|0.2.0 12-13|0.0.0.0 11-12|0.0.0.0.0 10-11|0.0.0.0.1 7-8|0.0.0.0.2 6-7|0.0.0.0.2.0 3-4|0.0.0.0.2.1 1-2|0.1.0 0-1|0.1.0.0.0.0+0.1.0.0.0+0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:01.496
(s / say-01 
      :ARG0 (m / method 
            :ARG1-of (d / describe-01 
                  :ARG1-of (a2 / available-02 
                        :manner (c / commercial) 
                        :polarity - 
                        :time (g / gene 
                              :ARG1-of (m2 / measure-01) 
                              :mod (e / each))) 
                  :time (p / previous))) 
      :ARG1 (p2 / prepare-02 
            :ARG1 (r / reagent 
                  :mod (t / thing 
                        :name (n / name 
                              :op1 "StaRT-PCR")))) 
      :op3-of (a / and 
            :op1 (p3 / primer) 
            :op2 (s2 / smi)))

# ::snt Sequence information for the primers is provided in Table 2 .
# ::tok Sequence information for the primers is provided in Table 2 .
# ::alignments 9-10|0.0.0 8-9|0.0 6-7|0 4-5|0.1.1 1-2|0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:01.523
(p / provide-01 
      :ARG0 (t / table 
            :mod 2) 
      :ARG1 (i / information 
            :poss (s / sequence) 
            :topic (p2 / primer)))

# ::snt Including an internal standard within a SMIS in each measurement controls for all known sources of variation during PCR , including inhibitors in samples , and generates virtually-multiplexed transcript abundance data that are directly comparable across multiple experiments and institutions [ 13 ] .
# ::tok Including an internal standard within a SMIS in each measurement controls for all known sources of variation during PCR , including inhibitors in samples , and generates virtually-multiplexed transcript abundance data that are directly comparable across multiple experiments and institutions [ 13 ] .
# ::alignments 41-42|0.0.1.2.1.0.0.0.0 39-40|0.0.1.2.1.0.1.0 38-39|0.0.1.2.1.0.1 37-38|0.0.1.2.1.0 36-37|0.0.1.2.1.0.1.0.0 35-36|0.0.1.2.1.0.0 34-35|0.0.1.2.1.0.0.0 33-34|0.0.1.2.1.0.0.0.1 30-31|0.0.1.2.1 29-30|0.0.1.2.1.2 28-29|0.0.1.2.1.3.0+0.0.1.2.1.3 27-28|0.0.1.2.1.1 26-27|0.0.1.2 25-26|0.0.1 23-24|0+0.0 21-22|0.0.0 16-17|0.0.1.1 14-15|0.0.1.0.0 13-14|0.0.1.0 12-13|0.0.1.2.1.0.0.0.1.0.0.0 10-11|0.0.1.2.1.0.0.0.1.0.0 9-10|0.0.1.2.1.0.0.0.1.0 8-9|0.0.1.2.1.0.0.0.1.0.0.1 6-7|0.0.1.2.0 3-4|0.0.1.0.1.0 2-3|0.0.1.0.1.0.0 0-1|0.0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:03.333
(s / sample-01 
      :ARG1 (t3 / thing 
            :location-of (i2 / inhibitor) 
            :op2-of (a4 / and 
                  :ARG3-of (k / know-02 
                        :ARG1 (s2 / source) 
                        :manner-of (i4 / include-01 
                              :ARG2 (s4 / standard 
                                    :mod (i3 / internal-02)))) 
                  :op1 (v2 / variation) 
                  :op3 (g / generate-01 
                        :ARG0 (s3 / smi) 
                        :ARG1 (d2 / data 
                              :ARG1-of (e / experiment-01 
                                    :op1-of (a2 / across 
                                          :location-of (c / comparable-03 
                                                :ARG1 13 
                                                :ARG1-of (d / direct-02 
                                                      :ARG1-of (m2 / measure-01 
                                                            :ARG1-of (c2 / control-01 
                                                                  :ARG0 (a5 / all) 
                                                                  :mod (e2 / each)))))) 
                                    :op1-of (a / and 
                                          :op2 (i / institution 
                                                :quant (m / multiple)))) 
                              :mod (v / virtually-multiplex) 
                              :source (a3 / abundance) 
                              :source (t / thing 
                                    :ARG1-of (t2 / transcribe-01)))))))

# ::snt The performance characteristics of StaRT-PCR are superior to other forms of commercially available quantitative PCR technology in the areas critical to this study .
# ::tok The performance characteristics of StaRT-PCR are superior to other forms of commercially available quantitative PCR technology in the areas critical to this study .
# ::alignments 22-23|0.0.0.1.0.0.1.1.0.0 21-22|0.0.0.1.0.0.1.1.0.0.0 19-20|0.0.0.1.0.0.1.1.0 18-19|0.0.0.1.0.0.1.1 15-16|0.0.0.1.0.0.1 13-14|0 12-13|0.0.0.1.0.0.1.0 11-12|0.0.0.1.0.0.1.0.0 9-10|0.0.0.1.0.0 8-9|0.0.0.1.0.0.0 6-7|0.0.0.1.0 4-5|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 2-3|0.0.0+0.0.0.1 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:03.753
(q / quantitative 
      :ARG1-of (p / perform-02 
            :purpose-of (c3 / characteristic-02 
                  :ARG1 (t3 / thing 
                        :name (n / name 
                              :op1 "StaRT-PCR")) 
                  :ARG2 (t4 / thing 
                        :ARG1-of (s2 / superior-01 
                              :prep-to (f / form 
                                    :mod (o / other) 
                                    :mod-of (t2 / technology 
                                          :ARG2-of (a2 / available-02 
                                                :manner (c2 / commercial)) 
                                          :location (a / area 
                                                :ARG1-of (c / critical-02 
                                                      :ARG2 (s / study-01 
                                                            :mod (t / this)))))))))))

# ::snt With respect to these studies , the key property of a quantitative PCR method is not whether the PCR products are measured kinetically or at endpoint , but rather whether there are internal standards in each measurement or not .
# ::tok With respect to these studies , the key property of a quantitative PCR method is not whether the PCR products are measured kinetically or at endpoint , but rather whether there are internal standards in each measurement or not .
# ::alignments 38-39|0.1.1.0.0.0 37-38|0.1.0.0.0 36-37|0.1.0.0.0.1 35-36|0.1.0.0.0.0 33-34|0.1.0.0 32-33|0.1.0 27-28|0 25-26|0.0 23-24|0.1.1.0.1.0.1 21-22|0.1.1.0.1.0 19-20|0.1.1.0.1.0.0 15-16|0.1.0.0.0.1.0 13-14|0.1.1.0.1 12-13|0.1.1.0.1.1 11-12|0.1.1.0.1.2 8-9|0.1.1.0 7-8|0.1.1.0.0 4-5|0.1 3-4|0.1.2 1-2|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:04.076
(c / contrast-01 
      :ARG1 (e2 / endpoint) 
      :ARG2 (s2 / study-01 
            :ARG1 (i / internal-02 
                  :ARG1 (s / standard 
                        :op1-of (o / or 
                              :mod (e / each) 
                              :op2 (m / measure-01 
                                    :ARG1 -)))) 
            :ARG1-of (r / respect-01 
                  :ARG0 (p3 / property 
                        :ARG1-of (k / key-02 
                              :ARG0 -) 
                        :poss (m3 / method 
                              :ARG0-of (m2 / measure-01 
                                    :ARG1 (p / product) 
                                    :op1-of (o2 / or)) 
                              :mod (p2 / PCR) 
                              :mod (q / quantitative)))) 
            :mod (t / this)))

# ::snt The overall performance characteristics of StaRT-PCR , including extensive validation of the method in independent laboratories have been presented in several recent articles and chapters [ 13-15 ] .
# ::tok The overall performance characteristics of StaRT-PCR , including extensive validation of the method in independent laboratories have been presented in several recent articles and chapters [ 13-15 ] .
# ::alignments 24-25|0.1.0.0.0 23-24|0.1.0.0 22-23|0.1.0.1 21-22|0.1.0.1.1 20-21|0.1.0.1.0 18-19|0.1.0 15-16|0.0 14-15|0.2+0 12-13|0.1.1.2.0.0.0 9-10|0.1.1.2.0.0 8-9|0.1.1.2.0 5-6|0.1.1.0.0.0+0.1.1.0.0+0.1.1.0 3-4|0.1.1+0.1 2-3|0.1.1.2 1-2|0.1.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:04.945
(d / depend-01 
      :ARG0 (l / laboratory) 
      :ARG1 (t2 / thing 
            :ARG1-of (p / present-01 
                  :ARG0 (a / and 
                        :op1 (c / chapter)) 
                  :location (a2 / article 
                        :quant (s / several) 
                        :time (r / recent))) 
            :ARG2-of (c2 / characteristic-02 
                  :ARG1 (t / thing 
                        :name (n / name 
                              :op1 "StaRT-PCR")) 
                  :mod (o / overall) 
                  :purpose (p2 / perform-02 
                        :ARG1 (e / extensive-03 
                              :ARG1 (v / validation 
                                    :poss (m / method)))))) 
      :polarity -)

# ::snt With respect to the genes measured in this study , for each gene the StaRT-PCR reagents had lower detection threshold of less than 10 molecules , linear dynamic range of more than six orders of magnitude ( less than 10 to over 107 molecules ) , and signal-to-analyte response of 100 % .
# ::tok With respect to the genes measured in this study , for each gene the StaRT-PCR reagents had lower detection threshold of less than 10 molecules , linear dynamic range of more than six orders of magnitude ( less than 10 to over 107 molecules ) , and signal-to-analyte response of 100 % .
# ::alignments 51-52|0.3.2 50-51|0.3.2.0 48-49|0.3 46-47|0 43-44|0.3.1 42-43|0.5.0.0 39-40|0.2.0 37-38|0.3.0 35-36|0.2.2.0 33-34|0.2.1 32-33|0.2.1.0 30-31|0.2.2 28-29|0.2 27-28|0.2.3 26-27|0.2.4 24-25|0.1 23-24|0.5.2.1.0.0.0 21-22|0.4 19-20|0.5 18-19|0.5.0 17-18|0.5.1 15-16|0.5.2.0 14-15|0.0.0.0+0.0.0+0.0 12-13|0.5.2.1.0.0.1.0 11-12|0.5.2.1.0.0.1 8-9|0.5.2.1.0.0 7-8|0.5.2.1.0.0.2 5-6|0.5.2.1.0 4-5|0.5.2.1 1-2|0.5.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:08.092
(a / and 
      :op1 (t2 / thing 
            :name (n / name 
                  :op1 "StaRT-PCR")) 
      :op2 (m4 / molecule) 
      :op3 (r2 / range-01 
            :ARG0 10 
            :ARG1 (o / order 
                  :quant 6) 
            :ARG2 (m3 / more 
                  :quant-of (m2 / magnitude)) 
            :mod (d / dynamic) 
            :mod (l2 / linear)) 
      :op4 (r / respond-01 
            :ARG0 (l / less) 
            :ARG1 (m / molecule) 
            :ARG2 (p / percentage-entity 
                  :value 100)) 
      :quant (l3 / less) 
      :time (t / threshold 
            :ARG0-of (d2 / detect-01 
                  :ARG2 107) 
            :ARG1-of (l4 / low-04) 
            :ARG2-of (r4 / respect-01 
                  :ARG0 (r3 / reagent) 
                  :ARG1 (g2 / gene 
                        :ARG0-of (m5 / measure-01 
                              :ARG1 (s / study-01 
                                    :ARG0 10 
                                    :ARG1 (e / each 
                                          :mod-of (g / gene)) 
                                    :mod (t3 / this)))))))

# ::snt In addition , the presence of an internal standard controls for inter-sample variation in presence of PCR inhibitors ( which often are gene-specific ) and ensures no false negatives ( if the PCR fails the internal standard PCR product is not observed and there are no data to report ) .
# ::tok In addition , the presence of an internal standard controls for inter-sample variation in presence of PCR inhibitors ( which often are gene-specific ) and ensures no false negatives ( if the PCR fails the internal standard PCR product is not observed and there are no data to report ) .
# ::alignments 48-49|0.3.0 46-47|0.3 45-46|0.2.0 42-43|0 41-42|0.2 40-41|0.2.2 38-39|0.2.1 36-37|0.2.1.0 35-36|0.2.1.1 33-34|0.1 28-29|0.0.0 27-28|0.0.0.0 26-27|0.0.2 25-26|0.0 24-25|0.0.1 20-21|0.1.0 17-18|0.0.1.0.1.0.0 14-15|0.0.1.0.1.0 12-13|0.0.1.0.1 9-10|0.0.1.0 8-9|0.0.1.0.0.0 7-8|0.0.1.0.0.0.0 4-5|0.0.1.0.0 1-2|0.0.1.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:09.342
(a / and 
      :ARG0-of (e / ensure-01 
            :ARG1 (n / negative 
                  :mod (f2 / false)) 
            :op1-of (a2 / and 
                  :ARG1-of (c / control-01 
                        :ARG0 (p3 / presence 
                              :poss (s2 / standard 
                                    :mod (i3 / internal-02))) 
                        :ARG2 (v / variation 
                              :location (p2 / presence 
                                    :mod (i2 / inhibitor))) 
                        :manner (a3 / addition))) 
            :polarity -) 
      :op1 (f / fail-01 
            :ARG1 (o2 / often)) 
      :op2 (o / observe-01 
            :ARG0 - 
            :ARG1 (p / product 
                  :ARG1-of (s / standard-02) 
                  :ARG1-of (i / internal-02)) 
            :polarity -) 
      :op3 (d / data 
            :ARG1-of (r / report-01)))

# ::snt False positives are eliminated through use of a control PCR reaction with no cDNA in it .
# ::tok False positives are eliminated through use of a control PCR reaction with no cDNA in it .
# ::alignments 13-14|0.2.0.0 12-13|0.0 10-11|0.2.0 8-9|0.2.0.1 5-6|0.2 3-4|0 1-2|0.1 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:09.431
(e / eliminate-01 
      :ARG0 - 
      :ARG1 (p / positive 
            :mod (f / false)) 
      :ARG2 (u / use-01 
            :ARG1 (r / react-01 
                  :ARG1 (c / cdna) 
                  :mod (c2 / control-01))))

# ::snt More than 6,000 transcript abundance measurements were conducted in multiple experiments over two years to assess the six transcription factors and sixteen antioxidant and DNA repair genes in NBEC samples from 49 individuals ( 24 non-BC individuals and 25 BC individuals ) .
# ::tok More than 6,000 transcript abundance measurements were conducted in multiple experiments over two years to assess the six transcription factors and sixteen antioxidant and DNA repair genes in NBEC samples from 49 individuals ( 24 non-BC individuals and 25 BC individuals ) .
# ::alignments 40-41|0.5.1 39-40|0.5.1.0 38-39|0.5.1.1 37-38|0.5 36-37|0.5.0 34-35|0.5.0.0 32-33|0.4 31-32|0.4.0 29-30|0.0.2.0.0.0+0.0.2.0.0.0.0 28-29|0.0.2.0.0.1.0+0.0.2.0.0.1+0.0.2.0.0 26-27|0.3 25-26|0.2.0 24-25|0.2 23-24|0 22-23|0.1 20-21|0.0.2 19-20|0.0.1 18-19|0.0.1.0 17-18|0.0.1.1 15-16|0.0 13-14|0.2.0.0.0.0+0.2.0.0.0 12-13|0.2.0.0 10-11|0.0.3 9-10|0.0.3.0 7-8|0.0.2.0 5-6|0.0.0 4-5|0.0.0.1 3-4|0.0.0.0.0+0.0.0.0 0-1|0.0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:12.462
(a2 / and 
      :ARG2-of (a5 / assess-01 
            :ARG0 (m2 / measure-01 
                  :ARG0 (t4 / thing 
                        :ARG1-of (t5 / transcribe-01)) 
                  :ARG1 (a6 / abundance) 
                  :quant (m3 / more-than)) 
            :ARG1 (f / factor 
                  :mod (t2 / transcription) 
                  :quant 6) 
            :op1-of (a4 / and 
                  :ARG1-of (c / conduct-01 
                        :ARG0 (o / organization 
                              :ARG0-of (s / sample-01 
                                    :ARG1 (t / thing)) 
                              :name (n / name 
                                    :op1 "NBEC")))) 
            :purpose (e / experiment-01 
                  :quant (m / multiple))) 
      :op1 (a3 / antioxidant) 
      :op2 (d / DNA 
            :mod-of (r / repair-01 
                  :ARG1 (23 / 2 
                        :quant-of (t3 / temporal-quantity 
                              :unit (y / year))))) 
      :op3 (g / gene) 
      :op4 (i3 / individual 
            :quant 49) 
      :op5 (a / and 
            :op1 (i2 / individual 
                  :quant 24) 
            :op2 (i / individual 
                  :mod "BC" 
                  :quant 25)))

# ::snt Correlation of each of the six transcription factors with each of the antioxidant or DNA repair genes was determined by Pearson 's correlation following logarithmic transformation .
# ::tok Correlation of each of the six transcription factors with each of the antioxidant or DNA repair genes was determined by Pearson 's correlation following logarithmic transformation .
# ::alignments 25-26|0.0.0.0 24-25|0.0.0.0.1 23-24|0.0.0 22-23|0.0 20-21|0.0.1.1.0+0.0.1.1+0.0.1 18-19|0 16-17|0.0.1.0.1.1 15-16|0.0.1.0 14-15|0.0.1.0.0 13-14|0.0.1.0.1 12-13|0.0.1.0.1.0 9-10|0.0.1.0.1.0.0 7-8|0.0.0.0.0.0 6-7|0.0.0.0.0.0.0 5-6|0.0.0.0.0.0.1 2-3|0.0.0.0.0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:13.049
(d / determined-02 
      :ARG0 (c / correlation 
            :ARG1-of (f / follow-01 
                  :ARG2 (t / transform-01 
                        :ARG1 (e2 / each 
                              :mod-of (f2 / factor 
                                    :mod (t2 / transcription) 
                                    :quant 6)) 
                        :mod (l / logarithmic))) 
            :poss (o / organization 
                  :ARG1-of (r / repair-01 
                        :mod (d2 / DNA) 
                        :op2-of (o2 / or 
                              :op1 (a / antioxidant 
                                    :mod (e / each)) 
                              :op3 (g / gene))) 
                  :name (n / name 
                        :op1 "Pearson"))) 
      :ARG1 (c2 / correlation))

# ::snt The transformation was necessary due to the wide biological variation in expression of each gene among the individuals .
# ::tok The transformation was necessary due to the wide biological variation in expression of each gene among the individuals .
# ::alignments 17-18|0.1.0 14-15|0.0 13-14|0.0.0 11-12|0 9-10|0.1.1.0 8-9|0.1.1.0.0 7-8|0.1.1 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:13.136
(e2 / express-01 
      :ARG1 (g / gene 
            :mod (e / each)) 
      :ARG1-of (t / transform-01 
            :ARG0 (i / individual) 
            :purpose-of (w / wide-02 
                  :ARG1 (v / variation 
                        :mod (b / biology)))))

# ::snt Significance level was defined as p < 0.01 following Bonferroni adjustment for multiple comparison , specifically comparison of each of six transcription factors to each of the antioxidant or DNA repair genes .
# ::tok Significance level was defined as p < 0.01 following Bonferroni adjustment for multiple comparison , specifically comparison of each of six transcription factors to each of the antioxidant or DNA repair genes .
# ::alignments 31-32|0.3.0.0.1 30-31|0.3.0.0.0 29-30|0.3.0.0.0.1 28-29|0.3.0.0 27-28|0.3.0 24-25|0.3 22-23|0 21-22|0.1 20-21|0.2 18-19|0.0 16-17|0.0.0 15-16|0.0.0.0 13-14|0.0.0.0.0 12-13|0.0.0.0.0.0.0.0.0 10-11|0.0.0.0.0.0 8-9|0.0.0.0.0.0.1 5-6|0.3.0.0.0.0 3-4|0.0.0.0.0.0.0.0 1-2|0.0.0.0.0.0.0 0-1|0.0.0.0.0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:13.541
(f / factor 
      :mod (e2 / each 
            :ARG1-of (c / compare-01 
                  :ARG1-of (s / specific-02 
                        :ARG0 (c2 / compare-01 
                              :ARG1-of (a2 / adjust-01 
                                    :ARG0 (l / level 
                                          :ARG1-of (d2 / define-01 
                                                :ARG0 (m / multiple)) 
                                          :mod (s2 / significance)) 
                                    :ARG1-of (f2 / follow-01)))))) 
      :mod (t / transcription) 
      :quant 6 
      :topic (e / each 
            :mod-of (a / antioxidant 
                  :op1-of (o / or 
                        :op2 (r / repair-01 
                              :ARG1 (p / p) 
                              :mod (d / DNA)) 
                        :op3 (g / gene)))))

# ::snt Comparison for significant differences between pairs of correlation coefficients was done by Fisher 's Z-transformation test [ 16 ] .
# ::tok Comparison for significant differences between pairs of correlation coefficients was done by Fisher 's Z-transformation test [ 16 ] .
# ::alignments 17-18|0.0.0.0.0 15-16|0.0.0.0.2 14-15|0.0.0.0.3.0.0+0.0.0.0.3.0+0.0.0.0.3 12-13|0.0.0.0.2.0.0.0+0.0.0.0.2.0.0+0.0.0.0.2.0 10-11|0.0.0.0.4.0 8-9|0.0 7-8|0 5-6|0.0.0 3-4|0.0.0.0 2-3|0.0.0.0.1 0-1|0.0.0.0.4 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:13.874
(c2 / correlation 
      :mod-of (c / coefficient 
            :ARG1-of (p2 / pair-01 
                  :ARG1-of (d2 / differ-01 
                        :ARG0 16 
                        :ARG1-of (s / significant-02) 
                        :ARG2 (t / test-01 
                              :ARG1 (p / person 
                                    :name (n2 / name 
                                          :op1 "Fisher"))) 
                        :op1-of (t2 / thing 
                              :name (n / name 
                                    :op1 "Z-transformation")) 
                        :purpose-of (c3 / comparison 
                              :ARG1-of (d / do-02))))))

# ::snt Analysis of the relationship between virtually-multiplexed transcript abundance data for each gene with age was assessed by Pearson 's correlation , with gender by t-test , and with smoking history by ANOVA followed by Duncan 's test .
# ::tok Analysis of the relationship between virtually-multiplexed transcript abundance data for each gene with age was assessed by Pearson 's correlation , with gender by t-test , and with smoking history by ANOVA followed by Duncan 's test .
# ::alignments 36-37|0.0.2.0.1.1.0.0 34-35|0.0.2.0.1.1.0.0.0.1.0+0.0.2.0.1.1.0.0.0.1+0.0.2.0.1.1.0.0.0 32-33|0.0.2.0.1.1.0 31-32|0.0.2.0.1.1.1.0+0.0.2.0.1.1.1+0.0.2.0.1.1 29-30|0.0.2.0.1.1.0.0.0.0.0 28-29|0.0.2.0.1.1.0.0.0.0 26-27|0.0.2.0.1 24-25|0.0.1 22-23|0.0.2.0.1.0 19-20|0.0.2.0.0 17-18|0.0.2.0.0.0.0.0+0.0.2.0.0.0.0+0.0.2.0.0.0 15-16|0.0.2.0 13-14|0 11-12|0.0.2.0.1.1.0.0.1 10-11|0.0.2.0.1.1.0.0.1.0 8-9|0.0.0 7-8|0.0.0.1 6-7|0.0.0.2.0+0.0.0.2 5-6|0.0.0.0 3-4|0.0 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:14.911
(a3 / age-01 
      :ARG0 (r / relation-03 
            :ARG0 (d / data 
                  :mod (v / virtually-multiplex) 
                  :source (a4 / abundance) 
                  :source (t3 / thing 
                        :ARG1-of (t4 / transcribe-01))) 
            :ARG1 (t2 / t-t) 
            :mod-of (a5 / analysi 
                  :ARG1-of (a2 / assess-01 
                        :ARG0 (c / correlation 
                              :poss (o2 / organization 
                                    :name (n3 / name 
                                          :op1 "Pearson"))) 
                        :location (a / and 
                              :op1 (g / gender) 
                              :op2 (o / organization 
                                    :ARG0-of (f / follow-01 
                                          :ARG1 (t / test-01 
                                                :ARG0 (p / person 
                                                      :ARG0-of (s / smoke-02 
                                                            :ARG1 (h / history)) 
                                                      :name (n / name 
                                                            :op1 "Duncan")) 
                                                :ARG1 (g2 / gene 
                                                      :mod (e / each)))) 
                                    :name (n2 / name 
                                          :op1 "ANOVA")))))))

# ::snt Transcription factor recognition site analysis .
# ::tok Transcription factor recognition site analysis .
# ::alignments 4-5|0 3-4|0.1 2-3|0.0 1-2|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:15.021
(a / analyze-01 
      :ARG0-of (r / recognize-01 
            :ARG1 (f / factor 
                  :mod (t / transcription))) 
      :ARG1 (s / site))

# ::snt The El Dorado ( Build 35 ) program from the Genomatix software package was used to locate the correlated genes within the genome and define 1101 base pairs of the promoter regions ( 1000 base pairs upstream of and 100 base pairs into the transcription start site ) for each gene ( Genomatix Software GmbH , Munich , Germany , [ 17 ] ) .
# ::tok The El Dorado ( Build 35 ) program from the Genomatix software package was used to locate the correlated genes within the genome and define 1101 base pairs of the promoter regions ( 1000 base pairs upstream of and 100 base pairs into the transcription start site ) for each gene ( Genomatix Software GmbH , Munich , Germany , [ 17 ] ) .
# ::alignments 61-62|0.0.0 58-59|0.1.0.1.2+0.1.0.1.1.0+0.1.0.1.1+0.1.0.1 56-57|0.1.2.0.1+0.1.2.0.0.0+0.1.2.0.0+0.1.2.0 52-55|0.1.0.2.0.2+0.1.0.2.0.1+0.1.0.2.0.0+0.1.0.2.0+0.1.0.2 50-51|0.1.1.3.1.1.0 49-50|0.1.1.3.1.1.0.0 46-47|0.1.1.3.2.0 45-46|0.1.1.3.2 44-45|0.1.1.3.2.0.0 41-42|0.0 40-41|0.0.1 39-40|0.1.1.3.0.0.0 38-39|0 36-37|0.2 35-36|0.1.2 34-35|0.1.2.1 33-34|0.1.1.0 31-32|0.1.1.3.1.1.1 30-31|0.1.1.3.1.1.1.0 27-28|0.1.1.3.1.1 26-27|0.1.1.2.0 25-26|0.1.1.3.1.1.2.0+0.1.1.3.1.1.2 24-25|0.1.1.3.1 23-24|0.1.1.3 22-23|0.1.1.2 19-20|0.1.1.3.0 18-19|0.1.1.3.0.0 16-17|0.1.1 14-15|0.1 12-13|0.1.1.1 11-12|0.1.1.1.0 10-11|0.1.1.1.0.0.0.0+0.1.1.1.0.0.0+0.1.1.1.0.0 7-8|0.1.0 5-6|0.1.1.3.1.0 4-5|0.1.0.1.0 1-3|0.1.0.0.0.1+0.1.0.0.0.0+0.1.0.0.0+0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:20.444
(a / and 
      :ARG1-of (p / pair-01 
            :ARG0 17 
            :mod (b / base)) 
      :op1 (u2 / use-01 
            :ARG1 (p6 / program 
                  :poss (c4 / country 
                        :name (n5 / name 
                              :op1 "El" 
                              :op2 "Dorado")) 
                  :poss (c / country 
                        :ARG0-of (b4 / build-01) 
                        :name (n / name 
                              :op1 "Germany") 
                        :wiki "Germany") 
                  :poss (o / organization 
                        :name (n3 / name 
                              :op1 "Genomatix" 
                              :op2 "Software" 
                              :op3 "GmbH"))) 
            :ARG2 (l / locate-02 
                  :ARG0 1000 
                  :ARG1 (p5 / package 
                        :name-of (s3 / software 
                              :mod (o2 / organization 
                                    :name (n4 / name 
                                          :op1 "Genomatix")))) 
                  :location (g2 / genome 
                        :quant (b3 / base)) 
                  :op1-of (a2 / and 
                        :op2 (g3 / gene 
                              :ARG1-of (c3 / correlate-01 
                                    :ARG0 100)) 
                        :op3 (d2 / define-01 
                              :ARG0 35 
                              :ARG1 (p4 / pair-01 
                                    :ARG0 (g / gene 
                                          :mod (e / each)) 
                                    :ARG1 (r / region 
                                          :ARG1-of (p3 / promote-01)) 
                                    :time (d / date-entity 
                                          :year 1101))) 
                        :op4 (s2 / start-01 
                              :mod-of (s / site 
                                    :mod (t / transcription))))) 
            :ARG2-of (p2 / pair-01 
                  :ARG0 (c2 / city 
                        :name (n2 / name 
                              :op1 "Munich") 
                        :wiki "Munich") 
                  :mod (b2 / base))) 
      :op2 (u / upstream))

# ::snt The 1101 base pair sequences obtained from the El Dorado program then were used as the target sequences for putative transcription factor recognition site identification using the MatInspector Version 4.2 program , which yielded sites for 11 transcription factors ( Genomatix Software GmbH , Munich , Germany , [ 17 ] ) .
# ::tok The 1101 base pair sequences obtained from the El Dorado program then were used as the target sequences for putative transcription factor recognition site identification using the MatInspector Version 4.2 program , which yielded sites for 11 transcription factors ( Genomatix Software GmbH , Munich , Germany , [ 17 ] ) .
# ::alignments 49-50|0.0.0.0 46-47|0.0.0.2.3.1.0.0.1.1+0.0.0.2.3.1.0.0.1.0.0+0.0.0.2.3.1.0.0.1.0+0.0.0.2.3.1.0.0.1 44-45|0.0.0.2.2.1+0.0.0.2.2.0.0+0.0.0.2.2.0+0.0.0.2.2 40-43|0.0.0.2.3.0.0.2+0.0.0.2.3.0.0.1+0.0.0.2.3.0.0.0+0.0.0.2.3.0.0+0.0.0.2.3.0 38-39|0.0 37-38|0 36-37|0.0.0.2.3.2.0.0 34-35|0.0.0.1 33-34|0.0.0 30-31|0.0.0.2.1 29-30|0.0.0.2.3.1.0.1 27-29|0.0.0.2.1.0.0.1+0.0.0.2.1.0.0.0+0.0.0.2.1.0.0+0.0.0.2.1.0 25-26|0.0.0.2 24-25|0.0.0.2.0 23-24|0.0.0.2.0.0 22-23|0.0.0.2.0.1 21-22|0.0.0.2.0.1.1 20-21|0.0.0.2.3.2.0.1 19-20|0.0.0.2.3.1.1.0 17-18|0.0.0.2.3.2 16-17|0.0.0.2.3.2.0 13-14|0.0.0.2.3 11-12|0.0.0.2.3.3 10-11|0.0.0.2.3.1.0.0 8-10|0.0.0.2.3.1.0.0.0.0.1+0.0.0.2.3.1.0.0.0.0.0+0.0.0.2.3.1.0.0.0.0+0.0.0.2.3.1.0.0.0 5-6|0.0.0.2.3.1.0 4-5|0.0.0.2.3.1 3-4|0.0.0.2.3.1.1 2-3|0.0.0.2.3.1.1.1 1-2|0.0.0.2.0.1.0.0+0.0.0.2.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:23.592
(t / transcription 
      :mod-of (f / factor 
            :ARG3-of (y / yield-01 
                  :ARG0 17 
                  :ARG1 (s / site) 
                  :purpose (u / use-01 
                        :ARG0 (i / identify-02 
                              :ARG1 (s2 / site) 
                              :ARG3-of (r / recognize-01 
                                    :ARG0 (d / date-entity 
                                          :year 1101) 
                                    :ARG1 (f2 / factor))) 
                        :ARG1 (p / program 
                              :mod (t2 / thing 
                                    :name (n4 / name 
                                          :op1 "MatInspector" 
                                          :op2 "Version"))) 
                        :location (c2 / city 
                              :name (n2 / name 
                                    :op1 "Munich") 
                              :wiki "Munich") 
                        :manner-of (u2 / use-01 
                              :ARG0 (o / organization 
                                    :name (n3 / name 
                                          :op1 "Genomatix" 
                                          :op2 "Software" 
                                          :op3 "GmbH")) 
                              :ARG1 (s4 / sequence 
                                    :ARG0-of (o2 / obtain-01 
                                          :ARG1 (p3 / program 
                                                :mod (c3 / country 
                                                      :name (n5 / name 
                                                            :op1 "El" 
                                                            :op2 "Dorado")) 
                                                :poss (c / country 
                                                      :name (n / name 
                                                            :op1 "Germany") 
                                                      :wiki "Germany")) 
                                          :ARG2 4.2) 
                                    :ARG1-of (p4 / pair-01 
                                          :ARG0 (p2 / putative) 
                                          :mod (b / base))) 
                              :ARG2 (s3 / sequence 
                                    :ARG1-of (t4 / target-01 
                                          :ARG0 11 
                                          :ARG3 (t3 / transcription))) 
                              :time (t5 / then))))))

# ::snt The parameters used were the standard ( 0.75 ) core similarity and the optimized matrix similarity [ 18 ] .
# ::tok The parameters used were the standard ( 0.75 ) core similarity and the optimized matrix similarity [ 18 ] .
# ::alignments 17-18|0.0.0.0 15-16|0.0.0.1.0 14-15|0.0.0.1.0.0 13-14|0.0.0.1 11-12|0 10-11|0.1 9-10|0.1.1 5-6|0.1.0 2-3|0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:23.702
(a / and 
      :op1 (p / parameter 
            :ARG1-of (u / use-01 
                  :ARG0 18 
                  :purpose-of (o / optimize-01 
                        :ARG1 (s / similarity 
                              :mod (m / matrix))))) 
      :op2 (s2 / similarity 
            :ARG1-of (s3 / standard-02) 
            :mod (c / core)))

# ::snt StaRT-PCR reagents were optimized for ten of these transcription factors , including CEBPB , CEBPE , CEBPG , E2F1 , E2F3 , E2F4 , E2F5 , E2F6 , EVI1 , and PAX5 .
# ::tok StaRT-PCR reagents were optimized for ten of these transcription factors , including CEBPB , CEBPE , CEBPG , E2F1 , E2F3 , E2F4 , E2F5 , E2F6 , EVI1 , and PAX5 .
# ::alignments 31-32|0.3.3.0.0+0.3.3.0+0.3.3 30-31|0.3 16-17|0.3.2.0.0+0.3.2.0+0.3.2 14-15|0.3.1.0.0+0.3.1.0+0.3.1 12-13|0.3.0.0.0+0.3.0.0+0.3.0 9-10|0 8-9|0.1 7-8|0.2 3-4|0.0 1-2|0.0.0 0-1|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:24.045
(f / factor 
      :ARG0-of (o4 / optimize-01 
            :ARG1 (r / reagent 
                  :mod (t4 / thing 
                        :name (n5 / name 
                              :op1 "StaRT-PCR")))) 
      :mod (t2 / transcription) 
      :mod (t3 / this) 
      :op1-of (a / and 
            :op2 (o3 / organization 
                  :name (n4 / name 
                        :op1 "CEBPB")) 
            :op3 (o2 / organization 
                  :name (n3 / name 
                        :op1 "CEBPE")) 
            :op4 (o / organization 
                  :name (n2 / name 
                        :op1 "CEBPG")) 
            :op5 (t / thing 
                  :name (n / name 
                        :op1 "PAX5"))))

# ::snt Four transcription factors were expressed at low and invariant levels among multiple NBEC samples and were therefore excluded from the study .
# ::tok Four transcription factors were expressed at low and invariant levels among multiple NBEC samples and were therefore excluded from the study .
# ::alignments 20-21|0.2.0.0 17-18|0.2.0 14-15|0.2 13-14|0.2.0.0.0+0.2.0.0.0.1 12-13|0.2.0.0.0.0.0.0+0.2.0.0.0.0.0+0.2.0.0.0.0 11-12|0.2.0.0.0.0.1 9-10|0.1 8-9|0.1.0.1 7-8|0.1.0 6-7|0.1.0.0 4-5|0 2-3|0.0 1-2|0.0.0 0-1|0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:24.292
(e2 / express-01 
      :ARG1 (f / factor 
            :mod (t2 / transcription)) 
      :location (l / level 
            :op3-of (a2 / and 
                  :op1 (l2 / low-04 
                        :ARG1 4) 
                  :op2 (i / invariant))) 
      :op1-of (a / and 
            :op2 (e / exclude-01 
                  :ARG2 (s / study-01 
                        :ARG2-of (s2 / sample-01 
                              :ARG0 (o / organization 
                                    :name (n / name 
                                          :op1 "NBEC") 
                                    :quant (m / multiple)) 
                              :ARG1 (t / thing))))))

# ::snt The remaining six , CEBPB , CEBPG , E2F1 , E2F3 , E2F6 , and EVI , were evaluated for correlation with an expanded group of ten antioxidant and six DNA repair genes .
# ::tok The remaining six , CEBPB , CEBPG , E2F1 , E2F3 , E2F6 , and EVI , were evaluated for correlation with an expanded group of ten antioxidant and six DNA repair genes .
# ::alignments 32-33|0.1.0.1.1.1 31-32|0.1.0 30-31|0.1.0.0 29-30|0.1.0.1.1.1.0 28-29|0.1.0.1.1 27-28|0.1.0.1 24-25|0.1.0.1.0 23-24|0.1.0.1.0.0 20-21|0.1.0.1.0.1.0 18-19|0.1.0.1.0.1 15-16|0.1.1.0+0.1.1+0.1 14-15|0 6-7|0.1.0.1.1.0.0.0+0.1.0.1.1.0.0+0.1.0.1.1.0 4-5|0.0.0.0+0.0.0+0.0 2-3|0.1.0.1.0.0.0.0 1-2|0.1.0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:24.602
(a3 / and 
      :op1 (o2 / organization 
            :name (n3 / name 
                  :op1 "CEBPB")) 
      :op2 (c2 / country 
            :ARG0-of (r / repair-01 
                  :mod (d / DNA) 
                  :part-of (a2 / antioxidant 
                        :consist (g2 / group 
                              :ARG0-of (e / expand-01 
                                    :ARG1 (r2 / remain-01 
                                          :ARG1 6)) 
                              :ARG2-of (e2 / evaluate-01 
                                    :ARG1 (c / correlation))) 
                        :op2-of (a / and 
                              :op1 (o / organization 
                                    :name (n2 / name 
                                          :op1 "CEBPG")) 
                              :op3 (g / gene 
                                    :quant 6)))) 
            :name (n / name 
                  :op1 "EVI")))

# ::snt Virtually-multiplexed transcript abundance data were obtained for each gene in each of the 49 samples , except for E2F1 measurement in sample 147 ( Table 3 ) .
# ::tok Virtually-multiplexed transcript abundance data were obtained for each gene in each of the 49 samples , except for E2F1 measurement in sample 147 ( Table 3 ) .
# ::alignments 25-26|0.1.0.0 24-25|0.1.0.0.0 21-22|0 19-20|0.2 16-17|0.2.0 14-15|0.0.0.0+0.0.0 13-14|0.0.0.1 10-11|0.0 8-9|0.1.0.1 7-8|0.1.0.1.0 5-6|0.1.0 3-4|0.1 2-3|0.1.2 1-2|0.1.3.0+0.1.3 0-1|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:25.151
(s / sample-01 
      :ARG0 (e2 / each 
            :mod-of (t2 / thing 
                  :ARG1-of (s2 / sample-01) 
                  :quant 49)) 
      :ARG1 (d / data 
            :ARG1-of (o / obtain-01 
                  :ARG0 (3 / 3 
                        :mod-of (t / table)) 
                  :ARG2 (g / gene 
                        :mod (e3 / each))) 
            :mod (v / virtually-multiplex) 
            :source (a / abundance) 
            :source (t3 / thing 
                  :ARG1-of (t4 / transcribe-01))) 
      :ARG1-of (m / measure-01 
            :ARG1-of (e / except-01)))

# ::snt A gene-specific inhibitor in sample 147 prevented amplification of E2F1 .
# ::tok A gene-specific inhibitor in sample 147 prevented amplification of E2F1 .
# ::alignments 7-8|0.1 6-7|0 4-5|0.0.0 2-3|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:25.168
(p / prevent-01 
      :ARG0 (i / inhibitor 
            :ARG1-of (s / sample-01)) 
      :ARG1 (a / amplification))

# ::snt Neither the internal standard , nor the native cDNA PCR product was observed .
# ::tok Neither the internal standard , nor the native cDNA PCR product was observed .
# ::alignments 12-13|0.0.1.0 10-11|0.0.0.1 9-10|0.0.0 8-9|0.0.0.0 7-8|0.0.0.1.0 3-4|0.0.1 2-3|0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:25.376
(n2 / neither 
      :op1 (i / internal-02 
            :ARG1 (p2 / PCR 
                  :mod (c / cdna) 
                  :mod-of (p / product 
                        :mod (n / native))) 
            :mod-of (s / standard 
                  :ARG1-of (o / observe-01))))

# ::snt The presence of gene-specific PCR inhibition was observable in some other samples as reduction in peak heights in internal standard PCR products relative to that expected for the number of internal standard molecules present at the beginning of the PCR reaction .
# ::tok The presence of gene-specific PCR inhibition was observable in some other samples as reduction in peak heights in internal standard PCR products relative to that expected for the number of internal standard molecules present at the beginning of the PCR reaction .
# ::alignments 40-41|0.4.0 36-37|0.4.0.1 33-34|0.4.0.1.0 32-33|0.4.1.0 31-32|0.4.1 30-31|0.4.1.0.0 28-29|0.4 25-26|0 24-25|0.0 22-23|0.3 21-22|0.1 19-20|0.1.0 18-19|0.1.1 16-17|0.4.0.0.0 15-16|0.4.0.0 13-14|0.4.0.0.0.0 11-12|0.2.0.0.0.0+0.2.0.0.0 10-11|0.2.0.0.0.1 9-10|0.2.0.0.0.2 7-8|0.2.0.0 5-6|0.2 1-2|0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:26.281
(e / expect-01 
      :ARG0 (t / that) 
      :ARG1 (p2 / product 
            :ARG1-of (s2 / standard-02) 
            :ARG1-of (i2 / internal-02)) 
      :ARG2 (i3 / inhibition 
            :mod-of (p4 / presence 
                  :domain-of (o2 / observable 
                        :location (t2 / thing 
                              :ARG1-of (s3 / sample-01) 
                              :mod (o / other) 
                              :quant (s4 / some))))) 
      :manner (r2 / relative) 
      :purpose (n / number 
            :ARG0-of (r / react-01 
                  :ARG1 (p3 / peak-01 
                        :ARG1 (h / height 
                              :ARG1-of (r3 / reduce-01))) 
                  :ARG1-of (b / begin-01 
                        :time-of (p / present))) 
            :ARG0-of (s / standard-02 
                  :ARG1 (m / molecule 
                        :ARG1-of (i / internal-02)))))

# ::snt However , in each such case , the PCR amplification was efficient enough to enable quantification .
# ::tok However , in each such case , the PCR amplification was efficient enough to enable quantification .
# ::alignments 15-16|0.0.1 14-15|0.0 12-13|0.0.0 11-12|0 9-10|0.1 8-9|0.1.1 5-6|0.1.0 4-5|0.1.0.0.0 3-4|0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:26.443
(e3 / efficient-01 
      :ARG0 (e / enable-01 
            :ARG0 (e2 / enough) 
            :ARG1 (q / quantification)) 
      :ARG1 (a / amplification 
            :ARG0-of (c / case-03 
                  :mod (e4 / each 
                        :mod-of (s / such))) 
            :mod (p / PCR)))

# ::snt In non-BC individuals there was significant ( p < 0.01 ) correlation between CEBPG and eight of the 16 antioxidant or DNA repair genes , specifically XRCC1 , ERCC5 , GSTP1 , SOD1 , GPX1 , ERCC1 , CAT and ERCC2 ( Table 4 ) .
# ::tok In non-BC individuals there was significant ( p < 0.01 ) correlation between CEBPG and eight of the 16 antioxidant or DNA repair genes , specifically XRCC1 , ERCC5 , GSTP1 , SOD1 , GPX1 , ERCC1 , CAT and ERCC2 ( Table 4 ) .
# ::alignments 43-44|0.1.1.0 42-43|0.1.1.0.0 39-40|0 38-39|0.1.1.1.0.1+0.1.1.1.0.0.0+0.1.1.1.0.0+0.1.1.1.0 25-26|0.0 23-24|0.1.2 22-23|0.1.1 21-22|0.1.1.2 20-21|0.1 19-20|0.1.0 18-19|0.1.0.0 15-16|0.1.0.1 14-15|0.1.1.3.1 13-14|0.1.1.3.0.0+0.1.1.3.0+0.1.1.3 11-12|0.1.1.1.1 7-8|0.0.1 5-6|0.1.1.1 2-3|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:26.787
(a / and 
      :op1 (s / specific-02 
            :ARG0 (i / individual) 
            :ARG1 (p2 / p)) 
      :op4-of (o / or 
            :op1 (a2 / antioxidant 
                  :quant 16 
                  :quant 8) 
            :op2 (r / repair-01 
                  :ARG0 (4 / 4 
                        :mod-of (t / table)) 
                  :ARG2-of (s2 / significant-02 
                        :ARG0 (p / product 
                              :name (n / name 
                                    :op1 "CAT-5") 
                              :wiki "Category_5_cable") 
                        :ARG1 (c / correlation)) 
                  :mod (d / DNA) 
                  :op1-of (o2 / organization 
                        :name (n2 / name 
                              :op1 "CEBPG") 
                        :op1-of (a3 / and))) 
            :op3 (g / gene)))

# ::snt In contrast , in BC individuals samples CEBPG was not correlated with any of the antioxidant or DNA repair genes .
# ::tok In contrast , in BC individuals samples CEBPG was not correlated with any of the antioxidant or DNA repair genes .
# ::alignments 19-20|0.0.0.0.0.1 18-19|0.0.0.0.0.0 17-18|0.0.0.0.0.0.0 16-17|0.0.0.0.0 15-16|0.0.0.0 12-13|0.0.0 10-11|0.0 9-10|0.0.3 6-7|0.0.1.0+0.0.1 5-6|0.0.2 4-5|0.0.2.0 1-2|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:26.893
(c2 / contrast-01 
      :ARG1 (c / correlate-01 
            :ARG0 (a2 / any 
                  :mod-of (a / antioxidant 
                        :op1-of (o / or 
                              :op2 (r / repair-01 
                                    :ARG1 (d / DNA)) 
                              :op3 (g / gene)))) 
            :ARG1 (t / thing 
                  :ARG1-of (s / sample-01)) 
            :location (i / individual 
                  :mod "BC") 
            :polarity -))

# ::snt These relationships were not observed with any of the other transcription factors studied .
# ::tok These relationships were not observed with any of the other transcription factors studied .
# ::alignments 12-13|0.0.0 11-12|0.0 10-11|0 9-10|0.0.1 6-7|0.0.0.0.0 4-5|0.0.0.0 3-4|0.0.0.0.2 1-2|0.0.0.0.1 0-1|0.0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:26.942
(t / transcription 
      :mod-of (f / factor 
            :ARG0-of (s / study-01 
                  :ARG1 (o2 / observe-01 
                        :ARG0 (a / any) 
                        :ARG1 (r / relation-03 
                              :mod (t2 / this)) 
                        :polarity -)) 
            :mod (o / other)))

# ::snt For XRCC1 , ERCC5 , GSTP1 , and SOD1 the correlation with CEBPG was significantly lower in BC individuals compared to non-BC individuals and the difference was nearly significant for GPX1 ( Fig. 1b ) .
# ::tok For XRCC1 , ERCC5 , GSTP1 , and SOD1 the correlation with CEBPG was significantly lower in BC individuals compared to non-BC individuals and the difference was nearly significant for GPX1 ( Fig. 1b ) .
# ::alignments 32-34|0.0.1+0+0.0+0.0.0 28-29|0.0.0.0.0.2.1 27-28|0.0.0.0.0.2.1.1 25-26|0.0.0.0.0.2.1.0 23-24|0.0.0.0.0.2 22-23|0.0.0.0.0.2.0.1 19-20|0.0.0.0.0.2.0 18-19|0.0.0.0.0.2.0.0 17-18|0.0.0.0.0.2.0.0.0 15-16|0.0.0.0.0 14-15|0.0.0.0 12-13|0.0.0.0.0.0.0.0.0+0.0.0.0.0.0.0.0+0.0.0.0.0.0.0 10-11|0.0.0.0.0.0 7-8|0.0.0.0.0.1 3-4|0.0.0.0.0.1.1.0.0+0.0.0.0.0.1.1.0+0.0.0.0.0.1.1 1-2|0.0.0.0.0.1.0.0.0+0.0.0.0.0.1.0.0+0.0.0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:27.641
(f / Fig. 
      :op1-of (n / name 
            :name-of (t / thing 
                  :ARG0-of (s2 / significant-02 
                        :ARG1 (l / low-04 
                              :ARG1 (c2 / correlation 
                                    :prep-with (o / organization 
                                          :name (n3 / name 
                                                :op1 "CEBPG"))) 
                              :ARG2 (a2 / and 
                                    :op1 (t3 / thing 
                                          :name (n5 / name 
                                                :op1 "XRCC1")) 
                                    :op2 (t2 / thing 
                                          :name (n4 / name 
                                                :op1 "ERCC5"))) 
                              :op1-of (a / and 
                                    :ARG1-of (c / compare-01 
                                          :ARG0 (i2 / individual 
                                                :mod "BC") 
                                          :ARG2 (i / individual)) 
                                    :op2 (s / significant-02 
                                          :ARG1 (d / differ-02) 
                                          :mod (n2 / nearly)))))) 
            :op2 1b))

# ::snt Scatter plots of the relationship between CEBPG and XRCC1 in non-BC individuals or BC individuals ( Fig. 2a , b ) are representative of the other four genes .
# ::tok Scatter plots of the relationship between CEBPG and XRCC1 in non-BC individuals or BC individuals ( Fig. 2a , b ) are representative of the other four genes .
# ::alignments 27-28|0.0.0.0.0.1.0.0 26-27|0.0.0.0.0.1.1.0.2 25-26|0.0.0.0.0.1.1.0.0 22-23|0.0.0.0.0.1.0 19-20|0.0.0.0.0.1.1.0.1.0.0 16-18|0.0.1+0+0.0+0.0.0 14-15|0.0.0.0.2 13-14|0.0.0.0.2.0 12-13|0.0.0.0 11-12|0.0.0.0.1 8-9|0.0.0.0.0.0.0+0.0.0.0.0.0+0.0.0.0.0 7-8|0.0.0.0.0.1 6-7|0.0.0.0.0.1.1.1.0+0.0.0.0.0.1.1.1+0.0.0.0.0.1.1 4-5|0.0.0.0.0.1.1.0 1-2|0.0.0.0.0.1.1.0.1 0-1|0.0.0.0.0.1.1.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:28.154
(f / Fig. 
      :op1-of (n / name 
            :name-of (t / thing 
                  :domain-of (o2 / or 
                        :op1 (t2 / thing 
                              :name (n2 / name 
                                    :op1 "XRCC1") 
                              :op2-of (a / and 
                                    :ARG0-of (r / represent-01 
                                          :ARG1 (g / gene)) 
                                    :op1 (o3 / organization 
                                          :ARG0-of (r2 / relation-03 
                                                :ARG2 (o / other) 
                                                :mod-of (p / plot 
                                                      :ARG1-of (s / scatter-01 
                                                            :ARG2 (b / b))) 
                                                :op1-of 4) 
                                          :name (n3 / name 
                                                :op1 "CEBPG")))) 
                        :op2 (i2 / individual) 
                        :op3 (i / individual 
                              :mod "BC"))) 
            :op2 2a))

# ::snt Neither CEBPG , nor XRCC1 , ERCC5 , GSTP1 , SOD1 or GPX1 was significantly correlated with age , gender , or smoking history in non-BC individuals , BC individuals , or the combined group .
# ::tok Neither CEBPG , nor XRCC1 , ERCC5 , GSTP1 , SOD1 or GPX1 was significantly correlated with age , gender , or smoking history in non-BC individuals , BC individuals , or the combined group .
# ::alignments 34-35|0.2 33-34|0.2.0 31-32|0 29-30|0.1 28-29|0.1.0 26-27|0.0 23-24|0.0.0.2 22-23|0.0.0.2.0 21-22|0.0.0 19-20|0.0.0.1 17-18|0.0.0.0 15-16|0.0.0.3 14-15|0.0.0.3.1 11-12|0.0.0.3.2 6-7|0.0.0.3.2.1.0.0+0.0.0.3.2.1.0+0.0.0.3.2.1 4-5|0.0.0.3.2.0.0.0+0.0.0.3.2.0.0+0.0.0.3.2.0 1-2|0.0.0.3.0.0.0+0.0.0.3.0.0+0.0.0.3.0 0-1|0.0.0.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:28.433
(o / or 
      :op1 (i2 / individual 
            :poss-of (o2 / or 
                  :op1 (a / age-01) 
                  :op2 (g2 / gender) 
                  :op3 (h / history 
                        :ARG1-of (s / smoke-02 
                              :ARG0 (n4 / neither))) 
                  :purpose-of (c2 / correlate-01 
                        :ARG1 (o4 / organization 
                              :name (n3 / name 
                                    :op1 "CEBPG")) 
                        :ARG1-of (s2 / significant-02) 
                        :op3-of (o3 / or 
                              :op1 (t2 / thing 
                                    :name (n2 / name 
                                          :op1 "XRCC1")) 
                              :op2 (t / thing 
                                    :name (n / name 
                                          :op1 "ERCC5")))))) 
      :op2 (i / individual 
            :mod "BC") 
      :op3 (g / group 
            :ARG2-of (c / combine-01)))

# ::snt In non-BC individuals , based on the r2 values from Pearson 's correlation analysis , CEBPG accounts for much of the variance in expression of XRCC1 ( 69 % ) , ERCC5 ( 62 % ) , GSTP1 ( 55 % ) , SOD1 ( 44 % ) , and GPX1 ( 52 % ) .
# ::tok In non-BC individuals , based on the r2 values from Pearson 's correlation analysis , CEBPG accounts for much of the variance in expression of XRCC1 ( 69 % ) , ERCC5 ( 62 % ) , GSTP1 ( 55 % ) , SOD1 ( 44 % ) , and GPX1 ( 52 % ) .
# ::alignments 53-54|0.2.0 52-53|0.2 49-50|0.0.2 46-47|0.1.0 45-46|0.1 40-41|0.3.1.1 39-40|0.3.1.1.0 34-35|0.3.2.0.2 33-34|0.3.2.0.2.0 31-32|0.0.2.0.0.0+0.0.2.0.0+0.0.2.0 28-29|0.3.0.0 27-28|0.3.0 25-26|0.0.1.0+0.0.1+0.0 23-24|0 21-22|0.3.1.2.0 18-19|0.3.1.2 16-17|0.3.1 15-16|0.3.1.0.0.0+0.3.1.0.0+0.3.1.0 13-14|0.3.2.0 12-13|0.3.2.0.1 10-11|0.3.2.0.0.0.0+0.3.2.0.0.0+0.3.2.0.0 8-9|0.3.2 4-5|0.3 2-3|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:29.742
(e / express-01 
      :ARG0 (p6 / person 
            :mod (i / individual) 
            :name (n2 / name 
                  :op1 "XRCC1") 
            :op1-of (a / and 
                  :op2 (t / thing 
                        :name (n / name 
                              :op1 "ERCC5")))) 
      :ARG1 (4 / 44 
            :value-of (p2 / percentage-entity)) 
      :op1-of (5 / 52 
            :value-of (p / percentage-entity)) 
      :purpose (b / base-02 
            :ARG0 (62 / 69 
                  :value-of (p5 / percentage-entity)) 
            :ARG1 (a2 / account-01 
                  :ARG0 (o / organization 
                        :name (n3 / name 
                              :op1 "CEBPG")) 
                  :ARG1 (p3 / percentage-entity 
                        :value 55) 
                  :ARG3 (m / much 
                        :part-of (v / variance))) 
            :ARG2 (v2 / value 
                  :source (a3 / analyze-01 
                        :ARG0 (o2 / organization 
                              :name (n4 / name 
                                    :op1 "Pearson")) 
                        :ARG1 (c / correlation) 
                        :ARG2 (p4 / percentage-entity 
                              :value 62)))))

# ::snt E2F1 accounts for some of the remaining variance .
# ::tok E2F1 accounts for some of the remaining variance .
# ::alignments 7-8|0.0 6-7|0 3-4|0.0.0 1-2|0.0.0.0 0-1|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:29.780
(r / remain-01 
      :ARG1 (v / variance 
            :quant (s / some 
                  :ARG0-of (a / account-01 
                        :ARG1 (e / E2F1)))))

# ::snt For example , when samples from all 49 non-BC individuals and BC individuals were assessed as a single group , E2F1 was significantly correlated with ERCC5 , GSTP1 and SOD1 ( Table 4 ) .
# ::tok For example , when samples from all 49 non-BC individuals and BC individuals were assessed as a single group , E2F1 was significantly correlated with ERCC5 , GSTP1 and SOD1 ( Table 4 ) .
# ::alignments 32-33|0.1.0.2.0.1 31-32|0.1.0.0 28-29|0.1.0.1.1 25-26|0.1.0.1.1.0.0.0+0.1.0.1.1.0.0+0.1.0.1.1.0 23-24|0.1.0.1 22-23|0.1.0.1.0 18-19|0.1.0.2 17-18|0.1.0.2.0 14-15|0.1.0 12-13|0.0.1 11-12|0.0.1.0 10-11|0.0 9-10|0.0.0 7-8|0.0.0.1 6-7|0.0.0.0 4-5|0+0.1 1-2|0.1.0.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:30.289
(s3 / sample-01 
      :ARG0 (a3 / and 
            :op1 (i2 / individual 
                  :quant (a4 / all) 
                  :quant 49) 
            :op2 (i / individual 
                  :mod "BC")) 
      :ARG1 (t3 / thing 
            :ARG1-of (a2 / assess-01 
                  :ARG0 (t / table) 
                  :ARG1-of (c / correlate-01 
                        :ARG1-of (s / significant-02) 
                        :ARG2 (a / and 
                              :op1 (t2 / thing 
                                    :name (n / name 
                                          :op1 "ERCC5")))) 
                  :ARG2 (g / group 
                        :ARG1-of (s2 / single-02 
                              :ARG0 (e / example) 
                              :ARG2 4)))))

# ::snt Further , in non-BC individuals , E2F1 was correlated with GSTP1 ( Fig. 1c ) and the correlation was lower in BC individuals .
# ::tok Further , in non-BC individuals , E2F1 was correlated with GSTP1 ( Fig. 1c ) and the correlation was lower in BC individuals .
# ::alignments 22-23|0.1.0.0 21-22|0.1.0 19-20|0.1 17-18|0.1.1 15-16|0 12-14|0.0.1.0.1+0.0.1.0.0+0.0.1.0+0.0.1 8-9|0.0 4-5|0.0.0 0-1|0.0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:30.374
(a / and 
      :op1 (c2 / correlate-01 
            :ARG0 (i2 / individual) 
            :ARG1 (t / thing 
                  :name (n / name 
                        :op1 (f / Fig.) 
                        :op2 1c)) 
            :mod (f2 / further)) 
      :op2 (l / low-04 
            :ARG0 (B / "BC" 
                  :mod-of (i / individual)) 
            :ARG1 (c / correlation)))

# ::snt However , the difference in correlation between non-BC individuals and BC individuals was not significant .
# ::tok However , the difference in correlation between non-BC individuals and BC individuals was not significant .
# ::alignments 14-15|0.2 13-14|0.2.1 11-12|0.1 10-11|0.1.0 9-10|0 8-9|0.0 5-6|0.2.0.0 3-4|0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:30.414
(a / and 
      :op1 (i2 / individual) 
      :op2 (i / individual 
            :mod "BC") 
      :op3 (s / significant-02 
            :ARG1 (d / differ-02 
                  :ARG1 (c / correlation)) 
            :polarity -))

# ::snt None of the other transcription factors were correlated with XRCC1 , ERCC5 , GSTP1 , SOD1 , or GPX1 ( Fig. 1a , d , e , f ) .
# ::tok None of the other transcription factors were correlated with XRCC1 , ERCC5 , GSTP1 , SOD1 , or GPX1 ( Fig. 1a , d , e , f ) .
# ::alignments 27-28|0.0.0.1.0.0.1 25-26|0.0.0.1.0.0.2 23-24|0.0.0.1.0.0.3 20-22|0.0.1+0+0.0+0.0.0 17-18|0.0.0.1 11-12|0.0.0.1.1.0.0+0.0.0.1.1.0+0.0.0.1.1 9-10|0.0.0.1.0.1.0+0.0.0.1.0.1+0.0.0.1.0 7-8|0.0.0.1.0.0 5-6|0.0.0.0.0 4-5|0.0.0.0.0.0 3-4|0.0.0.0 0-1|0.0.0.1.0.0.0.0+0.0.0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:30.963
(f2 / Fig. 
      :op1-of (n / name 
            :name-of (t / thing 
                  :domain-of (o2 / other 
                        :mod-of (f3 / factor 
                              :mod (t4 / transcription))) 
                  :domain-of (o / or 
                        :op1 (t3 / thing 
                              :ARG2-of (c / correlate-01 
                                    :ARG1 (p / person 
                                          :quant (n4 / none)) 
                                    :op1-of (f / f) 
                                    :op1-of (e / e) 
                                    :op1-of (d / d)) 
                              :name (n3 / name 
                                    :op1 "XRCC1")) 
                        :op2 (t2 / thing 
                              :name (n2 / name 
                                    :op1 "ERCC5")))) 
            :op2 1a))

# ::snt Comparison of gene expression with demographic characteristics .
# ::tok Comparison of gene expression with demographic characteristics .
# ::alignments 6-7|0.0.0.0+0.0.0 5-6|0.0.0.0.0 3-4|0.0 2-3|0.0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:31.021
(c2 / comparison 
      :ARG1-of (e / express-01 
            :ARG2 (t / thing 
                  :ARG2-of (c / characteristic-02 
                        :ARG1 (d / demography))) 
            :mod (g / gene)))

# ::snt E2F1 and GSTZ1 each were positively correlated with age .
# ::tok E2F1 and GSTZ1 each were positively correlated with age .
# ::alignments 8-9|0.2 6-7|0 5-6|0.3 3-4|0.0 1-2|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:31.070
(c / correlate-01 
      :ARG0 (e / each) 
      :ARG1 (a2 / and) 
      :ARG2 (a / age-01) 
      :degree (p / positive))

# ::snt GSTM1-5 was the only gene with a difference in expression by gender .
# ::tok GSTM1-5 was the only gene with a difference in expression by gender .
# ::alignments 11-12|0.1.0 9-10|0.1.1 7-8|0.1 4-5|0 3-4|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:31.094
(g2 / gene 
      :mod (o / only) 
      :topic (d / differ-02 
            :ARG0 (g / gender) 
            :prep-in (e / express-01)))

# ::snt There was a difference in ERCC2 expression between former and never smokers .
# ::tok There was a difference in ERCC2 expression between former and never smokers .
# ::alignments 11-12|0.2.0+0.2 9-10|0 8-9|0.1 6-7|0.0.0 3-4|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:31.128
(a / and 
      :ARG1-of (d / differ-02 
            :prep-in (e / express-01)) 
      :op1 (f / former) 
      :op2 (p / person 
            :ARG0-of (s / smoke-02)))

# ::snt In this study , we tested two hypotheses .
# ::tok In this study , we tested two hypotheses .
# ::alignments 7-8|0.1.0+0.1 6-7|0.1.1 5-6|0 4-5|0.0 2-3|0.0.0 1-2|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:31.157
(t2 / test-01 
      :ARG0 (w / we 
            :ARG0-of (s / study-01 
                  :mod (t3 / this))) 
      :ARG1 (t / thing 
            :ARG1-of (h / hypothesize-01) 
            :quant 2))

# ::snt First , that there is inter-individual variation in regulation of key antioxidant and DNA repair genes by one or more transcription factors .
# ::tok First , that there is inter-individual variation in regulation of key antioxidant and DNA repair genes by one or more transcription factors .
# ::alignments 21-22|0.2 20-21|0.2.0 19-20|0.1 18-19|0 15-16|0.0.1 14-15|0.0 13-14|0.0.0 12-13|0.0.1.0 11-12|0.0.1.0.1.0 10-11|0.0.1.0.1.0.0 8-9|0.0.1.0.1 6-7|0.0.1.0.0 3-4|0.0.1.0.0.1 2-3|0.0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:31.379
(o / or 
      :ARG1-of (r / repair-01 
            :mod (d / DNA) 
            :mod-of (g / gene 
                  :op2-of (a / and 
                        :example-of (v / variation 
                              :domain (t3 / that) 
                              :mod (t2 / there)) 
                        :op1 (r2 / regulate-01 
                              :ARG1 (a2 / antioxidant 
                                    :ARG1-of (k / key-02)))))) 
      :op1 (m / more) 
      :op2 (f / factor 
            :mod (t / transcription)))

# ::snt Second , that individuals with sub-optimal regulation are selected for development of BC if they smoke cigarettes .
# ::tok Second , that individuals with sub-optimal regulation are selected for development of BC if they smoke cigarettes .
# ::alignments 16-17|0 15-16|0.0 14-15|0.0.0 12-13|0.0.0.0.0.0 10-11|0.0.0.0.0 8-9|0.0.0.0 6-7|0.0.0.0.0.1.0 3-4|0.0.0.0.0.1 0-1|0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:31.473
(c / cigarette 
      :ARG1-of (s / smoke-02 
            :ARG0 (t / they 
                  :ARG1-of (s2 / select-01 
                        :ARG3 (d / develop-02 
                              :ARG1 "BC" 
                              :ARG2 (i / individual 
                                    :ARG1-of (r / regulate-01))))) 
            :ARG1-of (s3 / second-01)))

# ::snt These hypotheses are supported by the findings that a ) there was large inter-individual variation in transcript levels of CEBPG and each of the target genes and in non-BC individuals , b ) CEBPG transcript abundance values were significantly correlated by bivariate analysis with the transcript abundance values of four key antioxidant and DNA repair genes in non-BC individuals , and c ) that there was no correlation between CEBPG and these genes in BC individuals .
# ::tok These hypotheses are supported by the findings that a ) there was large inter-individual variation in transcript levels of CEBPG and each of the target genes and in non-BC individuals , b ) CEBPG transcript abundance values were significantly correlated by bivariate analysis with the transcript abundance values of four key antioxidant and DNA repair genes in non-BC individuals , and c ) that there was no correlation between CEBPG and these genes in BC individuals .
# ::alignments 75-76|0.1 74-75|0.1.0 72-73|0.0 71-72|0.0.0 70-71|0 67-68|0.2.1.1.3 66-67|0.2.3.0.0 61-62|0.2.3.0.1 60-61|0.2.1.1 58-59|0.2.1.1.2 55-56|0.2.3 54-55|0.2.3.0 53-54|0.2.3.0.2 52-53|0.2 51-52|0.2.1 50-51|0.2.1.0 49-50|0.2.0.0.0.0.1.0 47-48|0.2.0 46-47|0.2.0.0 45-46|0.2.0.0.0.1.0+0.2.0.0.0.1 42-43|0.2.0.0.0 41-42|0.2.0.0.0.2 39-40|0.2.0.0.0.0 38-39|0.2.0.0.0.0.1 36-37|0.2.0.0.0.0.0 35-36|0.2.0.0.0.0.0.0 34-35|0.2.0.0.0.0.0.0.0.0+0.2.0.0.0.0.0.0.0 31-32|0.2.0.0.0.0.2 29-30|0.2.2.0 26-27|0.2.2 25-26|0.2.1.1.0.2.3 24-25|0.2.1.1.0.2.3.0 21-22|0.2.1.1.0.2.2 20-21|0.2.1.1.0.2 19-20|0.2.1.1.0.2.1.0.0+0.2.1.1.0.2.1.0+0.2.1.1.0.2.1 17-18|0.2.1.1.0.2.0 16-17|0.2.1.1.0.2.0.0.0+0.2.1.1.0.2.0.0 14-15|0.2.1.1.1 12-13|0.2.1.1.1.0 6-7|0.2.1.1.0.0.0+0.2.1.1.0.0 3-4|0.2.1.1.0 1-2|0.2.1.1.0.1.0+0.2.1.1.0.1 0-1|0.2.1.1.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:39.999
(a / and 
      :op1 (g / gene 
            :mod (t / this)) 
      :op2 (i / individual 
            :mod "BC") 
      :op4-of (a3 / and 
            :op1 (v / value 
                  :mod (a5 / abundance 
                        :location-of (a6 / analyze-01 
                              :ARG0-of (c3 / correlate-01 
                                    :ARG1 (v2 / value 
                                          :mod (a7 / abundance 
                                                :mod (t4 / thing 
                                                      :ARG1-of (t5 / transcribe-01)))) 
                                    :ARG2 (s / significant-02 
                                          :ARG1 4) 
                                    :li (b2 / b)) 
                              :ARG1 (t2 / thing 
                                    :ARG1-of (t3 / transcribe-01)) 
                              :manner (b / bivariate)))) 
            :op2 (a4 / antioxidant 
                  :ARG1-of (k / key-02) 
                  :op2-of (a2 / and 
                        :ARG2-of (s2 / support-01 
                              :ARG0 (t9 / thing 
                                    :ARG1-of (f / find-01)) 
                              :ARG1 (t10 / thing 
                                    :ARG1-of (h / hypothesize-01) 
                                    :mod (t11 / this)) 
                              :op1-of (a9 / and 
                                    :extent (l / level 
                                          :mod (t7 / thing 
                                                :ARG1-of (t8 / transcribe-01))) 
                                    :op2 (o / organization 
                                          :name (n / name 
                                                :op1 "CEBPG")) 
                                    :op3 (e / each) 
                                    :op4 (g3 / gene 
                                          :ARG1-of (t6 / target-01)))) 
                        :op1 (v3 / variation 
                              :mod (l2 / large)) 
                        :op3 (i2 / individual) 
                        :op4 (c / correlation))) 
            :op2-of (a8 / and 
                  :op1 (i3 / individual)) 
            :op3 (g2 / gene 
                  :mod (r / repair-01 
                        :ARG0 - 
                        :ARG1 (c2 / c) 
                        :mod (d / DNA)))))

# ::snt These results support the hypothesis that each of the antioxidant or DNA repair genes correlated with CEBPG in non-BC individuals is regulated by CEBPG .
# ::tok These results support the hypothesis that each of the antioxidant or DNA repair genes correlated with CEBPG in non-BC individuals is regulated by CEBPG .
# ::alignments 21-22|0.3.0.1 19-20|0.3.0.2 16-17|0.3.0.0.0.0+0.3.0.0.0+0.3.0.0 14-15|0.3.0 13-14|0.3 12-13|0.2 11-12|0.2.0 10-11|0 9-10|0.1 6-7|0.1.0 4-5|0.0.1 2-3|0.0 1-2|0.0.0.0+0.0.0 0-1|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:40.463
(o2 / or 
      :op1 (s / support-01 
            :ARG0 (t / thing 
                  :ARG2-of (r3 / result-01) 
                  :mod (t2 / this)) 
            :ARG1 (h / hypothesi)) 
      :op2 (a / antioxidant 
            :mod (e / each)) 
      :op3 (r2 / repair-01 
            :mod (d / DNA)) 
      :op4 (g / gene 
            :ARG0-of (c / correlate-01 
                  :ARG1 (o / organization 
                        :name (n / name 
                              :op1 "CEBPG")) 
                  :ARG1-of (r / regulate-01) 
                  :time (i / individual))))

# ::snt This is supported by the specificity of the CEBPG correlation .
# ::tok This is supported by the specificity of the CEBPG correlation .
# ::alignments 9-10|0.2 8-9|0.2.0.0.0+0.2.0.0+0.2.0 5-6|0.0 2-3|0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:40.627
(s2 / support-01 
      :ARG0 (s / specificity) 
      :ARG1 (t / this) 
      :manner (c / correlation 
            :mod (o / organization 
                  :name (n / name 
                        :op1 "CEBPG"))))

# ::snt That is , there was lack of correlation between any of the other five transcription factors assessed and these target genes .
# ::tok That is , there was lack of correlation between any of the other five transcription factors assessed and these target genes .
# ::alignments 20-21|0.2.0.0 19-20|0.2.0.0.0 18-19|0.2.0.0.1 17-18|0.2.0 16-17|0.0 15-16|0 14-15|0.2 13-14|0.0.0.0 12-13|0.1 9-10|0.3 7-8|0.0.0.1 5-6|0.0.0 0-1|0.2.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:40.824
(f / factor 
      :ARG0-of (a2 / assess-01 
            :ARG1 (l / lack-01 
                  :ARG0 5 
                  :ARG1 (c / correlation))) 
      :mod (o / other) 
      :mod (t3 / transcription 
            :op1-of (a / and 
                  :op2 (g / gene 
                        :ARG1-of (t / target-01 
                              :ARG0 (t4 / that)) 
                        :mod (t2 / this)))) 
      :mod (a3 / any))

# ::snt Of particular note is the lack of correlation of the target genes with CEBPB , which binds to the same recognition site as CEBPG , and shares its recognition site within each of the antioxidant or DNA repair genes .
# ::tok Of particular note is the lack of correlation of the target genes with CEBPB , which binds to the same recognition site as CEBPG , and shares its recognition site within each of the antioxidant or DNA repair genes .
# ::alignments 38-39|0.0.1.1 37-38|0.0 36-37|0.0.0 35-36|0.0.1 34-35|0.0.1.0 31-32|0.0.1.0.0 29-30|0.1 28-29|0 26-27|0.1.0 25-26|0.1.0.1 23-24|0.1.0.1.0.1.1.0.0+0.1.0.1.0.1.1.0+0.1.0.1.0.1.1 21-22|0.1.0.1.0.1 20-21|0.1.0.1.0.1.2 19-20|0.1.0.1.0.1.0 16-17|0.1.0.1.0 13-14|0.1.0.0.0.0+0.1.0.0.0+0.1.0.0 11-12|0.1.0.1.0.0 10-11|0.1.0.1.0.0.0 7-8|0.1.0.1.0.0.0.0.0 5-6|0.1.0.1.0.0.0.0 2-3|0.1.0.1.0.1.2.0 1-2|0.1.0.1.0.1.2.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:41.902
(r2 / recognize-01 
      :ARG1 (r / repair-01 
            :ARG1 (d / DNA) 
            :op2-of (o / or 
                  :op1 (a / antioxidant 
                        :mod (e / each)) 
                  :op3 (g / gene))) 
      :mod-of (s / site 
            :ARG1-of (s2 / share-01 
                  :ARG0 (o3 / organization 
                        :name (n2 / name 
                              :op1 "CEBPB")) 
                  :op2-of (a2 / and 
                        :op1 (b / bind-01 
                              :ARG1 (g2 / gene 
                                    :ARG1-of (t / target-01 
                                          :ARG0 (l / lack-01 
                                                :ARG1 (c / correlation)))) 
                              :ARG4 (s3 / site 
                                    :ARG1-of (s4 / same-01) 
                                    :location (o2 / organization 
                                          :name (n / name 
                                                :op1 "CEBPG")) 
                                    :mod (r3 / recognize-01 
                                          :ARG1 (n3 / note 
                                                :mod (p / particular)))))))))

# ::snt However , there are alternative explanations for the observed correlation of CEBPG with antioxidant and DNA repair genes in non-BC individuals .
# ::tok However , there are alternative explanations for the observed correlation of CEBPG with antioxidant and DNA repair genes in non-BC individuals .
# ::alignments 20-21|0.3 17-18|0.2 16-17|0.1.0 15-16|0.1 14-15|0 13-14|0.0 11-12|0.1.0.0.0.1.0.0+0.1.0.0.0.1.0+0.1.0.0.0.1 9-10|0.1.0.0.0 8-9|0.1.0.0.0.0 5-6|0.1.0.0 4-5|0.1.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:42.029
(a / and 
      :op1 (a2 / antioxidant) 
      :op2 (d / DNA 
            :mod-of (r / repair-01 
                  :ARG1 (e / explain-01 
                        :ARG1 (c / correlation 
                              :ARG1-of (o2 / observe-01) 
                              :poss (o / organization 
                                    :name (n / name 
                                          :op1 "CEBPG"))) 
                        :mod (a3 / alternative)))) 
      :op3 (g / gene) 
      :op4 (i / individual))

# ::snt One possibility is that CEBPG and each of the correlated antioxidant or DNA repair genes is regulated by a transcription factor that is as yet undiscovered , and/or has a recognition site that is not yet known and was not in the Genomatix software database .
# ::tok One possibility is that CEBPG and each of the correlated antioxidant or DNA repair genes is regulated by a transcription factor that is as yet undiscovered , and/or has a recognition site that is not yet known and was not in the Genomatix software database .
# ::alignments 44-45|0.0.0.1.0.0 43-44|0.0.0.1.0 42-43|0.0.0.1.1.0+0.0.0.1.1+0.0.0.1 39-40|0.1.1.2.1.0.0 37-38|0 36-37|0.0 35-36|0.0.2 34-35|0.0.1 31-32|0.0.0 30-31|0.0.0.0 25-26|0.1.1.0.0.0 24-25|0.1.0 20-21|0.1.1.0.0 19-20|0.1.1.2.1.0.1 16-17|0.1.1.0 14-15|0.1.1.2.1.1 13-14|0.1.1.2.1.0 12-13|0.1.1.2.1.0.2 11-12|0.1.1.2.1 10-11|0.1.1.2 9-10|0.1.1.2.0 6-7|0.1.1.1 5-6|0.1.1 4-5|0.1.1.0.1.0.0+0.1.1.0.1.0+0.1.1.0.1 1-2|0.1 0-1|0.1.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:43.427
(a / and 
      :ARG3-of (k / know-02 
            :ARG1 (s2 / site 
                  :mod (r / recognize-01) 
                  :mod (o / organization 
                        :mod-of (s / software 
                              :mod-of (d / database)) 
                        :name (n / name 
                              :op1 "Genomatix"))) 
            :polarity - 
            :time (y / yet)) 
      :op1 (p / possible-01 
            :ARG1 (y2 / yet) 
            :op1-of (a3 / and 
                  :ARG1-of (r2 / regulate-01 
                        :ARG0 (f / factor 
                              :mod (u / undiscover)) 
                        :ARG2 (o3 / organization 
                              :name (n2 / name 
                                    :op1 "CEBPG"))) 
                  :op2 (e / each) 
                  :op3 (a2 / antioxidant 
                        :ARG1-of (c / correlate-01) 
                        :op1-of (o2 / or 
                              :op2 (r3 / repair-01 
                                    :ARG0 - 
                                    :ARG1 (t / transcription) 
                                    :mod (d2 / DNA)) 
                              :op3 (g / gene)))) 
            :quant 1))

# ::snt There also is more than one possible explanation for the observed lack of correlation between CEBPG and antioxidant or DNA repair genes in BC individuals .
# ::tok There also is more than one possible explanation for the observed lack of correlation between CEBPG and antioxidant or DNA repair genes in BC individuals .
# ::alignments 24-25|0.0.1.3.0 23-24|0.0.1.3 21-22|0.0.1.1.0.2 20-21|0.0 19-20|0 18-19|0.0.1.1.0 17-18|0.0.1.1.0.1 16-17|0.0.1.1.0.0.1 15-16|0.0.1.1.0.0.0.0+0.0.1.1.0.0.0+0.0.1.1.0.0 13-14|0.0.1.1.1 11-12|0.0.1.1 10-11|0.0.1.1.2 7-8|0.0.1 6-7|0.0.1.2 3-4|0.0.1.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:43.880
(d / DNA 
      :mod-of (r / repair-01 
            :ARG0 (a3 / also) 
            :ARG1 (e / explain-01 
                  :ARG0 (m / more) 
                  :ARG1 (l / lack-01 
                        :ARG0 (o / or 
                              :op1 (o2 / organization 
                                    :name (n / name 
                                          :op1 "CEBPG") 
                                    :op1-of (a2 / and)) 
                              :op2 (a / antioxidant) 
                              :op3 (g / gene)) 
                        :ARG1 (c / correlation) 
                        :ARG1-of (o3 / observe-01)) 
                  :ARG1-of (p / possible-01) 
                  :op1-of (B / "BC" 
                        :mod-of (i / individual)))))

# ::snt For example , the non-BC individual and BC individual groups are not perfectly matched with respect to age , gender or smoking history ( Table 1 ) and each of these factors could contribute to the observed difference in correlation between groups .
# ::tok For example , the non-BC individual and BC individual groups are not perfectly matched with respect to age , gender or smoking history ( Table 1 ) and each of these factors could contribute to the observed difference in correlation between groups .
# ::alignments 41-42|0.0.1.0.0.2.0.0 39-40|0.0.2.2 37-38|0.0.2 36-37|0.0.2.1 33-34|0.0 32-33|0.0.1 31-32|0 30-31|0.2 28-29|0.1 27-28|0.0.1.0 25-26|0.0.0 24-25|0.0.2.0 22-23|0.0.1.0.0.2.0.1.1 21-22|0.0.1.0.0.2.0.1.1.0 20-21|0.0.1.0.0.2.0.1 19-20|0.0.1.0.0.2.0.1.0 17-18|0.0.1.0.0.2.0 15-16|0.0.1.0.0.2 13-14|0.0.1.0.0 12-13|0.0.1.0.0.1 11-12|0.0.1.0.0.3 9-10|0.0.1.1.2 8-9|0.0.1.1.0 7-8|0.0.1.1.2.0 6-7|0.0.1.1 5-6|0.0.1.1.1 1-2|0.0.1.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:44.658
(f / factor 
      :ARG0-of (c2 / contribute-01 
            :ARG1 1 
            :ARG1-of (p / possible-01 
                  :op2-of (a / and 
                        :op1 (m / match-01 
                              :ARG1 (e2 / example) 
                              :ARG1-of (p2 / perfect-02) 
                              :ARG2 (r / respect-01 
                                    :ARG1 (a2 / age-01 
                                          :ARG1 (g / group) 
                                          :op1-of (o2 / or 
                                                :op2 (g2 / gender) 
                                                :op3 (h / history 
                                                      :ARG1-of (s / smoke-02))))) 
                              :polarity -)) 
                  :op3-of (a3 / and 
                        :mod (i / individual) 
                        :op1 (i2 / individual) 
                        :op2 (g3 / group 
                              :mod "BC"))) 
            :ARG2 (d / differ-02 
                  :ARG1 (t2 / table) 
                  :ARG1-of (o / observe-01) 
                  :prep-in (c / correlation))) 
      :mod (e / each) 
      :mod (t / this))

# ::snt However , the lack of association of transcript abundance level for CEBPG , XRCC1 , ERCC5 , GSTP1 , SOD1 , or GPX1 with age , gender or smoking history argues against such an explanation .
# ::tok However , the lack of association of transcript abundance level for CEBPG , XRCC1 , ERCC5 , GSTP1 , SOD1 , or GPX1 with age , gender or smoking history argues against such an explanation .
# ::alignments 34-35|0.0.0.0 32-33|0.0.0.0.0 30-31|0.0.0 29-30|0.0.2.0 28-29|0.0.2 27-28|0.0 26-27|0.0.1 24-25|0 21-22|0.0.2.1 17-18|0.0.2.1.4 15-16|0.0.2.1.3.0.0+0.0.2.1.3.0+0.0.2.1.3 13-14|0.0.2.1.2.0.0+0.0.2.1.2.0+0.0.2.1.2 11-12|0.0.2.1.1.0.0+0.0.2.1.1.0+0.0.2.1.1 9-10|0.0.2.1.0.0.0 8-9|0.0.2.1.0.0.0.0 7-8|0.0.2.1.0.0.0.1.0+0.0.2.1.0.0.0.1 5-6|0.0.2.1.0.0 3-4|0.0.2.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:45.184
(a2 / age-01 
      :op1-of (o / or 
            :ARG0-of (a / argue-01 
                  :ARG1 (e / explain-01 
                        :mod (s / such))) 
            :op2 (g / gender) 
            :op3 (s2 / smoke-02 
                  :ARG0 (h / history) 
                  :op5-of (o2 / or 
                        :ARG0-of (l2 / lack-01 
                              :ARG1 (a4 / associate-01 
                                    :ARG1 (l / level 
                                          :mod (a3 / abundance) 
                                          :mod (t3 / thing 
                                                :ARG1-of (t4 / transcribe-01))))) 
                        :op1 (o3 / organization 
                              :name (n3 / name 
                                    :op1 "CEBPG")) 
                        :op2 (t2 / thing 
                              :name (n2 / name 
                                    :op1 "XRCC1")) 
                        :op3 (t / thing 
                              :name (n / name 
                                    :op1 "ERCC5")) 
                        :op4 (g2 / GSTP1)))))

# ::snt One way to examine this possibility is through additional , larger , more closely matched studies .
# ::tok One way to examine this possibility is through additional , larger , more closely matched studies .
# ::alignments 15-16|0.0 14-15|0 13-14|0.1 12-13|0.1.0 10-11|0.0.1 8-9|0.0.2 5-6|0.0.0.0.0 4-5|0.0.0.0.0.0 3-4|0.0.0.0 1-2|0.0.0 0-1|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:45.243
(m / match-01 
      :ARG1 (s / study-01 
            :ARG0 (w / way 
                  :manner-of (e / examine-01 
                        :ARG1 (p / possible-01 
                              :mod (t / this))) 
                  :quant 1) 
            :manner (l / large) 
            :mod (a / additional)) 
      :manner (c / close 
            :degree (m2 / more)))

# ::snt Another possible explanation is that any differences in NBEC from BC individuals compared to non-BC individuals resulted from development of BC , instead of being a hereditary cause of increased risk for cancer .
# ::tok Another possible explanation is that any differences in NBEC from BC individuals compared to non-BC individuals resulted from development of BC , instead of being a hereditary cause of increased risk for cancer .
# ::alignments 32-33|0.1.1 30-31|0.1 29-30|0.1.0 27-28|0 26-27|0.2 22-23|0.0.0.0.0.0.1.0.0 20-21|0.0.0.0.0.0.1.0.1.0 18-19|0.0.0.0.0.0.1.0.1 16-17|0.0.0.0.0.0.1.0 15-16|0.0.0.0.0.0.1 12-13|0.0.0.0.0.0 11-12|0.0.0.0.0.0.0 10-11|0.0.0.0.0.0.0.0 8-9|0.0.0.0.0.1.0+0.0.0.0.0.1+0.0.0.0.0 6-7|0.0.0.0 5-6|0.0.0.0.1 2-3|0.0.0 1-2|0.0 0-1|0.0.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:45.747
(c2 / cause-01 
      :ARG0 (p / possible-01 
            :ARG1 (e / explain-01 
                  :ARG0 (d2 / differ-01 
                        :location (c4 / country 
                              :ARG1-of (c3 / compare-01 
                                    :ARG0 (i4 / individual 
                                          :mod "BC") 
                                    :ARG2 (i3 / individual 
                                          :ARG1-of (r2 / result-01 
                                                :ARG1-of (i2 / instead-of-91) 
                                                :ARG2 (d / develop-02 
                                                      :ARG1 "BC")))) 
                              :name (n / name 
                                    :op1 "NBEC")) 
                        :mod (a / any)) 
                  :mod (a2 / another))) 
      :ARG1 (r / risk-01 
            :ARG1-of (i / increase-01) 
            :ARG2 (c / cancer)) 
      :mod (h / hereditary))

# ::snt The best way to determine this will be to conduct a prospective study .
# ::tok The best way to determine this will be to conduct a prospective study .
# ::alignments 12-13|0.1.0.0 11-12|0.1.0.0.0 9-10|0.1.0 5-6|0.0 4-5|0 2-3|0.1 1-2|0.1.1.0+0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:45.788
(d / determine-01 
      :ARG1 (t / this) 
      :manner (w / way 
            :ARG0-of (c / conduct-01 
                  :ARG1 (s / study-01 
                        :mod (p / prospective))) 
            :mod (g / good 
                  :degree (m / most))))

# ::snt In such a study , individuals matched for smoking history will be monitored for development of BC over time .
# ::tok In such a study , individuals matched for smoking history will be monitored for development of BC over time .
# ::alignments 18-19|0.1.1.0.0.0.0 16-17|0.1.0 14-15|0.1 12-13|0 9-10|0.1.1.0.0 8-9|0.1.1.0.0.0 6-7|0.1.1.0 5-6|0.1.1 3-4|0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:46.011
(m / monitor-01 
      :ARG1 (s2 / study-01 
            :mod (s3 / such)) 
      :ARG2 (d / develop-02 
            :ARG1 "BC" 
            :ARG2 (i / individual 
                  :ARG1-of (m2 / match-01 
                        :ARG2 (h / history 
                              :ARG1-of (s / smoke-02 
                                    :ARG0 (t / time)))))))

# ::snt The correlation of transcript abundance values for CEBPG relative to transcript abundance values for each of the antioxidant or DNA repair genes will be assessed .
# ::tok The correlation of transcript abundance values for CEBPG relative to transcript abundance values for each of the antioxidant or DNA repair genes will be assessed .
# ::alignments 24-25|0.1.1.0 21-22|0.2 20-21|0.1 19-20|0.1.1 18-19|0 17-18|0.0 14-15|0.0.0 12-13|0.1.0.0 11-12|0.1.0.0.0 10-11|0.1.0.0.0.0.0+0.1.0.0.0.0 8-9|0.1.0 5-6|0.1.1.0.0.0 4-5|0.1.1.0.0.0.0 3-4|0.1.1.0.0.0.0.0.0+0.1.1.0.0.0.0.0 1-2|0.1.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:46.430
(o / or 
      :op1 (a2 / antioxidant 
            :mod (e / each)) 
      :op2 (r / repair-01 
            :ARG1 (r2 / relative 
                  :prep-to (v / value 
                        :mod (a3 / abundance 
                              :mod (t / thing 
                                    :ARG1-of (t2 / transcribe-01))))) 
            :mod (d / DNA 
                  :ARG4-of (a / assess-01 
                        :ARG1 (c / correlation 
                              :beneficiary (v2 / value 
                                    :mod (a4 / abundance 
                                          :mod (t3 / thing 
                                                :ARG1-of (t4 / transcribe-01)))))))) 
      :op3 (g / gene))

# ::snt It is expected that the greatest incidence of BC will be among the heaviest smokers .
# ::tok It is expected that the greatest incidence of BC will be among the heaviest smokers .
# ::alignments 14-15|0.1.0+0.1.0.0 13-14|0.1.0.1 8-9|0.0.1.0 6-7|0.0.1 5-6|0.0.0+0.0 2-3|0 0-1|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:46.547
(e / expect-01 
      :ARG0 (g / great 
            :degree (m / most) 
            :mod-of (i / incidence 
                  :mod "BC")) 
      :ARG1 (i2 / it 
            :ARG1-of (s / smoke-02 
                  :ARG0 (p / person) 
                  :mod (h / heavy))))

# ::snt Among the matched heaviest smokers , it is expected that CEBPG will be significantly correlated with each of the antioxidant or DNA repair genes among the non-BC individuals but not correlated in BC individuals .
# ::tok Among the matched heaviest smokers , it is expected that CEBPG will be significantly correlated with each of the antioxidant or DNA repair genes among the non-BC individuals but not correlated in BC individuals .
# ::alignments 33-34|0.1.0 32-33|0.1.0.0 30-31|0.1 29-30|0.1.2 28-29|0 27-28|0.0.3.0.0.0.0 23-24|0.0.3.0.0.1 22-23|0.0.3.0.0.0 21-22|0.0.3.0.0.0.1 20-21|0.0.3.0.0 19-20|0.0.3.0 16-17|0.0.3 14-15|0.0 13-14|0.0.1 10-11|0.0.0.0.0+0.0.0.0+0.0.0 8-9|0.0.2 4-5|0.0.2.0.0+0.0.2.0 3-4|0.1.1.0 2-3|0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:46.909
(c2 / contrast-01 
      :ARG1 (c3 / correlate-01 
            :ARG1 (o2 / organization 
                  :name (n / name 
                        :op1 "CEBPG")) 
            :ARG1-of (s / significant-02) 
            :ARG1-of (e2 / expect-01 
                  :ARG0 (p / person 
                        :ARG0-of (s2 / smoke-02))) 
            :ARG2 (e / each 
                  :mod-of (a / antioxidant 
                        :op1-of (o / or 
                              :op2 (r / repair-01 
                                    :ARG1 (i2 / individual) 
                                    :mod (d / DNA)) 
                              :op3 (g / gene))))) 
      :ARG2 (c / correlate-01 
            :ARG0 (i / individual 
                  :mod "BC") 
            :ARG1 (m / match-01 
                  :ARG1 (h / heavy)) 
            :polarity -))

# ::snt Thus , there are multiple possible explanations for the observed findings .
# ::tok Thus , there are multiple possible explanations for the observed findings .
# ::alignments 10-11|0.0.0+0.0 9-10|0.0.1 6-7|0 5-6|0.1 4-5|0.2 0-1|0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:46.955
(e / explain-01 
      :ARG1 (t / thing 
            :ARG1-of (f / find-01) 
            :ARG1-of (o / observe-01 
                  :ARG0 (t2 / thu))) 
      :ARG1-of (p / possible-01) 
      :quant (m / multiple))

# ::snt However , based on the preponderance of data thus far available , we conclude that CEBPG is responsible for optimal transcriptional regulation of key antioxidant or DNA repair genes in NBEC and that there is inter-individual variation in the regulation of each of these genes by CEBPG .
# ::tok However , based on the preponderance of data thus far available , we conclude that CEBPG is responsible for optimal transcriptional regulation of key antioxidant or DNA repair genes in NBEC and that there is inter-individual variation in the regulation of each of these genes by CEBPG .
# ::alignments 44-45|0.1.0.0.0.0.0 43-44|0.1.0.0.0.0.0.0 41-42|0.1.0.0.0.0 39-40|0.1.0.0.0 36-37|0.1.0.0.0.1 31-32|0.1.1.0.0 30-31|0.1.1.0.0.0.0.0+0.1.1.0.0.0.0+0.1.1.0.0.0 28-29|0.1.1.0.2 27-28|0.1.0.0 26-27|0.1.0.0.1 25-26|0.1.1.0 24-25|0.1.1.0.1 23-24|0.1.1.0.1.0 21-22|0.1.1 19-20|0.1.1.1 17-18|0.1 15-16|0.1.0.1.0+0.1.0.1+0.1.0 13-14|0 12-13|0.0 10-11|0.0.0.0.0.0 9-10|0.0.0.0.0.0.0 8-9|0.0.0.0.0.0.1 7-8|0.0.0.0.0 5-6|0.0.0.0 2-3|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:48.067
(c2 / conclude-02 
      :ARG0 (w / we 
            :ARG0-of (b / base-02 
                  :ARG2 (p / preponderance 
                        :mod (d2 / data 
                              :ARG2-of (a3 / available-02 
                                    :manner (f / far) 
                                    :mod (t2 / thus-far)))))) 
      :ARG1 (r4 / responsible-01 
            :ARG0 (o3 / organization 
                  :ARG0-of (r2 / repair-01 
                        :ARG1 (r / regulate-01 
                              :ARG1 (e / each 
                                    :mod-of (g / gene 
                                          :mod (t / this))) 
                              :topic-of (v / variation)) 
                        :mod (d / DNA)) 
                  :name (n2 / name 
                        :op1 "CEBPG")) 
            :ARG1 (r3 / regulate-01 
                  :ARG1 (o / or 
                        :location (a / and 
                              :op1 (c / country 
                                    :name (n / name 
                                          :op1 "NBEC"))) 
                        :op1 (a2 / antioxidant 
                              :ARG1-of (k / key-02)) 
                        :op2 (g2 / gene)) 
                  :mod (o2 / optimal))))

# ::snt If this conclusion is correct , the individuals at greatest risk for BC will be those with the most extreme smoking history combined with sub-optimal regulation of the largest number of antioxidant and DNA repair genes .
# ::tok If this conclusion is correct , the individuals at greatest risk for BC will be those with the most extreme smoking history combined with sub-optimal regulation of the largest number of antioxidant and DNA repair genes .
# ::alignments 35-36|0.1.0.0.1 34-35|0.1.0.0.1.0.1.0 33-34|0.1.0.0.1.0.1 32-33|0.1.0.0.1.0 31-32|0.1.0.0.1.0.0 29-30|0.1.0.0 28-29|0.1.0.0.0.0+0.1.0.0.0 25-26|0.1.0 22-23|0.1.0.1 21-22|0.1.0.1.0 20-21|0.1.0.1.0.0 19-20|0.0.0 18-19|0.0 12-13|0.1.0.0.1.0.1.0.0.1 10-11|0.1.0.0.1.0.1.0.0 9-10|0.1.0.0.1.0.1.0.0.2.0+0.1.0.0.1.0.1.0.0.2 7-8|0.1.0.0.1.0.1.0.0.0 4-5|0.1 2-3|0 1-2|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:48.336
(c3 / conclude-01 
      :ARG1 (m2 / most 
            :degree-of (e / extreme)) 
      :ARG1-of (c2 / correct-02 
            :ARG1-of (r2 / regulate-01 
                  :ARG0 (n / number 
                        :mod (l / large 
                              :degree (m / most)) 
                        :quant-of (g / gene 
                              :op3-of (a / and 
                                    :op1 (a2 / antioxidant) 
                                    :op2 (d / DNA 
                                          :ARG1-of (r / repair-01 
                                                :ARG1-of (r3 / risk-01 
                                                      :ARG0 (i / individual) 
                                                      :ARG2 "BC" 
                                                      :mod (g2 / great 
                                                            :degree (m3 / most)))))))) 
                  :ARG2-of (c / combine-01 
                        :ARG1 (h / history 
                              :ARG1-of (s / smoke-02))))) 
      :mod (t / this))

# ::snt This , in turn , leads to increased representation among BC individuals of individuals with lack of correlation between CEBPG and each of the affected antioxidant and/or DNA repair genes .
# ::tok This , in turn , leads to increased representation among BC individuals of individuals with lack of correlation between CEBPG and each of the affected antioxidant and/or DNA repair genes .
# ::alignments 29-30|0.1.0 28-29|0.1 27-28|0.1.0.0 25-26|0.0 24-25|0 21-22|0.0.0.3 20-21|0.0.0 19-20|0.0.0.2.0.0+0.0.0.2.0+0.0.0.2 17-18|0.0.0.1.1 15-16|0.0.0.1 13-14|0.0.0.1.0 11-12|0.0.0.0.0.0 10-11|0.0.0.0.0.0.0 8-9|0.0.0.0.0 7-8|0.0.0.0 5-6|0.0.0.0.1 3-4|0.0.0.0.2 0-1|0.0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:49.125
(a2 / affect-01 
      :ARG1 (a / antioxidant 
            :op5-of (a3 / and 
                  :op1 (i3 / increase-01 
                        :ARG1 (r2 / representation-02 
                              :ARG0 (i2 / individual 
                                    :mod "BC")) 
                        :ARG1-of (l2 / lead-03 
                              :ARG0 (t2 / this)) 
                        :ARG2 (t / turn-01)) 
                  :op2 (l / lack-01 
                        :ARG0 (i / individual) 
                        :ARG1 (c / correlation)) 
                  :op3 (o / organization 
                        :name (n / name 
                              :op1 "CEBPG")) 
                  :op4 (e / each))) 
      :ARG2-of (r / repair-01 
            :mod-of (g / gene 
                  :op1-of (d / DNA))))

# ::snt CEBPG is a truncated CEBP transcription factor [ 19 ] and possesses the sequences necessary for DNA binding and heterodimer formation , but lacks the sequences necessary for transactivation [ 20 ] .
# ::tok CEBPG is a truncated CEBP transcription factor [ 19 ] and possesses the sequences necessary for DNA binding and heterodimer formation , but lacks the sequences necessary for transactivation [ 20 ] .
# ::alignments 30-31|0.0.0.0.0.0 28-29|0.0.0.0.0.1 25-26|0.1.0 23-24|0.1 22-23|0 20-21|0.1.1.0.1 19-20|0.1.1.0.1.1 18-19|0.1.1 17-18|0.1.1.0 16-17|0.1.1.0.0 13-14|0.0.1.0 11-12|0.0.1 10-11|0.0 8-9|0.1.1.0.1.0 6-7|0.0.0.0 5-6|0.0.0.0.1 3-4|0.0.0.0.0 0-1|0.0.0.1.0+0.0.0.1+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:49.493
(c / contrast-01 
      :ARG1 (a2 / and 
            :op1 (o / organization 
                  :domain-of (f2 / factor 
                        :mod (t3 / truncate-01 
                              :ARG0 20 
                              :ARG1 (t / transactivation)) 
                        :mod (t2 / transcription)) 
                  :name (n / name 
                        :op1 "CEBPG")) 
            :op2 (p / possess-01 
                  :ARG1 (s2 / sequence))) 
      :ARG2 (l / lack-01 
            :ARG1 (s / sequence) 
            :op2-of (a / and 
                  :op1 (b / binding-07 
                        :ARG0 (d / DNA) 
                        :ARG1 (f / form-01 
                              :ARG0 19 
                              :ARG1 (h / heterodim))))))

# ::snt CEBPG forms heterodimers with other CEBP family members and in other tissues this leads to increased [ 21 ] or decreased [ 20 ] transcription of the regulated gene .
# ::tok CEBPG forms heterodimers with other CEBP family members and in other tissues this leads to increased [ 21 ] or decreased [ 20 ] transcription of the regulated gene .
# ::alignments 28-29|0.3.0.0 27-28|0.3.0.0.0 24-25|0.3.0 22-23|0.2.0.0.0 20-21|0.3 19-20|0.3.1 17-18|0.3.0.0.0.0 15-16|0.2.0.0 13-14|0.2 12-13|0.2.0 11-12|0.2.1 10-11|0.2.1.0 8-9|0 7-8|0.1.0.1+0.1.0+0.1 6-7|0.1.0.0 4-5|0.2.1.1 2-3|0.0.1 1-2|0.0 0-1|0.0.0.0.0+0.0.0.0+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:49.931
(a / and 
      :op1 (f2 / form-02 
            :ARG0 (o4 / organization 
                  :name (n / name 
                        :op1 "CEBPG")) 
            :ARG1 (h2 / heterodimer)) 
      :op2 (p / person 
            :ARG0-of (h / have-org-role-91 
                  :ARG1 (f / family) 
                  :ARG2 (m / member))) 
      :op3 (l / lead-03 
            :ARG0 (t2 / this 
                  :ARG0-of (i / increase-01 
                        :ARG1 20)) 
            :ARG1 (t3 / tissue 
                  :mod (o2 / other) 
                  :mod (o3 / other))) 
      :op4 (d / decrease-01 
            :ARG1 (t / transcription 
                  :poss (g / gene 
                        :ARG1-of (r / regulate-01 
                              :ARG0 21))) 
            :op1-of (o / or)))

# ::snt CEBPG is known to have stimulatory effect on the IL-6 and IL-8 promoters in B cell lines [ 21 ] , and can also act as a dominant negative regulator of CEBPA and CEBPB in fibroblast and B cell lines [ 20 ] .
# ::tok CEBPG is known to have stimulatory effect on the IL-6 and IL-8 promoters in B cell lines [ 21 ] , and can also act as a dominant negative regulator of CEBPA and CEBPB in fibroblast and B cell lines [ 20 ] .
# ::alignments 41-42|0.0.1.0.0.1 39-40|0.1.1.2 38-39|0.1.1.2.0 37-38|0.1.1.1.1+0.1.1.1.0.0+0.1.1.1.0+0.1.1.1 36-37|0.1.1 35-36|0.1.1.0 33-34|0.1.0.0+0.1.0+0.1 32-33|0 31-32|0.0.0.0+0.0.0+0.0 29-30|0.0.1 28-29|0.0.1.2 27-28|0.0.1.1 24-25|0.0.1.0 23-24|0.0.1.0.2 22-23|0.0.1.0.1 21-22|0.0.1.0.3 18-19|0.0.1.0.3.0.0 16-17|0.0.1.0.3.1 15-16|0.0.1.0.3.1.0 14-15|0.0.1.0.3.1.0.0.1+0.0.1.0.3.1.0.0.0.0+0.0.1.0.3.1.0.0.0+0.0.1.0.3.1.0.0 12-13|0.0.1.0.0.0.0+0.0.1.0.0.0 11-12|0.0.1.0.0.0.1.1.0.0+0.0.1.0.0.0.1.1.0+0.0.1.0.0.0.1.1 10-11|0.0.1.0.0.0.1 9-10|0.0.1.0.0.0.1.0.0.0+0.0.1.0.0.0.1.0.0+0.0.1.0.0.0.1.0 6-7|0.0.1.0.0 2-3|0.0.1.0.3.0 0-1|0.0.1.0.3.0.1.0.0+0.0.1.0.3.0.1.0+0.0.1.0.3.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:53.612
(a2 / and 
      :op1 (o2 / organization 
            :name (n3 / name 
                  :op1 "CEBPA") 
            :poss-of (r / regulator 
                  :ARG1-of (a3 / act-02 
                        :ARG0 (e / effect-03 
                              :ARG0 (p2 / person 
                                    :ARG0-of (p3 / promote-02) 
                                    :op3-of (a6 / and 
                                          :op1 (t2 / thing 
                                                :name (n7 / name 
                                                      :op1 "IL-6")) 
                                          :op2 (t / thing 
                                                :name (n6 / name 
                                                      :op1 "IL-8")))) 
                              :ARG1 20) 
                        :ARG1-of (p / possible-01) 
                        :mod (a4 / also) 
                        :op3-of (a5 / and 
                              :ARG3-of (k / know-02 
                                    :ARG0 21 
                                    :ARG1 (o3 / organization 
                                          :name (n8 / name 
                                                :op1 "CEBPG"))) 
                              :op1 (l3 / line 
                                    :mod (c2 / cell 
                                          :mod (l4 / location 
                                                :name (n5 / name 
                                                      :op1 "B") 
                                                :wiki -))) 
                              :op2 p)) 
                  :ARG1-of (d / dominate-01) 
                  :mod (n4 / negative))) 
      :op2 (o / organization 
            :name (n2 / name 
                  :op1 "CEBPB") 
            :op1-of (a / and 
                  :op2 (f / fibroblast) 
                  :op3 (l2 / location 
                        :name (n / name 
                              :op1 "B") 
                        :wiki -) 
                  :op4 (l / line 
                        :mod (c / cell)))))

# ::snt The data from CEBPG knockout mice support a role for CEBPG in protecting lungs from oxidant damage .
# ::tok The data from CEBPG knockout mice support a role for CEBPG in protecting lungs from oxidant damage .
# ::alignments 16-17|0.2.2 15-16|0.2.2.0 13-14|0.2.1 12-13|0.2 8-9|0.1 6-7|0 5-6|0.2.0 4-5|0.2.0.0 3-4|0.2.0.1.0.0+0.2.0.1.0+0.2.0.1 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:53.941
(s / support-01 
      :ARG0 (d2 / data) 
      :ARG1 (r / role) 
      :ARG2 (p / protect-01 
            :ARG0 (m / mouse 
                  :mod (k / knockout) 
                  :mod (o2 / organization 
                        :name (n / name 
                              :op1 "CEBPG"))) 
            :ARG1 (l / lung) 
            :ARG2 (d / damage-01 
                  :ARG1 (o / oxidant))))

# ::snt CEBPG - / - knockout mice are healthy at birth but begin to die within 24 hours , and histological examination reveals emphysematous lungs [ 22 ] .
# ::tok CEBPG - / - knockout mice are healthy at birth but begin to die within 24 hours , and histological examination reveals emphysematous lungs [ 22 ] .
# ::alignments 25-26|0.0.1 23-24|0.1 22-23|0.1.0 21-22|0 20-21|0.0 19-20|0.0.0 18-19|0.3 16-17|0.2.1+0.2 15-16|0.2.0 13-14|0.3.0.0.1 11-12|0.3.0.0 10-11|0.3.0 9-10|0.3.0.0.0.0 7-8|0.3.0.0.0.1 5-6|0.3.0.0.0 4-5|0.3.0.0.0.2 2-3|0.3.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:54.731
(r / reveal-01 
      :ARG0 (e2 / examine-01 
            :ARG0 (h / histological) 
            :ARG1 22) 
      :ARG1 (l / lung 
            :mod (e / emphysematou)) 
      :ARG2 (t / temporal-quantity 
            :quant 24 
            :unit (h2 / hour)) 
      :op1-of (a / and 
            :ARG1-of (c / contrast-01 
                  :ARG2 (b / begin-01 
                        :ARG0 (m / mouse 
                              :ARG1-of (b2 / birth-01) 
                              :domain-of (h3 / healthy) 
                              :mod (k / knockout)) 
                        :ARG1 (d / die-01 
                              :ARG1 (s / slash))))))

# ::snt In humans , risk for emphysema is associated with antioxidant capacity [ 23 ] , and there is a strong correlation between risk for emphysema and risk for BC .
# ::tok In humans , risk for emphysema is associated with antioxidant capacity [ 23 ] , and there is a strong correlation between risk for emphysema and risk for BC .
# ::alignments 28-29|0.1.0.1.0.1 26-27|0.1.0 25-26|0.1.0.1 24-25|0.1.0.1.0.0 22-23|0.1.0.1.0 20-21|0.1 19-20|0.1.1 15-16|0 12-13|0.1.0.0 10-11|0.0.0 9-10|0.0.2 7-8|0.0 5-6|0.0.1.0 3-4|0.0.1 1-2|0.2 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:55.210
(a2 / and 
      :op1 (a4 / associate-01 
            :ARG0 (c2 / capacity) 
            :ARG1 (r3 / risk-01 
                  :ARG2 (e2 / emphysema)) 
            :ARG2 (a3 / antioxidant)) 
      :op2 (c / correlation 
            :ARG0-of (r / risk-01 
                  :ARG1 23 
                  :op1-of (a / and 
                        :ARG1-of (r2 / risk-01 
                              :ARG0 (e / emphysema) 
                              :ARG2 "BC"))) 
            :ARG1-of (s / strong-02)) 
      :prep-in (h / human))

# ::snt However , it will be important to obtain direct experimental evidence in NBECs for the role of CEBPG in regulating the antioxidant and DNA repair genes included in this study .
# ::tok However , it will be important to obtain direct experimental evidence in NBECs for the role of CEBPG in regulating the antioxidant and DNA repair genes included in this study .
# ::alignments 29-30|0.0.0 28-29|0.0.0.1 26-27|0.0 25-26|0.3 24-25|0.0.0.0 23-24|0.0.0.0.0 22-23|0 21-22|0.2.0 19-20|0.2 15-16|0.1 12-13|0.1.0.2 10-11|0.1.0 9-10|0.1.0.3 8-9|0.1.0.0 7-8|0.1.0.1 5-6|0.1.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:55.995
(a / and 
      :ARG1-of (i / include-01 
            :ARG2 (s / study-01 
                  :ARG2 (r / repair-01 
                        :ARG1 (d / DNA)) 
                  :mod (t / this))) 
      :op1 (r3 / role 
            :ARG1-of (e / evidence-01 
                  :ARG1-of (d2 / direct-02) 
                  :ARG1-of (o / obtain-01 
                        :domain-of (i2 / important)) 
                  :location (n / nbec) 
                  :mod (e2 / experiment-01))) 
      :op2 (r2 / regulate-01 
            :ARG1 (a2 / antioxidant)) 
      :op3 (g / gene))

# ::snt Correlation between CEBPG and target gene transcript levels may not be associated with correlation at the protein level .
# ::tok Correlation between CEBPG and target gene transcript levels may not be associated with correlation at the protein level .
# ::alignments 17-18|0.3.0.1.0 16-17|0.3.0.1.0.0 13-14|0.3.0.1 11-12|0.3.0 9-10|0.3.1 8-9|0.3 7-8|0.2 6-7|0.2.0+0.2.0.0 5-6|0.2.1 4-5|0.1 3-4|0 2-3|0.0.0.0+0.0.0+0.0 0-1|0.3.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:56.737
(a2 / and 
      :op1 (o / organization 
            :name (n / name 
                  :op1 "CEBPG")) 
      :op2 (t3 / target-01) 
      :op3 (l2 / level 
            :ARG2-of (t2 / transcribe-01 
                  :ARG1 (t / thing)) 
            :mod (g / gene)) 
      :op4 (p2 / possible-01 
            :ARG1 (a / associate-01 
                  :ARG1 (c2 / correlation) 
                  :ARG2 (c / correlation 
                        :location (l / level 
                              :mod (p / protein)))) 
            :polarity -))

# ::snt In this study , E2F1 correlation with DNA repair and antioxidant genes was less than the correlation observed with CEBPG , and the E2F1 correlation was observed in both non-BC individuals as well as BC individuals .
# ::tok In this study , E2F1 correlation with DNA repair and antioxidant genes was less than the correlation observed with CEBPG , and the E2F1 correlation was observed in both non-BC individuals as well as BC individuals .
# ::alignments 35-36|0.2.0.2.0.1.2 34-35|0.2.0.2.0.1.2.0 30-31|0.2.0.2.0.1.0 28-29|0.2.0.2.0.1.0.0 26-27|0.2.0.2.0.1 24-25|0.2.0.2.0.1.1 21-22|0.2.0.2.0 19-20|0.2.0.1.0.0+0.2.0.1.0+0.2.0.1 17-18|0.2.0 16-17|0.2.0.0 13-14|0.2.0.2 11-12|0.1 10-11|0.1.0 9-10|0 8-9|0.0 7-8|0.0.0 5-6|0.2 4-5|0.2.1 2-3|0.2.0.2.0.0 1-2|0.2.0.2.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:57.215
(a3 / and 
      :op1 (r / repair-01 
            :ARG1 (d / DNA)) 
      :op2 (g / gene 
            :mod (a2 / antioxidant)) 
      :topic-of (c3 / correlation 
            :ARG1-of (o3 / observe-01 
                  :ARG0 (c2 / correlation) 
                  :ARG2 (o2 / organization 
                        :name (n / name 
                              :op1 "CEBPG")) 
                  :compared-to-of (l / less 
                        :op1-of (a / and 
                              :ARG1-of (s / study-01 
                                    :mod (t / this)) 
                              :op2 (o / observe-01 
                                    :ARG0 (i2 / individual 
                                          :mod (b / both)) 
                                    :ARG1 (c / correlation) 
                                    :ARG2 (i / individual 
                                          :mod "BC"))))) 
            :mod (e / E2F1)))

# ::snt The maintained correlation of E2F1 with DNA repair and antioxidant genes in BC individuals suggests that this function is more tightly controlled in the population and does not play a role in determination of risk for BC .
# ::tok The maintained correlation of E2F1 with DNA repair and antioxidant genes in BC individuals suggests that this function is more tightly controlled in the population and does not play a role in determination of risk for BC .
# ::alignments 36-37|0.1.0.0.1 34-35|0.1.0.0.0.0.0 32-33|0.1.0.0.0.0 30-31|0.1.0.0.0 28-29|0.1.0.0 27-28|0.1.0.0.2 25-26|0.1.0 24-25|0.1.3 21-22|0.1 20-21|0.1.2 19-20|0.1.2.0 17-18|0.1.1 16-17|0.1.1.1 14-15|0 13-14|0.1.1.0.0 12-13|0.1.1.0 10-11|0.1.1.2.1 9-10|0.1.1.2.1.0 8-9|0.1.1.2 7-8|0.1.1.2.0 6-7|0.1.1.2.0.0 2-3|0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:58.729
(s / suggest-01 
      :ARG0 (c2 / correlation 
            :ARG1-of (m2 / maintain-01)) 
      :ARG1 (c / control-01 
            :ARG0 (a / and 
                  :op1 (p / play-01 
                        :ARG1 (r2 / role 
                              :ARG2-of (d / determine-01 
                                    :ARG1 (r / risk-01))) 
                        :ARG2 "BC" 
                        :polarity -)) 
            :ARG1 (f / function-01 
                  :ARG2 (B2 / "BC" 
                        :mod-of (i / individual)) 
                  :mod (t2 / this) 
                  :op3-of (a3 / and 
                        :op1 (r3 / repair-01 
                              :ARG1 (d2 / DNA)) 
                        :op2 (g / gene 
                              :mod (a2 / antioxidant)))) 
            :ARG1-of (t / tight-05 
                  :degree (m / more)) 
            :location (p2 / population)))

# ::snt E2F1 has previously been reported to regulate transcription of DNA repair enzyme genes in other cell types , including primary human fibroblasts and mouse epidermal cells [ 24,25 ] .
# ::tok E2F1 has previously been reported to regulate transcription of DNA repair enzyme genes in other cell types , including primary human fibroblasts and mouse epidermal cells [ 24,25 ] .
# ::alignments 25-26|0.4 24-25|0.4.0 23-24|0.4.0.0 22-23|0 21-22|0.3 20-21|0.3.0 19-20|0.3.1 16-17|0.2.0 15-16|0.2 14-15|0.2.0.0 12-13|0.1 11-12|0.1.0 10-11|0.1.0.0 9-10|0.1.0.0.0 7-8|0.0.0 6-7|0.0 4-5|0.0.1 2-3|0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:59.272
(a / and 
      :ARG0-of (r2 / regulate-01 
            :ARG1 (t2 / transcription) 
            :ARG1-of (r3 / report-01 
                  :time (p2 / previous))) 
      :op1 (g / gene 
            :mod (e2 / enzyme 
                  :ARG0-of (r / repair-01 
                        :mod (d / DNA)))) 
      :op2 (c2 / cell 
            :mod-of (t / type 
                  :mod (o / other))) 
      :op3 (f / fibroblast 
            :mod (h / human) 
            :mod (p / primary)) 
      :op4 (c / cell 
            :mod (e / epidermal 
                  :mod (m / mouse))))

# ::snt Clearly this would have survival value since DNA repair gene up-regulation in response to E2F1 provides additional DNA repair when the DNA is replicating and is particularly vulnerable to damage .
# ::tok Clearly this would have survival value since DNA repair gene up-regulation in response to E2F1 provides additional DNA repair when the DNA is replicating and is particularly vulnerable to damage .
# ::alignments 29-30|0 27-28|0.1 26-27|0.1.0 24-25|0.1.1 23-24|0.1.1.2.1 21-22|0.1.1.2.1.0 18-19|0.1.1.2.0 17-18|0.1.1.2.0.0 16-17|0.1.1.2.0.0.0 15-16|0.1.1.2 12-13|0.1.1.0 9-10|0.1.1.2.2.0.0.0.0 8-9|0.1.1.2.2.0.0.0 7-8|0.1.1.2.2.0.0.0.1 6-7|0.1.1.2.2 5-6|0.1.1.2.2.0 4-5|0.1.1.2.2.0.0 1-2|0.0 0-1|0.1.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:59.542
(d / damage-01 
      :ARG1 (t / this) 
      :prep-to-of (v / vulnerable 
            :mod (p / particular) 
            :op2-of (a / and 
                  :ARG1-of (r3 / respond-01) 
                  :ARG1-of (c / clear-06) 
                  :op1 (p2 / provide-01 
                        :ARG1 (r2 / repair-01 
                              :ARG1 (d3 / DNA 
                                    :mod (a2 / additional))) 
                        :concession (r / replicate-01 
                              :ARG1 (d2 / DNA)) 
                        :op1-of (s / since 
                              :time-of (v2 / value-01 
                                    :ARG1 (s2 / survive-01 
                                          :ARG1 (r4 / repair-01 
                                                :ARG1 (g / gene) 
                                                :mod (d4 / DNA)))))))))

# ::snt Epidemiologic assessment of the correlation between a particular variation in DNA sequence , or polymorphism , and risk for BC has been a dominant paradigm for many years .
# ::tok Epidemiologic assessment of the correlation between a particular variation in DNA sequence , or polymorphism , and risk for BC has been a dominant paradigm for many years .
# ::alignments 27-28|0.1.3.1+0.1.3 26-27|0.1.3.0 24-25|0.1.0 23-24|0.1.0.0 19-20|0.1.2 17-18|0.1 16-17|0 14-15|0.1.4.1 13-14|0.1.4 11-12|0.0 10-11|0.0.0 8-9|0.1.4.0 7-8|0.1.4.0.0 4-5|0.1.1.0 1-2|0.1.1 0-1|0.1.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:59.713
(a / and 
      :op1 (s / sequence 
            :mod (d2 / DNA)) 
      :op2 (r / risk-01 
            :ARG0 (p / paradigm 
                  :ARG1-of (d / dominate-01)) 
            :ARG1 (a2 / assess-01 
                  :ARG1 (c / correlation) 
                  :mod (e / epidemiologic)) 
            :ARG2 "BC" 
            :mod (t / temporal-quantity 
                  :op1-of (m / many) 
                  :unit (y / year)) 
            :op3-of (o / or 
                  :op1 (v / variation 
                        :mod (p3 / particular)) 
                  :op2 (p2 / polymorphism))))

# ::snt Thus far , these efforts have met with scant success [ 26 ] .
# ::tok Thus far , these efforts have met with scant success [ 26 ] .
# ::alignments 11-12|0.0.0.0.0 9-10|0.0.0 8-9|0.0.0.1 6-7|0 4-5|0.0 3-4|0.0.1 1-2|0.1 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:12:59.821
(m / meet-03 
      :ARG0 (e / effort 
            :ARG0-of (s / succeed-01 
                  :ARG1 (t2 / thu 
                        :poss 26) 
                  :ARG1-of (s2 / scant-02)) 
            :mod (t / this)) 
      :degree (f / far))

# ::snt A common limitation in design of such studies is that they involve assessment of a single polymorphism or occasionally , a few polymorphisms .
# ::tok A common limitation in design of such studies is that they involve assessment of a single polymorphism or occasionally , a few polymorphisms .
# ::alignments 22-23|0.0.1 21-22|0.0.1.0 18-19|0 17-18|0.0 16-17|0.0.0.0 15-16|0.0.0.0.0 12-13|0.0.0 11-12|0.0.0.1 10-11|0.0.0.1.0 7-8|0.0.0.1.1 6-7|0.0.0.1.1.1 4-5|0.0.0.1.1.0 2-3|0.0.0.1.2 1-2|0.0.0.1.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:00.521
(o / occasional 
      :op1-of (o2 / or 
            :ARG1-of (a / assess-01 
                  :ARG0 (p2 / polymorphism 
                        :ARG1-of (s / single-02)) 
                  :ARG1-of (i / involve-01 
                        :ARG0 (t / they) 
                        :ARG1-of (s2 / study-01 
                              :ARG1-of (d / design-01) 
                              :mod (s3 / such)) 
                        :ARG1-of (l / limit-01 
                              :mod (c / common)))) 
            :op2 (p / polymorphism 
                  :quant (f / few))))

# ::snt Further , although the polymorphism assessed typically resides within a gene known to protect bronchial epithelium from carcinogens , oxidants , or DNA damage , the selection of the particular polymorphism for study is largely empiric , and not based on known functional properties .
# ::tok Further , although the polymorphism assessed typically resides within a gene known to protect bronchial epithelium from carcinogens , oxidants , or DNA damage , the selection of the particular polymorphism for study is largely empiric , and not based on known functional properties .
# ::alignments 43-44|0.3.1 42-43|0.3.1.0 41-42|0.1 39-40|0.3 38-39|0.3.2 37-38|0 35-36|0.2 34-35|0.2.0 32-33|0.4.0 30-31|0.4 29-30|0.4.1 26-27|0.3.0 23-24|0.3.0.0.0.1 22-23|0.3.0.0.0.1.1 21-22|0.3.0.0.0 19-20|0.3.0.0 17-18|0.3.0.0.0.0 15-16|0.3.0.0.0.1.2.0 14-15|0.3.0.0.0.1.2.0.0 13-14|0.3.0.0.0.1.2 11-12|0.3.0.0.0.1.2.1 10-11|0.3.0.0.0.1.2.1.0 7-8|0.0.0 6-7|0.0 5-6|0.0.0.0.0 4-5|0.0.0.0 0-1|0.3.0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:02.636
(a / and 
      :ARG1-of (t / typical-02 
            :manner-of (r / reside-01 
                  :ARG1 (p5 / polymorphism 
                        :ARG1-of (a2 / assess-01)))) 
      :ARG1-of (k / know-02) 
      :op1 (e / empiric 
            :degree (l / large)) 
      :op2 (b / base-02 
            :ARG1 (s2 / select-01 
                  :ARG1 (o2 / oxidant 
                        :op2-of (o / or 
                              :op1 (c / carcinogen) 
                              :op3 (d / damage-01 
                                    :ARG0 (f2 / further) 
                                    :ARG1 (d2 / DNA) 
                                    :ARG2-of (p4 / protect-01 
                                          :ARG1 (e2 / epithelium 
                                                :mod (b2 / bronchial)) 
                                          :purpose-of (k2 / know-02 
                                                :ARG1 (g / gene))))))) 
            :ARG2 (p / property 
                  :mod (f / functional)) 
            :polarity -) 
      :poss (p2 / polymorphism 
            :ARG1-of (s / study-01) 
            :mod (p3 / particular)))

# ::snt These are problems because multiple infrequent polymorphisms at different sites may all contribute to risk and unless the key polymorphisms can be identified through a functional test , a statistically valid assessment would require much larger study populations [ 27 ] .
# ::tok These are problems because multiple infrequent polymorphisms at different sites may all contribute to risk and unless the key polymorphisms can be identified through a functional test , a statistically valid assessment would require much larger study populations [ 27 ] .
# ::alignments 39-40|0.2.0.0.0 37-38|0.0.1 36-37|0.0.1.0 35-36|0.0.1.1 34-35|0.1.3.0 33-34|0.0 31-32|0.0.0 30-31|0.0.0.0 29-30|0.0.0.0.0 26-27|0.2.2 25-26|0.2.2.0 22-23|0.2 20-21|0.2.1 19-20|0.2.0 18-19|0.2.0.0 15-16|0 14-15|0.1.3 12-13|0.1 11-12|0.1.4 10-11|0.1.2 9-10|0.1.1 8-9|0.1.1.0 6-7|0.1.0 5-6|0.1.0.0 4-5|0.1.0.1 3-4|0.1.2.0 2-3|0.1.2.0.0 0-1|0.1.2.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:04.651
(a2 / and 
      :ARG2-of (r / require-01 
            :ARG0 (a / assess-01 
                  :ARG1-of (v / valid-02 
                        :degree (s2 / statistics))) 
            :ARG1 (p / population 
                  :ARG0-of (s / study-01) 
                  :mod (l / large))) 
      :op1 (c / contribute-01 
            :ARG0 (p5 / polymorphism 
                  :mod (i2 / infrequent) 
                  :quant (m2 / multiple)) 
            :ARG1 (s3 / site 
                  :ARG1-of (d / differ-02)) 
            :ARG1-of (p4 / possible-01 
                  :ARG0-of (c2 / cause-01 
                        :ARG1 (p6 / problem 
                              :domain (t2 / this)))) 
            :ARG2 (r2 / risk-01 
                  :ARG1 (m / much)) 
            :manner (a3 / all)) 
      :op2 (i / identify-01 
            :ARG1 (p3 / polymorphism 
                  :ARG1-of (k / key-02 
                        :ARG0 27)) 
            :ARG1-of (p2 / possible-01) 
            :ARG2 (t / test-01 
                  :ARG1 (f / functional))))

# ::snt The findings of this study support a novel approach to identifying clinically useful biomarkers .
# ::tok The findings of this study support a novel approach to identifying clinically useful biomarkers .
# ::alignments 13-14|0.0.0 12-13|0.0 11-12|0 10-11|0.0.0.0 8-9|0.0.0.0.0 7-8|0.0.0.0.0.1 5-6|0.0.0.0.0.0 4-5|0.0.0.0.1 3-4|0.0.0.0.1.0 1-2|0.0.0.0.0.0.0.0+0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:05.124
(c / clinically 
      :mod-of (u / useful-05 
            :ARG1 (b / biomarker 
                  :ARG1-of (i / identify-01 
                        :ARG1-of (a / approach-02 
                              :ARG1-of (s / support-01 
                                    :ARG0 (t2 / thing 
                                          :ARG1-of (f / find-01))) 
                              :mod (n / novel)) 
                        :manner (s2 / study-01 
                              :mod (t / this))))))

# ::snt According to the paradigm used in this study , a ) a normal phenotype results from regulated transcription of a group of genes by one or more transcription factors , b ) the corresponding risk-conferring or disease phenotype results from sub-optimal interaction among those same genes , and c ) each phenotype is identifiable and distinguishable through virtually-multiplexed transcript abundance analysis .
# ::tok According to the paradigm used in this study , a ) a normal phenotype results from regulated transcription of a group of genes by one or more transcription factors , b ) the corresponding risk-conferring or disease phenotype results from sub-optimal interaction among those same genes , and c ) each phenotype is identifiable and distinguishable through virtually-multiplexed transcript abundance analysis .
# ::alignments 60-61|0.1.0.1.0.0 59-60|0.1.0.1.0.0.1 58-59|0.1.0.1.0.0.0.0+0.1.0.1.0.0.0 57-58|0.1.0.1.0.0.2 55-56|0.1.1.0.0 54-55|0.1.1.1 53-54|0.1.1 51-52|0.1.1.0 50-51|0.1.1.0.1 48-49|0.1.1.1.0 47-48|0.1 45-46|0.1.0.1.0.1.0 44-45|0.1.0.1.0.1.0.0 41-42|0.1.0.1.0.1 38-39|0.1.0.1.0 37-38|0.1.0 36-37|0.1.0.0 35-36|0.1.0.1 34-35|0.1.0.1.2 33-34|0.1.0.1.2.0 30-31|0.1.0.1.0.2 28-29|0.1.0.1.1.1.0 27-28|0.1.0.1.1.1.0.0 26-27|0.1.0.1.1.1.0.1.0 25-26|0.1.0.1.1.1.0.1 22-23|0.1.0.1.1.1.1.1.0 20-21|0.1.0.1.1.1.1.1 17-18|0.1.0.1.1.1.1 16-17|0.1.0.1.1.1.1.0 14-15|0.1.0.1.1.1 13-14|0.1.0.1.1 12-13|0.1.0.1.1.0 7-8|0.0.0.0 6-7|0.0.0.0.0 4-5|0.0.0 3-4|0.0 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:07.951
(s3 / say-01 
      :ARG0 (p4 / paradigm 
            :ARG1-of (u / use-01 
                  :ARG2 (s2 / study-01 
                        :mod (t5 / this)))) 
      :ARG1 (a4 / and 
            :op1 (p2 / phenotype 
                  :mod (d2 / disease) 
                  :op3-of (o / or 
                        :ARG0-of (r / result-01 
                              :ARG1 (a / analyze-01 
                                    :ARG0 (t / thing 
                                          :ARG1-of (t2 / transcribe-01)) 
                                    :ARG1 (a2 / abundance) 
                                    :manner (v / virtually-multiplex)) 
                              :ARG2 (i2 / interact-01 
                                    :ARG0 (g / gene 
                                          :ARG1-of (s / same-01))) 
                              :li (b / b)) 
                        :op1 (p3 / phenotype 
                              :ARG1-of (n / normal-02) 
                              :ARG1-of (r4 / result-01 
                                    :ARG0 (f / factor 
                                          :mod (t3 / transcription) 
                                          :op2-of (o2 / or 
                                                :op1 (m / more))) 
                                    :ARG2 (t4 / transcription 
                                          :ARG1-of (r3 / regulate-01) 
                                          :poss (g3 / group 
                                                :consist-of (g2 / gene))))) 
                        :op2 (r2 / risk-conferr 
                              :ARG1-of (c2 / correspond-01)))) 
            :op2 (i / identifiable 
                  :domain (p / phenotype 
                        :domain-of (d / distinguishable) 
                        :mod (e / each)) 
                  :op1-of (a3 / and 
                        :li (c / c)))))

# ::snt The data presented here support the utility of this paradigm in identifying genes associated with risk for BC .
# ::tok The data presented here support the utility of this paradigm in identifying genes associated with risk for BC .
# ::alignments 17-18|0.2.1.0.0.0 15-16|0.2.1.0.0 13-14|0.2.1.0 12-13|0.2.1 11-12|0.2 9-10|0.2.0 8-9|0.2.0.0 6-7|0.1 4-5|0 3-4|0.0.0.0 2-3|0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:08.342
(s / support-01 
      :ARG0 (d / data 
            :ARG1-of (p2 / present-01 
                  :location (h / here))) 
      :ARG1 (u / utility) 
      :ARG2 (i / identify-01 
            :ARG0 (p / paradigm 
                  :mod (t / this)) 
            :ARG1 (g / gene 
                  :ARG1-of (a / associate-01 
                        :ARG2 (r / risk-01 
                              :ARG2 "BC")))))

# ::snt The next step will be to identify polymorphisms that affect regulation of XRCC1 , ERCC5 , GSTP1 , SOD1 , and GPX1 by CEBPG .
# ::tok The next step will be to identify polymorphisms that affect regulation of XRCC1 , ERCC5 , GSTP1 , SOD1 , and GPX1 by CEBPG .
# ::alignments 23-24|0.4.0.0+0.4.0+0.4 20-21|0 16-17|0.3 14-15|0.2.0.0+0.2.0+0.2 12-13|0.1.0.0+0.1.0+0.1 10-11|0.0 9-10|0.0.0 7-8|0.0.0.0 6-7|0.0.0.0.0 2-3|0.0.0.0.0.0 1-2|0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:08.512
(a / and 
      :ARG1-of (r / regulate-01 
            :ARG1-of (a2 / affect-01 
                  :ARG0 (p3 / polymorphism 
                        :ARG1-of (i / identify-01 
                              :ARG0 (s / step 
                                    :mod (n4 / next)))))) 
      :op1 (p2 / person 
            :name (n3 / name 
                  :op1 "XRCC1")) 
      :op2 (p / person 
            :name (n2 / name 
                  :op1 "ERCC5")) 
      :op3 (g / GSTP1) 
      :op4 (o / organization 
            :name (n / name 
                  :op1 "CEBPG")))

# ::snt Such polymorphisms should yield biomarkers suitable for more readily accessible samples , such as peripheral blood or buccal smears .
# ::tok Such polymorphisms should yield biomarkers suitable for more readily accessible samples , such as peripheral blood or buccal smears .
# ::alignments 18-19|0.1.1.0.0.2.1 17-18|0.1.1.0.0.2.1.0 16-17|0.1.1.0.0.2 15-16|0.1.1.0.0.2.0 14-15|0.1.1.0.0.2.0.0 12-13|0.0 10-11|0.1.1.0.0.0+0.1.1.0.0 9-10|0.1.1.0.0.1 8-9|0.1.1.0.0.1.0 7-8|0.1.1.0.0.1.0.0 5-6|0.1.1.0 4-5|0.1.1 3-4|0.1 2-3|0 1-2|0.1.0 0-1|0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:08.752
(r2 / recommend-01 
      :ARG0 (s2 / such) 
      :ARG1 (y / yield-01 
            :ARG0 (p2 / polymorphism 
                  :mod (s5 / such)) 
            :ARG1 (b3 / biomarker 
                  :ARG1-of (s4 / suitable-04 
                        :ARG2 (t / thing 
                              :ARG1-of (s3 / sample-01) 
                              :ARG1-of (a / access-01 
                                    :ARG1-of (r / ready-02 
                                          :degree (m / more))) 
                              :example (o / or 
                                    :op1 (b2 / blood 
                                          :mod (p / peripheral)) 
                                    :op2 (s / smear-02 
                                          :mod (b / buccal))))))))

# ::snt A biomarker combining polymorphisms that affect regulation with those that affect function of antioxidant and DNA repair genes is likely to be the most accurate for identifying individuals at risk for BC .
# ::tok A biomarker combining polymorphisms that affect regulation with those that affect function of antioxidant and DNA repair genes is likely to be the most accurate for identifying individuals at risk for BC .
# ::alignments 31-32|0.1.0.0.0.0.2.0.1.1.0 29-30|0.1.0.0.0.0.2.0.1.1 27-28|0.1.0.0.0.0.2.0.1.0 26-27|0.1.0.0.0.0.2.0.1 24-25|0.1.0.0.0.0.2.0 23-24|0.1.0.0.0.0.2.0.0 19-20|0.1.0.0.0.0.2 17-18|0.1.0.0.0 16-17|0.1.0.0.0.0.1.0 15-16|0.1.0.0.0.0.1 14-15|0.1.0.0.0.0 13-14|0.1.0.0.0.0.0 11-12|0.1.0.0 10-11|0.1.0 6-7|0.1 5-6|0 3-4|0.0 2-3|0.0.0 1-2|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:09.109
(a5 / affect-01 
      :ARG0 (p / polymorphism 
            :ARG1-of (c / combine-01 
                  :ARG0 (b / biomark))) 
      :ARG1 (r3 / regulate-01 
            :ARG1 (a4 / affect-01 
                  :ARG1 (f / function-01 
                        :ARG1 (g / gene 
                              :op3-of (a2 / and 
                                    :op1 (a3 / antioxidant) 
                                    :op2 (d / DNA 
                                          :ARG1-of (r2 / repair-01)) 
                                    :op4 (l / likely-01 
                                          :ARG1 (a / accurate 
                                                :degree (m / most) 
                                                :purpose (i2 / identify-01 
                                                      :ARG1 (i / individual) 
                                                      :manner (r / risk-01 
                                                            :ARG2 "BC"))))))))))

# ::snt Biomarkers that accurately identify individuals at risk for BC will improve efficacy of chemoprevention and early detection clinical trials .
# ::tok Biomarkers that accurately identify individuals at risk for BC will improve efficacy of chemoprevention and early detection clinical trials .
# ::alignments 18-19|0.1.2 17-18|0.1.2.1 16-17|0.1.2.0 15-16|0.1.1 14-15|0.1 13-14|0.1.0 11-12|0.0 10-11|0 8-9|0.2.0 6-7|0.2 4-5|0.2.1.1 3-4|0.2.1 2-3|0.2.1.2 0-1|0.2.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:09.666
(i / improve-01 
      :ARG1 (e2 / efficacy) 
      :ARG2 (a / and 
            :op1 (c2 / chemoprevention) 
            :op2 (e / early) 
            :op3 (t / trial-06 
                  :ARG1-of (d / detect-01) 
                  :mod (c / clinical))) 
      :ARG3 (r / risk-01 
            :ARG2 "BC" 
            :manner-of (i3 / identify-01 
                  :ARG0 (b / biomarker) 
                  :ARG1 (i2 / individual) 
                  :time (a2 / accurate))))

# ::snt The observed inter-sample variation in the presence of gene-specific inhibitors of PCR provides evidence supporting the need for inclusion of an internal standard in each quantitative PCR transcript abundance measurement .
# ::tok The observed inter-sample variation in the presence of gene-specific inhibitors of PCR provides evidence supporting the need for inclusion of an internal standard in each quantitative PCR transcript abundance measurement .
# ::alignments 29-30|0.0 28-29|0 27-28|0.0.0.0+0.0.0 25-26|0.0.1.0.3 24-25|0.0.2 22-23|0.0.1.0.2.0 21-22|0.0.1.0.2 18-19|0.0.1.0.0.0 16-17|0.0.1.0.0 14-15|0.0.1.0 13-14|0.0.1 12-13|0.0.1.1 9-10|0.0.1.1.1 6-7|0.0.1.1.1.0 3-4|0.0.1.1.0 1-2|0.0.1.0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:10.176
(a / abundance 
      :ARG1-of (m / measure-01 
            :ARG0 (t / thing 
                  :ARG1-of (t2 / transcribe-01)) 
            :ARG1-of (e2 / evidence-01 
                  :ARG0-of (s2 / support-01 
                        :ARG1 (n / need-01 
                              :ARG1 (i2 / inclusion)) 
                        :ARG1-of (o / observe-01) 
                        :ARG1-of (i / internal-02 
                              :mod-of (s / standard)) 
                        :time (q / quantitative)) 
                  :ARG1-of (p / provide-01 
                        :ARG0 (v / variation) 
                        :location (i3 / inhibitor 
                              :mod-of (p2 / presence)))) 
            :mod (e / each)))

# ::snt Including such internal standards in the form of standardized mixtures of internal standards improves the reproducibility of transcript abundance measurement and enables development of a standardized database comprising virtually-multiplexed transcript abundance data .
# ::tok Including such internal standards in the form of standardized mixtures of internal standards improves the reproducibility of transcript abundance measurement and enables development of a standardized database comprising virtually-multiplexed transcript abundance data .
# ::alignments 31-32|0.1.1.1.0 30-31|0.1.1.1.0.1 29-30|0.1.1.1.0.2.0+0.1.1.1.0.2 28-29|0.1.1.1.0.0 27-28|0.1.1.1 26-27|0.1.1.0 25-26|0.1.1.0.0 22-23|0.1.1 21-22|0.1 20-21|0 19-20|0.0.1.0 18-19|0.0.1.0.1 17-18|0.0.1.0.0.0+0.0.1.0.0 15-16|0.0.1 13-14|0.0 12-13|0.0.0 11-12|0.0.0.0 9-10|0.0.0.1 8-9|0.0.0.1.0 6-7|0.0.0.1.1 3-4|0.1.0 2-3|0.1.0.1 1-2|0.1.0.2 0-1|0.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:11.780
(a2 / and 
      :op1 (i / improve-01 
            :ARG0 (s2 / standard 
                  :ARG1-of (i2 / internal-02) 
                  :consist (m2 / mixtur 
                        :ARG1-of (s3 / standardize-01) 
                        :mod-of (f / form))) 
            :ARG1 (r / reproducibility 
                  :topic-of (m / measure-01 
                        :ARG0 (t3 / thing 
                              :ARG1-of (t4 / transcribe-01)) 
                        :ARG1 (a3 / abundance)))) 
      :op2 (e / enable-01 
            :ARG0 (s4 / standard 
                  :ARG1-of (i4 / include-01) 
                  :ARG1-of (i3 / internal-02) 
                  :mod (s5 / such)) 
            :ARG1 (d3 / develop-02 
                  :ARG1 (d2 / database 
                        :ARG1-of (s / standardize-01)) 
                  :ARG1-of (c / comprise-01 
                        :ARG2 (d / data 
                              :mod (v / virtually-multiplex) 
                              :source (a / abundance) 
                              :source (t / thing 
                                    :ARG1-of (t2 / transcribe-01)))))))

# ::snt Virtually-multiplexed transcript abundance data are highly suited to identification of genes that have correlated transcript abundance values .
# ::tok Virtually-multiplexed transcript abundance data are highly suited to identification of genes that have correlated transcript abundance values .
# ::alignments 16-17|0.1 15-16|0 14-15|0.0.0+0.0 13-14|0.1.0 10-11|0.1.0.0 8-9|0.1.0.0.0 6-7|0.1.0.0.0.0 5-6|0.1.0.0.0.0.1 3-4|0.1.0.0.0.0.0 2-3|0.1.0.0.0.0.0.1 1-2|0.1.0.0.0.0.0.2.0+0.1.0.0.0.0.0.2 0-1|0.1.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:12.204
(a / abundance 
      :mod (t / thing 
            :ARG1-of (t2 / transcribe-01)) 
      :mod-of (v / value 
            :ARG1-of (c / correlate-01 
                  :ARG0 (g / gene 
                        :ARG1-of (i / identify-02 
                              :ARG2-of (s / suit-01 
                                    :ARG1 (d / data 
                                          :mod (v2 / virtually-multiplex) 
                                          :source (a2 / abundance) 
                                          :source (t3 / thing 
                                                :ARG1-of (t4 / transcribe-01))) 
                                    :degree (h / high)))))))

# ::snt Correlation at the transcript abundance level is an important property of genes that are co-regulated at the transcription level .
# ::tok Correlation at the transcript abundance level is an important property of genes that are co-regulated at the transcription level .
# ::alignments 18-19|0.1 17-18|0 11-12|0.0.0.0.0.0.1 9-10|0.0.0.0.0.0 8-9|0.0.0.0.0.0.0 5-6|0.0.0.0 4-5|0.0.0.0.1 3-4|0.0+0.0.0 0-1|0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:12.278
(t / transcription 
      :ARG0-of (t3 / transcribe-01 
            :ARG1 (t2 / thing 
                  :mod-of (l2 / level 
                        :location-of (c / correlation 
                              :domain-of (p / property 
                                    :mod (i / important) 
                                    :mod (g / gene))) 
                        :mod (a / abundance)))) 
      :mod-of (l / level))

# ::snt We conclude that in non-BC individuals , CEBPG regulates transcription of key antioxidant or DNA repair genes in NBEC and that in smokers who develop BC , CEBPG regulation is sub-optimal for a sufficient number of antioxidant and/or DNA repair genes to cause increased risk .
# ::tok We conclude that in non-BC individuals , CEBPG regulates transcription of key antioxidant or DNA repair genes in NBEC and that in smokers who develop BC , CEBPG regulation is sub-optimal for a sufficient number of antioxidant and/or DNA repair genes to cause increased risk .
# ::alignments 44-45|0.1 43-44|0.1.1 42-43|0 40-41|0.1.1.0 39-40|0.1.1.0.0 38-39|0.1.1.0.0.1 36-37|0.1.0 34-35|0.0.1.3.2.0 33-34|0.0.1.3.2 28-29|0.0.3 25-26|0.0.1.3.1.0 24-25|0.0.1.3.1 22-23|0.0.1.3.0+0.0.1.3 19-20|0.0 18-19|0.1.1.0.0.0.0.0+0.1.1.0.0.0.0+0.1.1.0.0.0 16-17|0.0.1.2 15-16|0.0.1.1 14-15|0.0.1.1.0 13-14|0.0.1 12-13|0.0.1.0 11-12|0.0.1.0.0 9-10|0.0.2.1 8-9|0.0.2 7-8|0.0.2.0.0.0+0.0.2.0.0+0.0.2.0 5-6|0.0.2.2 1-2|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:12.857
(c / cause-01 
      :ARG0 (a2 / and 
            :ARG1-of (c3 / conclude-02 
                  :ARG0 (w / we)) 
            :location-of (o / or 
                  :op1 (a3 / antioxidant 
                        :ARG1-of (k / key-02)) 
                  :op2 (r4 / repair-01 
                        :mod (d3 / DNA)) 
                  :op3 (g2 / gene) 
                  :op4 (p / person 
                        :ARG0-of (s2 / smoke-02) 
                        :ARG0-of (d2 / develop-02 
                              :ARG1 "BC") 
                        :ARG1-of (s / suffice-01 
                              :ARG0 (n / number)))) 
            :op1 (r5 / regulate-01 
                  :ARG0 (o2 / organization 
                        :name (n3 / name 
                              :op1 "CEBPG")) 
                  :ARG1 (t / transcription) 
                  :location (i2 / individual)) 
            :op2 (r3 / regulate-01)) 
      :ARG1 (r / risk-01 
            :ARG1 (a / antioxidant) 
            :ARG1-of (i / increase-01 
                  :ARG0 (g / gene 
                        :mod (r2 / repair-01 
                              :ARG0 (c2 / country 
                                    :name (n2 / name 
                                          :op1 "NBEC")) 
                              :ARG1 (d / DNA))))))

# ::snt JCW and ELC each have significant equity interest in Gene Express , Inc. , which produces and markets StaRT-PCR  reagents used in this study .
# ::tok JCW and ELC each have significant equity interest in Gene Express , Inc. , which produces and markets StaRT-PCR  reagents used in this study .
# ::alignments 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:12.860
# THERE WAS AN EXCEPTION IN THE PARSER.  Returning an empty graph.
# java.lang.AssertionError: assertion failed
# 	at scala.Predef$.assert(Predef.scala:165)
# 	at edu.cmu.lti.nlp.amr.Annotation$$anonfun$makeLeftRight$1.apply$mcVI$sp(Annotation.scala:86)
# 	at scala.collection.immutable.Range.foreach$mVc$sp(Range.scala:141)
# 	at edu.cmu.lti.nlp.amr.Annotation.makeLeftRight(Annotation.scala:67)
# 	at edu.cmu.lti.nlp.amr.Annotation.<init>(Annotation.scala:18)
# 	at edu.cmu.lti.nlp.amr.Input.<init>(Input.scala:24)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply$mcV$sp(AMRParser.scala:220)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3$$anonfun$apply$1.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.time(AMRParser.scala:93)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:214)
# 	at edu.cmu.lti.nlp.amr.AMRParser$$anonfun$main$3.apply(AMRParser.scala:212)
# 	at scala.collection.TraversableLike$WithFilter$$anonfun$foreach$1.apply(TraversableLike.scala:772)
# 	at scala.collection.IndexedSeqOptimized$class.foreach(IndexedSeqOptimized.scala:33)
# 	at scala.collection.mutable.ArrayOps$ofRef.foreach(ArrayOps.scala:108)
# 	at scala.collection.TraversableLike$WithFilter.foreach(TraversableLike.scala:771)
# 	at edu.cmu.lti.nlp.amr.AMRParser$.main(AMRParser.scala:212)
# 	at edu.cmu.lti.nlp.amr.AMRParser.main(AMRParser.scala)
(a / amr-empty)

# ::snt DNM participated in the design of the study , performed the TF identification , carried out TA measurements , coordinated and participated in the statistical analysis and drafted the manuscript .
# ::tok DNM participated in the design of the study , performed the TF identification , carried out TA measurements , coordinated and participated in the statistical analysis and drafted the manuscript .
# ::alignments 29-30|0.2.1.0 27-28|0.2.1 26-27|0.2 25-26|0.3.0 24-25|0.3.0.0 21-22|0.3 20-21|0 19-20|0.1 17-18|0.0.1 16-17|0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 14-15|0.0 12-13|0.2.0.0 9-10|0.2.0 7-8|0.0.0.0 4-5|0.0.0 1-2|0.0.0.1 0-1|0.0.0.1.0.0.0+0.0.0.1.0.0+0.0.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:13.223
(a3 / and 
      :op1 (c2 / carry-out-03 
            :ARG0 (d2 / design-01 
                  :ARG1 (s2 / study-01) 
                  :ARG1-of (p3 / participate-01 
                        :ARG0 (o2 / organization 
                              :name (n2 / name 
                                    :op1 "DNM")))) 
            :ARG1 (m2 / measure-01 
                  :ARG0 (o / organization 
                        :name (n / name 
                              :op1 "TA")))) 
      :op2 (c / coordinate-01) 
      :op2-of (a / and 
            :op1 (p2 / perform-02 
                  :ARG1 (i / identify-02)) 
            :op3 (d / draft-01 
                  :ARG1 (m / manuscript))) 
      :op3 (p / participate-01 
            :ARG1 (a2 / analyze-01 
                  :manner (s / statistic))))

# ::snt ELC contributed the preliminary data , participated in the design of the study and carried out TA measurements .
# ::tok ELC contributed the preliminary data , participated in the design of the study and carried out TA measurements .
# ::alignments 17-18|0.0.0.0.0 16-17|0.0.0.0.0.0.0.0+0.0.0.0.0.0.0+0.0.0.0.0.0 14-15|0.0.0.0 13-14|0 12-13|0.0.0.1.0.0 9-10|0.0.0.1.0 6-7|0.0.0.1 4-5|0.0.1 3-4|0.0.1.0 1-2|0.0 0-1|0.0.0.2.0+0.0.0.2+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:13.306
(a / and 
      :op1 (c2 / contribute-01 
            :ARG0 (o2 / organization 
                  :ARG0-of (c / carry-01 
                        :ARG1 (m / measure-01 
                              :ARG0 (o / organization 
                                    :name (n / name 
                                          :op1 "TA")))) 
                  :ARG0-of (p / participate-01 
                        :ARG1 (d / design-01 
                              :ARG1 (s / study-01))) 
                  :name (n2 / name 
                        :op1 "ELC")) 
            :ARG1 (d2 / data 
                  :mod (p2 / preliminary))))

# ::snt SAK performed the statistical analysis for interpretation of data .
# ::tok SAK performed the statistical analysis for interpretation of data .
# ::alignments 8-9|0.0.0.0.0 6-7|0.0.0.0 4-5|0 3-4|0.1 1-2|0.0 0-1|0.0.0.1.0+0.0.0.1+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:13.336
(a / analyze-01 
      :ARG1-of (p / perform-02 
            :ARG0 (o / organization 
                  :ARG0-of (i / interpret-01 
                        :ARG1 (d / data)) 
                  :name (n / name 
                        :op1 "SAK"))) 
      :manner (s / statistic))

# ::snt DAH and YY consented patients and obtained the primary samples necessary for the study according to IRB regulations .
# ::tok DAH and YY consented patients and obtained the primary samples necessary for the study according to IRB regulations .
# ::alignments 17-18|0.0 14-15|0 13-14|0.1.3 9-10|0.1.1.0+0.1.1 8-9|0.1.1.0.0 6-7|0.1 5-6|0.1.2 4-5|0.1.2.0.1.0.0+0.1.2.0.1.0+0.1.2.0.1 3-4|0.1.2.0 1-2|0.1.2.0.0 0-1|0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:13.430
(s / say-01 
      :ARG0 (r / regulate-01) 
      :ARG1 (o / obtain-01 
            :ARG0 (d / dah) 
            :ARG1 (t / thing 
                  :ARG1-of (s3 / sample-01 
                        :mod (p / primary))) 
            :op2-of (a / and 
                  :op1 (c / consent-01 
                        :ARG0 (a2 / and) 
                        :ARG1 (p2 / person 
                              :ARG0-of (h / have-rel-role-91 
                                    :ARG2 (p3 / patient))))) 
            :purpose (s2 / study-01)))

# ::snt JCW conceived of the study , participated in its design and coordination , and helped to draft the manuscript .
# ::tok JCW conceived of the study , participated in its design and coordination , and helped to draft the manuscript .
# ::alignments 18-19|0.0.1.0 16-17|0.0.1 14-15|0.0 13-14|0 11-12|0.0.0.1.1.0 10-11|0.0.0.1.1 9-10|0.0.0.1.0 6-7|0.0.0.1 4-5|0.0.0.0.0 1-2|0.0.0.0 0-1|0.0.0.2.0+0.0.0.2+0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:13.725
(a / and 
      :op1 (h / help-01 
            :ARG0 (o / organization 
                  :ARG0-of (c2 / conceive-01 
                        :ARG1 (s / study-01)) 
                  :ARG0-of (p / participate-01 
                        :ARG1 (d2 / design-01) 
                        :location (a2 / and 
                              :op1 (c / coordinate-01))) 
                  :name (n / name 
                        :op1 "JCW")) 
            :ARG1 (d / draft-01 
                  :ARG1 (m / manuscript))))

# ::snt All authors read and approved the final manuscript .
# ::tok All authors read and approved the final manuscript .
# ::alignments 7-8|0.1.0.0 6-7|0.1.0.0.0 4-5|0.1.0 3-4|0.1 2-3|0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:13.797
(r / read-01 
      :ARG1 (a3 / author-01 
            :mod (a4 / all)) 
      :op1-of (a2 / and 
            :ARG0-of (a / approve-01 
                  :ARG1 (m / manuscript 
                        :mod (f / final)))))

# ::snt The pre-publication history for this paper can be accessed here : .
# ::tok The pre-publication history for this paper can be accessed here : .
# ::alignments 9-10|0.0.1 8-9|0.0 6-7|0 5-6|0.0.0.0 4-5|0.0.0.0.0 2-3|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:13.844
(p / possible-01 
      :ARG1 (a / access-01 
            :ARG1 (h2 / history 
                  :topic (p2 / paper 
                        :mod (t / this))) 
            :location (h / here)))

# ::snt These studies and manuscript preparation were supported by grants from the National Cancer Institute ( NCI ) , including CA85147 and CA 95806 , and the George Isaac Cancer Research Fund .
# ::tok These studies and manuscript preparation were supported by grants from the National Cancer Institute ( NCI ) , including CA85147 and CA 95806 , and the George Isaac Cancer Research Fund .
# ::alignments 26-31|0.0.1.0.4+0.0.1.0.3+0.0.1.0.2+0.0.1.0.1+0.0.1.0.0+0.0.1.0+0.0.1 24-25|0.0 21-22|0.2.2.1+0.2.2.0.0+0.2.2.0+0.2.2 20-21|0.2 19-20|0.2.1.0.0+0.2.1.0+0.2.1 15-16|0.2.0.0.0+0.2.0.0+0.2.0 11-14|0.0.0.0.0.2+0.0.0.0.0.1+0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 8-9|0.0.0 6-7|0 4-5|0.1.0 3-4|0.1.0.0 2-3|0.1 1-2|0.1.1 0-1|0.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:14.428
(s2 / support-01 
      :ARG0 (a / and 
            :op1 (g / grant-01 
                  :ARG0 (o3 / organization 
                        :name (n5 / name 
                              :op1 "National" 
                              :op2 "Cancer" 
                              :op3 "Institute"))) 
            :op2 (o / organization 
                  :name (n / name 
                        :op1 "George" 
                        :op2 "Isaac" 
                        :op3 "Cancer" 
                        :op4 "Research" 
                        :op5 "Fund"))) 
      :ARG1 (a3 / and 
            :ARG1-of (p / prepare-02 
                  :ARG2 (m / manuscript)) 
            :op1 (s3 / study-01 
                  :mod (t2 / this))) 
      :op1-of (a2 / and 
            :op2 (o2 / organization 
                  :name (n4 / name 
                        :op1 "NCI")) 
            :op3 (t / thing 
                  :name (n3 / name 
                        :op1 "CA85147")) 
            :op4 (s / state 
                  :name (n2 / name 
                        :op1 "CA") 
                  :wiki "California")))

# ::snt StaRT-PCR reagents for measurement of some of the genes were provided at no cost by Gene Express , Inc. .
# ::tok StaRT-PCR reagents for measurement of some of the genes were provided at no cost by Gene Express , Inc. .
# ::alignments 18-19|0.0.0.0.0+0.0.0.0+0.0.0 15-17|0.1.0.1+0.1.0.0+0.1.0+0.1 13-14|0.0 12-13|0.0.1.2 10-11|0 8-9|0.0.1.0.0 5-6|0.0.1.0 3-4|0.0.1 1-2|0.0.1.1 0-1|0.0.1.1.0.0.0+0.0.1.1.0.0+0.0.1.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:14.699
(p2 / provide-01 
      :ARG1 (c / cost-01 
            :ARG0 (o / organization 
                  :name (n / name 
                        :op1 "Inc.")) 
            :ARG1 (m / measure-01 
                  :ARG1 (s / some 
                        :quant-of (g / gene)) 
                  :purpose-of (r / reagent 
                        :mod (t / thing 
                              :name (n3 / name 
                                    :op1 "StaRT-PCR"))) 
                  :time -)) 
      :ARG2 (p / person 
            :name (n2 / name 
                  :op1 "Gene" 
                  :op2 "Express")))

# ::snt Neither the NCI nor Gene Express , Inc. had any role in study design , collection , analysis , or interpretation of data , writing of the manuscript , or in the decision to submit the manuscript for publication .
# ::tok Neither the NCI nor Gene Express , Inc. had any role in study design , collection , analysis , or interpretation of data , writing of the manuscript , or in the decision to submit the manuscript for publication .
# ::alignments 38-39|0.0.1.2.0.1.0.0+0.0.1.2.0.1.0 36-37|0 34-35|0.0 32-33|0.0.0 29-30|0.0.1.2 27-28|0.0.1.1 24-25|0.0.1 22-23|0.0.1.2.0.0.0 20-21|0.0.1.2.0.1 19-20|0.0.1.2.0 17-18|0.0.1.2.0.0 15-16|0.0.1.2.0.0.0.0 13-14|0.0.1.1.0 12-13|0.0.1.1.0.1 10-11|0.0.1.1.0.2 9-10|0.0.1.1.0.2.0 7-8|0.0.1.1.0.1.0.0.0+0.0.1.1.0.1.0.0+0.0.1.1.0.1.0 4-6|0.0.1.0.0.1+0.0.1.0.0.0+0.0.1.0.0+0.0.1.0 2-3|0.0.1.1.0.0.0.0+0.0.1.1.0.0.0+0.0.1.1.0.0 0-1|0.0.1.1.0.1.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:15.653
(m / manuscript 
      :ARG1-of (s / submit-01 
            :ARG1-of (d / decide-01) 
            :purpose-of (w / write-01 
                  :ARG0 (p2 / person 
                        :name (n2 / name 
                              :op1 "Gene" 
                              :op2 "Express")) 
                  :ARG1 (m2 / manuscript 
                        :ARG1-of (d3 / design-01 
                              :ARG0 (o4 / organization 
                                    :name (n3 / name 
                                          :op1 "NCI")) 
                              :mod (s2 / study-01 
                                    :ARG0 (o3 / organization 
                                          :name (n / name 
                                                :op1 "Inc.")) 
                                    :ARG1 (n4 / neither)) 
                              :op1-of (r / role 
                                    :mod (a2 / any)))) 
                  :op2-of (o / or 
                        :op1 (o2 / or 
                              :op1 (a / analyze-01 
                                    :ARG1 (d2 / data 
                                          :ARG1-of (c / collect-01))) 
                              :op2 (i / interpret-01 
                                    :ARG1 (p / publication 
                                          :wiki -)))))))

# ::snt Correlation of each transcription factor with XRCC1 , ERCC5 , GSTP1 , SOD1 , or GPX1 .
# ::tok Correlation of each transcription factor with XRCC1 , ERCC5 , GSTP1 , SOD1 , or GPX1 .
# ::alignments 14-15|0.0 10-11|0.0.2 8-9|0.0.1.0.0+0.0.1.0+0.0.1 6-7|0.0.0.0.0+0.0.0.0+0.0.0 4-5|0 3-4|0.2 2-3|0.1 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:15.701
(f / factor 
      :example (o / or 
            :op1 (p2 / person 
                  :name (n2 / name 
                        :op1 "XRCC1")) 
            :op2 (p / person 
                  :name (n / name 
                        :op1 "ERCC5")) 
            :op3 (g / GSTP1)) 
      :mod (e / each) 
      :mod (t / transcription))

# ::snt ( a-f ) Each panel presents the correlation coefficients ( r values ) for one transcription factor in relation to each of the five genes : ( a ) CEBPB , ( b ) CEBPG , ( c ) E2F1 , ( d ) E2F3 , ( e ) E2F6 , ( f ) EVI1 .
# ::tok ( a-f ) Each panel presents the correlation coefficients ( r values ) for one transcription factor in relation to each of the five genes : ( a ) CEBPB , ( b ) CEBPG , ( c ) E2F1 , ( d ) E2F3 , ( e ) E2F6 , ( f ) EVI1 .
# ::alignments 52-53|0.0.0.3 42-43|0.0.0.5 37-38|0.0.0.6 34-35|0.0.0.2.0.0+0.0.0.2.0+0.0.0.2 32-33|0.0.0.4 29-30|0.0.0.0.0.0+0.0.0.0.0+0.0.0.0 24-25|0.0.0.1.1.2 23-24|0.0.0.1.1.3 20-21|0.0.0.1.1.2.0 18-19|0.0.0 16-17|0.0.0.1 15-16|0.0.0.1.0 11-12|0.0 10-11|0 8-9|0.0.0.1.1.1 7-8|0.0.0.1.1.1.0 5-6|0.0.0.1.1 4-5|0.0.0.1.1.0 3-4|0.0.0.1.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:16.758
(r2 / r 
      :mod-of (v / value 
            :ARG2-of (r / relate-01 
                  :ARG0 (o2 / organization 
                        :name (n2 / name 
                              :op1 "CEBPB")) 
                  :ARG1 (f2 / factor 
                        :mod (t / transcription) 
                        :purpose-of (p / present-01 
                              :ARG0 (p2 / panel 
                                    :mod (e2 / each)) 
                              :ARG1 (c2 / coefficient 
                                    :mod (c3 / correlation)) 
                              :ARG2 (g / gene 
                                    :mod (e / each)) 
                              :op1-of 5)) 
                  :op1-of (o / organization 
                        :name (n / name 
                              :op1 "CEBPG")) 
                  :op1-of (f / f) 
                  :op1-of (b / b) 
                  :op1-of (d / d) 
                  :op1-of (c / c))))

# ::snt The p value for each significant correlation is provided above the bar .
# ::tok The p value for each significant correlation is provided above the bar .
# ::alignments 11-12|0.1.0 9-10|0.1 8-9|0 6-7|0.0.1 5-6|0.0.1.0 4-5|0.0.1.1 2-3|0.0 1-2|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:16.882
(p / provide-01 
      :ARG1 (v / value-01 
            :ARG1 (p2 / p) 
            :ARG2 (c / correlation 
                  :ARG1-of (s / significant-02) 
                  :mod (e / each))) 
      :ARG2 (a / above 
            :op1 (b / bar-01)))

# ::snt For CEBPG , presented in panel b , the difference in r value between non-BC individuals and BC individuals was significant or nearly significant for each correlated gene , and the p value for each comparison is provided below the corresponding pair of bars .
# ::tok For CEBPG , presented in panel b , the difference in r value between non-BC individuals and BC individuals was significant or nearly significant for each correlated gene , and the p value for each comparison is provided below the corresponding pair of bars .
# ::alignments 43-44|0.1.0.0 41-42|0.1.0 40-41|0.1.0.1 38-39|0.1.0.2 37-38|0.1 35-36|0.1.1.1 34-35|0.1.1.1.0 32-33|0 31-32|0.0 29-30|0.1.1 27-28|0.1.1.2.0.0 26-27|0.1.1.2.0.0.0 25-26|0.1.1.2.0.0.1 23-24|0.1.1.2.1 22-23|0.1.1.2.1.1 21-22|0.1.1.2 20-21|0.1.1.2.0 18-19|0.1.1.2.1.0.0.2 17-18|0.1.1.2.1.0.0.2.0 16-17|0.1.1.2.1.0.0 15-16|0.1.1.2.1.0.0.1 12-13|0.1.1.2.1.0.0.0 11-12|0.1.1.2.1.0.0.0.0 9-10|0.1.1.2.1.0 6-7|0.1.1.2.0.1 5-6|0.1.1.0.1 3-4|0.1.1.0 1-2|0.1.1.0.0.0.0+0.1.1.0.0.0+0.1.1.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:18.763
(v / value-01 
      :ARG1 (p3 / p) 
      :ARG1-of (p2 / provide-01 
            :ARG2 (p / pair-01 
                  :ARG1 (b / bar) 
                  :ARG1-of (c / correspond-01) 
                  :op1-of (b2 / below)) 
            :op2-of (a / and 
                  :ARG0-of (p5 / present-01 
                        :ARG1 (o2 / organization 
                              :name (n2 / name 
                                    :op1 "CEBPG")) 
                        :time (p4 / panel)) 
                  :ARG1-of (c2 / compare-01 
                        :mod (e / each)) 
                  :op1 (o / or 
                        :op1 (s2 / significant-02 
                              :ARG0 (g / gene 
                                    :ARG1-of (c3 / correlate-01) 
                                    :mod (e2 / each)) 
                              :ARG1 (b3 / b)) 
                        :op2 (s / significant-02 
                              :ARG0 (d / differ-02 
                                    :ARG0 (a2 / and 
                                          :op1 (v2 / value-01 
                                                :ARG1 (r / r)) 
                                          :op2 (i2 / individual) 
                                          :op3 (i / individual 
                                                :mod "BC"))) 
                              :mod (n / nearly))))))

# ::snt Scatter plot representation of bivariate correlation of CEBPG with XRCC1 .
# ::tok Scatter plot representation of bivariate correlation of CEBPG with XRCC1 .
# ::alignments 9-10|0.0.0.0.0+0.0.0.0+0.0.0 7-8|0.0.2.1.0.0+0.0.2.1.0+0.0.2.1 5-6|0.0.2 4-5|0.0.2.0 2-3|0.0 1-2|0.0.1 0-1|0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:18.812
(s / scatter-01 
      :ARG1 (r / representation-02 
            :ARG0 (p / person 
                  :name (n / name 
                        :op1 "XRCC1")) 
            :ARG0-of (p2 / plot-01) 
            :ARG1 (c / correlation 
                  :mod (b / bivariate) 
                  :poss (o / organization 
                        :name (n2 / name 
                              :op1 "CEBPG")))))

# ::snt ( a , b ) CEBPG/XRCC1 data from Figure 1b presented as scatter plots : ( a ) non-BC individuals , ( b ) BC individuals .
# ::tok ( a , b ) CEBPG/XRCC1 data from Figure 1b presented as scatter plots : ( a ) non-BC individuals , ( b ) BC individuals .
# ::alignments 25-26|0.0.1.0.0.0.0 24-25|0.0.1.0.0.0 22-23|0 19-20|0.0.1.0.0 13-14|0.0.1 12-13|0.0 10-11|0.0.1.0 9-10|0.0.1.1.0 8-9|0.0.1.1 6-7|0.0.1.0.1 3-4|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:18.996
(b / b 
      :ARG2-of (s / scatter-01 
            :ARG0 (b2 / b) 
            :mod-of (p / plot 
                  :ARG3-of (p2 / present-01 
                        :ARG0 (i2 / individual 
                              :mod-of (B / "BC" 
                                    :mod-of (i / individual))) 
                        :ARG1 (d / data)) 
                  :mod (f / figure 
                        :mod 1b))))

# ::snt Demographic data of patients from whom the NBEC samples were obtained .
# ::tok Demographic data of patients from whom the NBEC samples were obtained .
# ::alignments 10-11|0.1.0 8-9|0+0.1 7-8|0.0.0.0+0.0.0+0.0 3-4|0.1.0.0.1+0.1.0.0+0.1.0.0.0 1-2|0.1.0.0.0.0 0-1|0.1.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:19.120
(s / sample-01 
      :ARG0 (c / country 
            :name (n / name 
                  :op1 "NBEC")) 
      :ARG1 (t / thing 
            :ARG1-of (o / obtain-01 
                  :ARG1-of (h / have-rel-role-91 
                        :ARG0 (p / person 
                              :consist (d / data 
                                    :mod (d2 / demographic))) 
                        :ARG2 (p2 / patient)))))

# ::snt 1Pack years ; 2Non-bronchogenic carcinoma individual ; 3White ; 4African-American ; 5Non-smoker ; 6Not available ; 7Hispanic ; 8Bronchogenic carcinoma individual ; 9Non-small cell lung cancer ; 10Squamous carcinoma ; 11Small cell lung cancer ; 12Carcinoma-in-situ ; 13Adenocarcinoma ; 14Bronchogenic Cancer , histology not specified ; 15Poorly differentiated carcinoma .
# ::tok 1Pack years ; 2Non-bronchogenic carcinoma individual ; 3White ; 4African-American ; 5Non-smoker ; 6Not available ; 7Hispanic ; 8Bronchogenic carcinoma individual ; 9Non-small cell lung cancer ; 10Squamous carcinoma ; 11Small cell lung cancer ; 12Carcinoma-in-situ ; 13Adenocarcinoma ; 14Bronchogenic Cancer , histology not specified ; 15Poorly differentiated carcinoma .
# ::alignments 48-49|0.1.1.1 47-48|0.1.1.1.0 44-45|0 43-44|0.3 42-43|0.2 39-41|0.1.0.1+0.1.0.0+0.1.0+0.1 37-38|0.1.1.9 33-34|0.1.1.8 32-33|0.1.1.8.0 31-32|0.1.1.8.0.0 28-29|0.1.1.7 27-28|0.1.1.7.0 25-26|0.1.1.6 24-25|0.1.1.6.0 23-24|0.1.1.6.0.0 20-21|0.1.1.5 19-20|0.1.1.5.0 16-17|0.1.1.4 14-15|0.1.1.4.0 13-14|0.1.1.4.0.0 11-12|0.1.1.3 7-8|0.1.1.2 5-6|0.1.1.0 4-5|0.1.1.0.0 2-3|0.1.1 1-2|0.0.0+0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:19.959
(s / specify-01 
      :ARG0 (t2 / temporal-quantity 
            :unit (y / year)) 
      :ARG1 (t / thing 
            :name (n / name 
                  :op1 14Bronchogenic 
                  :op2 (c2 / Cancer)) 
            :op10-of (a2 / and 
                  :op1 (i2 / individual 
                        :mod (c9 / carcinoma)) 
                  :op11 (c / carcinoma 
                        :ARG1-of (d / differentiate-01)) 
                  :op2 3White 
                  :op3 5non-smok 
                  :op4 (7 / 7Hispanic 
                        :ARG1-of (a / available-02 
                              :ARG2 6Not)) 
                  :op5 (i / individual 
                        :mod (c8 / carcinoma)) 
                  :op6 (c6 / cancer 
                        :mod (l2 / lung 
                              :mod (c7 / cell))) 
                  :op7 (c5 / carcinoma 
                        :mod 10squamou) 
                  :op8 (c3 / cancer 
                        :mod (l / lung 
                              :mod (c4 / cell))) 
                  :op9 13Adenocarcinoma)) 
      :manner (h / histology) 
      :polarity -)

# ::snt Sequence for each primer used for StaRT-PCR virtually-multiplexed transcript abundance measurement or for internal standard preparation ( CT ) [ 15 ] .
# ::tok Sequence for each primer used for StaRT-PCR virtually-multiplexed transcript abundance measurement or for internal standard preparation ( CT ) [ 15 ] .
# ::alignments 20-21|0.2.0 17-18|0.2.2.0.0.0+0.2.2.0.0+0.2.2.0 15-16|0.2 14-15|0.2.2 13-14|0.2.1 11-12|0 10-11|0.1 9-10|0.1.1 8-9|0.1.0.0+0.1.0 7-8|0.1.2.0 6-7|0.0.0.0+0.0.0+0.0 4-5|0.1.2 3-4|0.1.2.1 2-3|0.1.2.1.1 0-1|0.1.2.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:20.467
(o / or 
      :op1 (t3 / thing 
            :name (n2 / name 
                  :op1 "StaRT-PCR")) 
      :op2 (m / measure-01 
            :ARG0 (t / thing 
                  :ARG1-of (t2 / transcribe-01)) 
            :ARG1 (a / abundance) 
            :ARG2-of (u / use-01 
                  :ARG0 (v / virtually-multiplex) 
                  :ARG1 (p2 / primer 
                        :beneficiary-of (s2 / sequence) 
                        :mod (e / each)))) 
      :op3 (p / prepare-02 
            :ARG1 15 
            :ARG1-of (i / internal-02) 
            :ARG1-of (s / standard-02 
                  :ARG0 (c / country 
                        :name (n / name 
                              :op1 "CT")))))

# ::snt Virtually-multiplexed transcript abundance data .
# ::tok Virtually-multiplexed transcript abundance data .
# ::alignments 3-4|0.0 2-3|0 1-2|0.0.1.0+0.0.1 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:20.482
(a / abundance 
      :source-of (d / data 
            :mod (v / virtually-multiplex) 
            :source (t / thing 
                  :ARG1-of (t2 / transcribe-01))))

# ::snt Virtually-multiplexed transcript abundance data for each gene ( in the form of molecules/106 -actin molecules ) from all experiments were included in the same Standardized Expression Database ( SED ) .
# ::tok Virtually-multiplexed transcript abundance data for each gene ( in the form of molecules/106 -actin molecules ) from all experiments were included in the same Standardized Expression Database ( SED ) .
# ::alignments 28-29|0.0.2.1.0.0+0.0.2.1.0+0.0.2.1 24-27|0.1.2.2+0.1.2.1+0.1.2.0+0.1.2+0.1 23-24|0.1.1 20-21|0 18-19|0.1.0 17-18|0.1.0.1 14-15|0.1.1.0 10-11|0.1.0.0 6-7|0.0.2.0.0 5-6|0.0.2.0.0.0 3-4|0.0 2-3|0.0.1 1-2|0.0.2.0+0.0.2 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:20.756
(i / include-01 
      :ARG1 (d / data 
            :mod (v / virtually-multiplex) 
            :source (a2 / abundance) 
            :source (t / thing 
                  :ARG1-of (t2 / transcribe-01 
                        :ARG0 (g / gene 
                              :mod (e2 / each))) 
                  :domain (o / organization 
                        :name (n / name 
                              :op1 "SED")))) 
      :ARG2 (o2 / organization 
            :ARG1-of (e / experiment-01 
                  :ARG0 (f / form) 
                  :quant (a / all)) 
            :ARG1-of (s / same-01 
                  :ARG0 (m / molecule)) 
            :name (n2 / name 
                  :op1 "Standardized" 
                  :op2 "Expression" 
                  :op3 "Database")))

# ::snt These data are now directly comparable to previously published virtually-multiplexed transcript abundance data from this laboratory [ 15 ] , or to Virtually-multiplexed transcript abundance data collected by others who use the NCI-funded ( R24 CA 95806 ) Standardized Expression Measurement ( SEM ) Center .
# ::tok These data are now directly comparable to previously published virtually-multiplexed transcript abundance data from this laboratory [ 15 ] , or to Virtually-multiplexed transcript abundance data collected by others who use the NCI-funded ( R24 CA 95806 ) Standardized Expression Measurement ( SEM ) Center .
# ::alignments 44-45|0.1.0.0.0.0.0 42-43|0.1.0.1.0.2.0.0.0.0+0.1.0.1.0.2.0.0.0+0.1.0.1.0.2.0.0 38-41|0.1.0.0.0.0.1.2+0.1.0.0.0.0.1.1+0.1.0.0.0.0.1.0+0.1.0.0.0.0.1+0.1.0.0.0.0 35-37|0.3.0.1+0.3.0.0+0.3.0+0.3 32-33|0.2.0.0+0.2.0+0.2 30-31|0.1.0.0.0 28-29|0.1.0.0 26-27|0.1.0 25-26|0.1 24-25|0.1.2 23-24|0.1.3.0+0.1.3 22-23|0.1.1 20-21|0 17-18|0.1.0.1.0.0 15-16|0.0 14-15|0.0.0 12-13|0.1.0.1.0.2 11-12|0.1.0.1.0.2.3 10-11|0.1.0.1.0.2.2.0+0.1.0.1.0.2.2 9-10|0.1.0.1.0.2.1 8-9|0.1.0.1.0.2.0 7-8|0.1.0.1.0.2.0.1 5-6|0.1.0.1.0 4-5|0.1.0.1 3-4|0.1.0.1.0.3 1-2|0.1.0.1.0.1 0-1|0.1.0.1.0.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:22.552
(o4 / or 
      :op1 (l / laboratory 
            :mod (t5 / this)) 
      :op2 (d / data 
            :ARG1-of (c3 / collect-01 
                  :ARG0 (o3 / other 
                        :ARG0-of (u / use-01 
                              :ARG1 (o2 / organization 
                                    :mod-of (c / center) 
                                    :name (n2 / name 
                                          :op1 "Standardized" 
                                          :op2 "Expression" 
                                          :op3 "Measurement")))) 
                  :ARG2 (d3 / direct-02 
                        :ARG1 (c4 / comparable-03 
                              :ARG0 15 
                              :ARG1 (d4 / data 
                                    :mod (t8 / this)) 
                              :ARG2 (d2 / data 
                                    :ARG1-of (p / publish-01 
                                          :ARG0 (o / organization 
                                                :name (n / name 
                                                      :op1 "SEM")) 
                                          :time (p2 / previous)) 
                                    :mod (v2 / virtually-multiplex) 
                                    :mod (t6 / thing 
                                          :ARG1-of (t7 / transcribe-01)) 
                                    :source (a2 / abundance)) 
                              :time (n5 / now)))) 
            :mod (v / virtually-multiplex) 
            :source (a / abundance) 
            :source (t3 / thing 
                  :ARG1-of (t4 / transcribe-01))) 
      :op3 (t2 / thing 
            :name (n4 / name 
                  :op1 "NCI-funded")) 
      :op4 (t / thing 
            :name (n3 / name 
                  :op1 (c2 / CA) 
                  :op2 95806)))

# ::snt The data presented here represent more than 6,000 Virtually-multiplexed transcript abundance measurements conducted in multiple experiments .
# ::tok The data presented here represent more than 6,000 Virtually-multiplexed transcript abundance measurements conducted in multiple experiments .
# ::alignments 15-16|0.0.0.1 14-15|0.0.0.1.0 12-13|0.0.0 11-12|0.0.0.0 10-11|0.0.0.0.0 9-10|0.0.0.0.1.0+0.0.0.0.1 8-9|0.0.0.0.2 5-6|0.1 4-5|0 3-4|0.0.1.0 2-3|0.0.1 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:23.058
(r / represent-01 
      :ARG0 (d / data 
            :ARG0-of (c / conduct-01 
                  :ARG1 (m2 / measure-01 
                        :ARG0 (a / abundance) 
                        :ARG1 (t / thing 
                              :ARG1-of (t2 / transcribe-01)) 
                        :mod (v / virtually-multiplex)) 
                  :topic (e / experiment-01 
                        :quant (m / multiple))) 
            :ARG1-of (p / present-01 
                  :location (h / here))) 
      :ARG1 (m3 / more))

# ::snt The sixteen antioxidant or DNA repair genes and each of the six transcription factors except for E2F1 were measured in each NBEC sample from 49 individuals ( 24 non-BC individuals and 25 BC individuals ) .
# ::tok The sixteen antioxidant or DNA repair genes and each of the six transcription factors except for E2F1 were measured in each NBEC sample from 49 individuals ( 24 non-BC individuals and 25 BC individuals ) .
# ::alignments 33-34|0.0.1.1 32-33|0.0.1.1.0 31-32|0.0.1.1.1 30-31|0.0.1 29-30|0.0.1.0 27-28|0.0.1.0.0 25-26|0.0.0.1.2.0.0 24-25|0.0.0.1.2.0.0.0 22-23|0.1 21-22|0.1.0.0.0+0.1.0.0+0.1.0 20-21|0.1.1 18-19|0 14-15|0.0.0.1.2.0 13-14|0.0.0.1.2 12-13|0.0.0.1.2.1 11-12|0.0.0.1.2.2 8-9|0.0.2 7-8|0.0 6-7|0.0.0.1.1 5-6|0.0.0.1.0 4-5|0.0.0.1.0.0 3-4|0.0.0.1 2-3|0.0.0 1-2|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:24.397
(m / measure-01 
      :ARG1 (a2 / and 
            :op1 (a3 / antioxidant 
                  :mod (s2 / sixteen) 
                  :op1-of (o / or 
                        :op2 (r / repair-01 
                              :ARG1 (d / DNA)) 
                        :op3 (g / gene) 
                        :poss (f / factor 
                              :ARG2-of (e2 / except-01 
                                    :ARG1 (i3 / individual 
                                          :quant 49)) 
                              :mod (t / transcription) 
                              :quant 6))) 
            :op1-of (a / and 
                  :op2 (i2 / individual 
                        :quant 24) 
                  :op3 (i / individual 
                        :mod "BC" 
                        :quant 25)) 
            :op2 (e3 / each)) 
      :ARG1-of (s / sample-01 
            :ARG0 (c / country 
                  :name (n / name 
                        :op1 "NBEC")) 
            :mod (e / each)))

# ::snt 1ND , Not detectable ( When 60 molecules of Competitive Template ( CT ) were added to the reaction , CT was detected but native template was not . )
# ::tok 1ND , Not detectable ( When 60 molecules of Competitive Template ( CT ) were added to the reaction , CT was detected but native template was not . )
# ::alignments 27-28|0.1.0.2 25-26|0.1.0.0 24-25|0.1.0.0.0 23-24|0.1 22-23|0.1.0 18-19|0.2 15-16|0 12-13|0.2.0.0.0+0.2.0.0+0.2.0 9-11|0.0.0.1+0.0.0.0+0.0.0+0.0 7-8|0.1.0.1 6-7|0.1.0.0.0.0 3-4|0.2.1 2-3|0.2.1.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:24.756
(a / add-01 
      :ARG1 (t2 / thing 
            :name (n3 / name 
                  :op1 (c3 / Competitive) 
                  :op2 (t3 / Template))) 
      :ARG1-of (c / contrast-01 
            :ARG2 (d / detect-01 
                  :ARG0 (t / template 
                        :mod (n / native 
                              :poss-of 60)) 
                  :ARG1 (m / molecule) 
                  :ARG2 -)) 
      :ARG2 (r / react-01 
            :ARG0 (c2 / country 
                  :name (n2 / name 
                        :op1 "CT")) 
            :ARG1 (d2 / detectable 
                  :mod -)))

# ::snt 2NA , Not available .
# ::tok 2NA , Not available .
# ::alignments 3-4|0 2-3|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:24.762
(a / available-02 
      :degree -)

# ::snt E2F1 was measured in all of the samples except for one BC individual ( 24 non-BC individuals and 24 BC individuals ) .
# ::tok E2F1 was measured in all of the samples except for one BC individual ( 24 non-BC individuals and 24 BC individuals ) .
# ::alignments 20-21|0.1 19-20|0.1.0 18-19|0.1.1 17-18|0 16-17|0.0 14-15|0.0.1 12-13|0.0.0.1.0 11-12|0.0.0.1.0.0 8-9|0.0.0.1 7-8|0.0.0.1.1.0+0.0.0.1.1 4-5|0.0.0.1.1.1 2-3|0.0.0 0-1|0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:24.933
(a / and 
      :op1 (i2 / individual 
            :ARG0-of (m / measure-01 
                  :ARG1 (e2 / E2F1) 
                  :time (e / except-01 
                        :ARG1 (i3 / individual 
                              :mod "BC") 
                        :ARG2 (t / thing 
                              :ARG1-of (s / sample-01) 
                              :quant (a2 / all)))) 
            :quant 24) 
      :op2 (i / individual 
            :mod "BC" 
            :quant 24))

# ::snt Bivariate analysis of virtually-multiplexed transcript abundance data values for each antioxidant or DNA repair gene versus each transcription factor .
# ::tok Bivariate analysis of virtually-multiplexed transcript abundance data values for each antioxidant or DNA repair gene versus each transcription factor .
# ::alignments 18-19|0.1.2.0.0 17-18|0.1.2.0 16-17|0.1.2.0.0.0 15-16|0.1.2.0.0.1 14-15|0.1.3 13-14|0.1.2 12-13|0.1.2.1 11-12|0.1 10-11|0.1.1 9-10|0.1.0 7-8|0 6-7|0.0.1 5-6|0.0.1.1 4-5|0.0.1.2.0+0.0.1.2 3-4|0.0.1.0 1-2|0.0 0-1|0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:25.705
(v2 / value-01 
      :ARG0 (a3 / analyze-01 
            :ARG0 (b / bivariate) 
            :ARG1 (d2 / data 
                  :mod (v3 / virtually-multiplex) 
                  :source (a2 / abundance) 
                  :source (t2 / thing 
                        :ARG1-of (t3 / transcribe-01)))) 
      :ARG1 (o / or 
            :mod (e2 / each) 
            :op1 (a / antioxidant) 
            :op2 (r / repair-01 
                  :ARG0 (t / transcription 
                        :mod-of (f / factor 
                              :mod (e / each) 
                              :op1-of (v / versu))) 
                  :ARG1 (d / DNA)) 
            :op3 (g / gene)))

# ::snt The correlation of logarithmically transformed virtually-multiplexed transcript abundance data ( Table 3 ) from each of the six transcription factors with each of the sixteen antioxidant or DNA repair genes was determined .
# ::tok The correlation of logarithmically transformed virtually-multiplexed transcript abundance data ( Table 3 ) from each of the six transcription factors with each of the sixteen antioxidant or DNA repair genes was determined .
# ::alignments 31-32|0 29-30|0.1.3 28-29|0.1.2 27-28|0.1.2.2 26-27|0.1 25-26|0.1.1 24-25|0.1.1.0 21-22|0.0.0.0.1 19-20|0.1.0 18-19|0.1.0.1 17-18|0.1.0.2 14-15|0.1.0.0 11-12|0.1.2.0 10-11|0.1.2.1 8-9|0.0.0.0.0 7-8|0.0.0.0.0.1 6-7|0.0.0.0.0.2.0+0.0.0.0.0.2 5-6|0.0.0.0.0.0 4-5|0.0.0.0 3-4|0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:26.460
(d / determined-02 
      :ARG0 (c / correlation 
            :mod (l / logarithmically 
                  :ARG0-of (t5 / transform-01 
                        :ARG1 (d3 / data 
                              :mod (v / virtually-multiplex) 
                              :source (a2 / abundance) 
                              :source (t3 / thing 
                                    :ARG1-of (t4 / transcribe-01))) 
                        :ARG2 (e / each)))) 
      :ARG1 (o / or 
            :op1 (f / factor 
                  :mod (e2 / each) 
                  :mod (t / transcription) 
                  :quant 6) 
            :op2 (a / antioxidant 
                  :mod (s / sixteen)) 
            :op3 (r / repair-01 
                  :ARG0 3 
                  :ARG1 (t2 / table) 
                  :mod (d2 / DNA)) 
            :op4 (g / gene)))

# ::snt The transformation was necessary due to the wide range of expression of each gene among the samples .
# ::tok The transformation was necessary due to the wide range of expression of each gene among the samples .
# ::alignments 16-17|0+0.0 13-14|0.0.0 12-13|0.0.0.1 10-11|0.0.0.0 8-9|0.0.0.0.0 7-8|0.0.0.0.0.0 1-2|0.0.0.0.0.0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:26.541
(s / sample-01 
      :ARG1 (t / thing 
            :poss-of (g / gene 
                  :ARG1-of (e2 / express-01 
                        :ARG1-of (r / range-01 
                              :ARG2 (w / wide-02 
                                    :ARG1 (t2 / transform-01)))) 
                  :mod (e / each))))

# ::snt The correlation coefficient ( r value ) and level of significance ( p value ) for each correlation are presented .
# ::tok The correlation coefficient ( r value ) and level of significance ( p value ) for each correlation are presented .
# ::alignments 19-20|0.0.0.0.0.0 17-18|0.0.0 16-17|0.0 13-14|0.0.0.0.0.1 12-13|0.0.0.0.0.1.0 10-11|0.0.0.0 8-9|0.0.0.0.0.3 7-8|0.0.0.0.0 5-6|0 4-5|0.1 2-3|0.0.0.0.0.2 1-2|0.0.0.0.0.2.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:26.965
(v2 / value-01 
      :ARG0 (e / each 
            :mod-of (c / correlation 
                  :ARG1-of (s / significant-02 
                        :op3-of (a / and 
                              :ARG1-of (p / present-01) 
                              :ARG2-of (v / value-01 
                                    :ARG1 (p2 / p)) 
                              :op1 (c2 / coefficient 
                                    :mod (c3 / correlation)) 
                              :op2 (l / level))))) 
      :ARG1 (r / r))

# ::snt Significance ( p < 0.01 ) was determined using a two-tailed test following Bonferroni adjustment for six multiple comparisons ( comparison of each of six transcription factors to each of the antioxidant or DNA repair genes ) .
# ::tok Significance ( p < 0.01 ) was determined using a two-tailed test following Bonferroni adjustment for six multiple comparisons ( comparison of each of six transcription factors to each of the antioxidant or DNA repair genes ) .
# ::alignments 35-36|0.1.0.1.0.1.1 34-35|0.1.0.1.0 33-34|0.1.0.1.0.0 32-33|0.1.0.1.0.1 31-32|0.1.0.1.0.1.0 28-29|0.1.0.1.0.1.0.0 26-27|0.1.0.1.0.1.0.0.0 25-26|0.1.0.1.0.1.0.0.0.0 24-25|0.1.0.1.0.1.0.0.0.2 22-23|0.1.0.1.0.1.0.0.0.1 20-21|0.1.0.1.0.1.0.0.0.1.0 18-19|0.1.1 17-18|0.1.0.0.0 16-17|0.1.1.1 14-15|0.1.0.1.1 13-14|0.1.0.1.1.0.0.0+0.1.0.1.1.0.0+0.1.0.1.1.0 12-13|0.1.0.1 11-12|0.1.0 10-11|0.1.0.0 8-9|0.1 7-8|0 2-3|0.1.1.0 0-1|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:27.598
(d2 / determined-02 
      :ARG0 (s / significance) 
      :ARG1 (u / use-01 
            :ARG1 (t2 / test-01 
                  :ARG1 (t3 / two-tail 
                        :domain (m / multiple)) 
                  :ARG1-of (f2 / follow-01 
                        :ARG1-of (r / repair-01 
                              :mod (d / DNA) 
                              :op2-of (o / or 
                                    :op1 (a / antioxidant 
                                          :mod (e / each 
                                                :topic-of (f / factor 
                                                      :mod (t / transcription) 
                                                      :mod (e2 / each 
                                                            :ARG1-of (c / compare-01)) 
                                                      :quant 6))) 
                                    :op3 (g / gene))) 
                        :ARG2 (a2 / adjust-01 
                              :ARG1 (o2 / organization 
                                    :name (n / name 
                                          :op1 "Bonferroni"))))) 
            :ARG2 (c2 / compare-01 
                  :ARG1 (p / p) 
                  :quant 6)))

# ::snt * values for E2F1 obtained in all but one BC individuals .
# ::tok * values for E2F1 obtained in all but one BC individuals .
# ::alignments 10-11|0.0.0.0 9-10|0.0.0.0.0 7-8|0 6-7|0.1 4-5|0.0.0 1-2|0.0 ::annotator JAMR dev v0.3 ::date 2018-04-22T03:13:27.650
(c / contrast-01 
      :ARG0 (v / value 
            :ARG1-of (o / obtain-01 
                  :ARG0 (i / individual 
                        :mod "BC"))) 
      :ARG1 (a / all))

